

Selection Criteria:

| | | | |
|----------------------------|------------|-------------|-----------------|
| Product Name: | | | |
| Product Active Ingredient: | | | |
| Active Ingredient: | REMDESIVIR | | |
| Active Moiety: | | | |
| FDA Received Date: | From: | 01-Feb-2020 | To: 02-Jun-2020 |
| MedDRA® Version* : | 23.0 | | |
| Total Cases**: | 446 | | |
| Number of Pages: | 183 | | |

Disclaimer: Submission of a safety report does not constitute an admission that medical personnel, user facility, importer, distributor, manufacturer or product caused or contributed to the event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

*. "MedDRA® Version" refers to the name and version of the dictionary in use at the time the cases were retrieved from the FDA Adverse Event Reporting System (FAERS). MedDRA Medical Dictionary for Regulatory Activities (MedDRA®) is a medical terminology developed under the support of the International Conference on Harmonization (ICH) and is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). MedDRA is used by FDA, other regulatory agencies, and pharmaceutical manufacturers to code adverse events, medication errors and other information associated with the use of medical products. A MedDRA® Preferred Term (PT) is used to standardize a "medical concept" in a report. For example, a report of "heart attack" or "myocardial infarct" are standardized to the same Preferred Term, "Myocardial Infarction". MedDRA is updated twice a year.

**."Total Cases" reflects the number of individual patient case reports associated with the product of interest that were submitted to FDA within the specified time period. A case consists of an initial report and any follow-up reports submitted to FDA. Because FDA may receive reports on the same patient from more than one source, some of these cases may be duplicate patient reports.

The information in this report is generated from the FDA Adverse Event Reporting System (FAERS) by using a report query where suspect product(s) or active ingredients are selected from a standardized dictionary and a date range is specified as search criteria. The table below provides the definitions for field headings that are listed on the report.

FAERS data have limitations, including the following. There is no certainty that the reported event was actually due to the product. Reports are often incomplete - a blank field means that no data were provided. FDA does not receive reports on all adverse events that occur with a product. Many factors can influence whether or not an event will be reported, therefore, FAERS data cannot be used to compare products or calculate how frequently an event occurs in the U.S. population.

| Field Heading | Definition |
|----------------------|---|
| FDA Received Date | The date that FDA received the most recent information regarding a case, either as an initial report or follow-up report. The FDA Received Date may not be the same as the date that the event occurred. The event may have occurred days or even months (or years) before the report was sent to (and received by) FDA. Note the displayed date on the report may be later than the query date range if FDA received follow-up information for a case. FDA provides the most current case information available. |
| Case # | A unique number assigned by FDA that identifies a FAERS case. A case includes the information received in the initial report plus any additional information received in follow-up reports. |
| Case Type | There are three case types in FAERS: Expedited (15-Day): submitted to FDA by manufacturers; these are reports containing serious, unexpected adverse events Nonexpedited: submitted periodically to FDA by manufacturers; these are reports containing adverse events other than those qualifying for expedited (15-day) reporting. Direct: submitted "directly" to FDA by healthcare professionals, patients and other consumers. |
| Health Prof | Indicates whether the initial source who provided information about the event is a health professional. Possible values are; Y - Yes, N – No or the field is blank if it was not reported |
| Outcomes | Based on FDA regulations, the reported outcome(s) determines whether a case is serious. The outcome categories include congenital anomaly/birth defect (CA), death (DE), disability (DS), hospitalization (HO), life-threatening (LT), other serious important medical event (OT), and required intervention to prevent permanent impairment/damage (RI). A case can have more than one outcome. |
| Mfr Control # | The Manufacturer Control Number is the manufacturer's unique identifier associated with the case. Also referred to as the Company Report Number. |
| 503B Facility | Indicates whether the organization that sent the report to FDA is an outsourcing facility. An outsourcing facility is a facility at one geographic location or address that is engaged in the compounding of sterile drugs; has elected to register as an outsourcing facility; and complies with all of the requirements of section 503B of the Food, Drug, and Cosmetic Act. Possible value is Y – Yes. |
| Age | The patient's age, with age unit, based on information provided in the report. |
| Sex | Patient sex (Male, Female, Unknown). |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | |
|----------------|---|
| Country | The country where the event occurred. If not reported, then the country of the reporter. The International Organization for Standardization (ISO) 3166-1 alpha-3 country code is used as an abbreviation for the country. |
| Preferred Term | A Medical Dictionary for Regulatory Activities (MedDRA®) Preferred Term (PT) is used to standardize a "medical concept" in a report. For example, a report of "heart attack" or "myocardial infarct" are standardized to the same Preferred Term, "Myocardial Infarction". MedDRA is a medical terminology developed under the support of the International Conference on Harmonization (ICH) and is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). MedDRA is used by FDA, other regulatory agencies, and pharmaceutical manufacturers to "code" adverse events, medication errors and other information associated with the use of medical products. |
| Product | Name of a drug or biologic in the case report. A product name can appear as either a brand name (trade name) or an active ingredient name, depending on what was reported. |
| Comp. | Indicates whether the suspect product is a compounded drug, as identified in the report. Compounding is a practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient. Possible value is Y – Yes. |
| OTC | Indicates whether the suspect product is an over-the-counter (OTC) drug, as identified in the report. OTC drug products are those drugs that are available to consumers without a prescription. Possible value is Y – Yes. |
| Role | There are two roles for products listed on the cases. Suspect (S) identifies the product(s) that the initial reporter deemed most likely to be associated with the event. Concomitant (C) identifies products taken at the same time as the suspect product, but not deemed by the initial reporter as being associated with the event. |
| Route | Reported route of product administration (e.g., oral, topical, injection, sublingual, inhalation). |
| Dosage Text | Refers to the amount of the product that was taken or given to a patient, and the frequency of administration. For example, 20 mg twice daily. |
| Duration | The length of time the product was used. For example, if someone reported taking Drug A from January 1 to January 30, the duration would be 30 days. |
| Mfr | The manufacturer of the product, as indicated in the report. |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 01-May-2020 | 17731692 | NON-EXPEDITED | | OT | US-SA-2020SA110743 | | | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Anaemia; Aspartate Aminotransferase Increased; Blood Calcium Decreased; Blood Potassium Decreased; Gastrointestinal Haemorrhage | Lovenox | | | S | Subcutaneous | 100 Mg, Bid | | Sanofi |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | Unk | | Not Reported |
| | Eliquis | | | C | Unknown | Unk | | Not Reported |
| | Acetaminophen | | | C | Unknown | Unk | | Not Reported |
| | Ascorbic Acid | | | C | Unknown | Unk | | Not Reported |
| | Atorvastatin | | | C | Unknown | Unk | | Not Reported |
| | Dexmedetomidine | | | C | Unknown | Unk | | Not Reported |
| | Apixaban | | | C | Unknown | Unk | | Not Reported |
| | Aspirin [Acetylsalicylic Acid] | | | C | Unknown | Unk | | Not Reported |
| | Azithromycin | | | C | Unknown | Unk | | Not Reported |
| | Docusate Sodium | | | C | Unknown | Unk | | Not Reported |
| | Fluticasone Furoate;Vilanterol | | | C | Unknown | Unk | | Not Reported |
| | Gabapentin | | | C | Unknown | Unk | | Not Reported |
| | Hydrocodone | | | C | Unknown | Unk | | Not Reported |
| | Insulin Aspart | | | C | Unknown | Unk | | Not Reported |
| | Lantus | | | C | Unknown | Unk | | Not Reported |
| | Loratadine | | | C | Unknown | Unk | | Not Reported |
| | Polyethylene Glycol | | | C | Unknown | Unk | | Not Reported |
| | Prednisone | | | C | Unknown | Unk | | Not Reported |
| | Sertraline | | | C | Unknown | Unk | | Not Reported |
| | Inula Helenium Root;Senna Alexandrina Leaf | | | C | | Unk | | Not Reported |
| | Quetiapine | | | C | | Unk | | Not Reported |
| | Propofol | | | C | | Unk | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|----------------|---|-----|--------------|
| Pantoprazole | C | Unk | Not Reported |
| Multivitaminum | C | Unk | Not Reported |
| Hydromorphone | C | Unk | Not Reported |
| Enoxaparin | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 08-May-2020 | 17770443 | DIRECT | Y | OT | | | 55 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Chills; Hyperhidrosis; Hypotension; Infusion Related Reaction; Infusion Site Reaction; Nausea; Vomiting | Remdesivir | Y | | S | Intravenous drip | | 30 MIN | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 09-May-2020 | 17770487 | DIRECT | Y | OT | | | 62 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Covid-19 Pneumonia; Disease Progression; Hypertension; Oxygen Saturation Decreased | Remdesivir | Y | | S | Intravenous drip | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 11-May-2020 | 17770490 | DIRECT | Y | OT | | | 62 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------|--------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Endotracheal Intubation | Remdesivir | | | S | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|----------------|------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|------------|----------------|
| 11-May-2020 | 17770498 | DIRECT | Y | DE | | | 65 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Cardiac Arrest; Pulseless Electrical Activity; Ventricular Fibrillation | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--|----------------|------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|------------|----------------|
| 11-May-2020 | 17770540 | DIRECT | Y | OT | | | 48 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatinine Increased; Liver Function Test Increased; Therapy Cessation | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------------------|----------------|------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|------------|----------------|
| 11-May-2020 | 17770559 | DIRECT | Y | | | | 79 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Aspartate Aminotransferase Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--|----------------|------------------|--------------------|-----------------|----------------------|-----------------------|-----------------|--------------|----------------|
| 12-May-2020 | 17770551 | DIRECT | Y | OT | | | 72 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Chills; Clinical Trial Participant; Product Use In Unapproved Indication | Remdesivir | | | S | Intravenous drip | Other Frequency:Once; | | Gilead | |
| | Acetaminophen | | | C | | | | Not Reported | |
| | Allopurinol | | | C | | | | Not Reported | |
| | Aspirin | | | C | | | | Not Reported | |
| | Digoxin | | | C | | | | Not Reported | |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | |
|----------------------|---|--------------|
| Famotidine | C | Not Reported |
| Metoprolol Succinate | C | Not Reported |
| Warfarin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 12-May-2020 | 17774804 | DIRECT | Y | HO | | | 61 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Blood Creatinine Increased; Therapy Interrupted | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 12-May-2020 | 17774838 | DIRECT | Y | DE | | | 74 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Cardio-Respiratory Arrest; Dialysis; Pneumonia | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 12-May-2020 | 17774848 | DIRECT | Y | HO | | | 69 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-------------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatinine Increased; Oliguria | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Vancomycin | | | C | | | | Not Reported |
| | Potassium Chloride | | | C | | | | Not Reported |
| | Etomidate | | | C | | | | Not Reported |
| | Succinylcholine | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Naloxone | | | C | | | | Not Reported |
| | Piperacillin/Tazobactam | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Inhaled Epoprostenol | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Aspirin Chewable | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|-------------------------------|---|--------------|
| Bisacodyl Suppository | C | Not Reported |
| Gabapentin | C | Not Reported |
| Insulin Lispro | C | Not Reported |
| Propofol | C | Not Reported |
| Senna | C | Not Reported |
| Iv Furosemide 40 Mg X 1 | C | Not Reported |
| Hydroxychloroquine Or Placebo | C | Not Reported |
| Enoxaparin | C | Not Reported |
| Heparin | C | Not Reported |
| Metolazone 10 Mg | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 12-May-2020 | 17774850 | DIRECT | Y | OT | | | 61 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|------------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Covid-19 Pneumonia; Haemodynamic Instability; Hypotension; Renal Tubular Necrosis; Respiratory Failure; Weight Decreased | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Cefepime | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Diazepam | | | C | | | | Not Reported |
| | Docusate | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Heparin 7,500 Units Sq | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Quetiapine | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 12-May-2020 | 17774851 | DIRECT | Y | HO | | | 54 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Renal Impairment | Remdesivir | Y | | S | Intravenous drip | | 2 DAY | Gilead |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 13-May-2020 | 17775263 | DIRECT | Y | | | | | Unknown | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Incorrect Dose Administered; Product Label Confusion | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 13-May-2020 | 17776492 | DIRECT | Y | | | | 76 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Clinical Trial Participant; Thrombocytopenia | Remdesivir | | | S | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Amlodipine | | | C | | | | Not Reported |
| | Cholecalciferol | | | C | | | | Not Reported |
| | Torsemide | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Levothyroxine | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 13-May-2020 | 17781018 | DIRECT | Y | DE | | | 69 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|-------------------|-----------------------|-----------------|------------|
| Cardio-Respiratory Arrest; Clinical Trial Participant; Product Use In Unapproved Indication | Remdesivir | | | S | Intravenous bolus | Other Frequency:Once; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 13-May-2020 | 17781025 | DIRECT | Y | | | | 41 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--|--------------|------------|---------------------------------|--------------|--------------------|-----------------|--|
| Blood Creatinine Increased; Chest X-Ray Abnormal; Clinical Trial Participant; Oxygen Consumption Increased; Product Use In Unapproved Indication; White Blood Cell Count Increased | Remdesivir Fentanyl Hydralazine Piperacillin-Tazobactam Pantoprazole Enoxaparin Propofol | | | S C C C C C C | | | | Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 14-May-2020 | 17784372 | DIRECT | Y | OT | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---|--------------|------------|---|------------------|-----------------------|-----------------|--|
| Clinical Trial Participant; Diarrhoea; Nausea; Product Use In Unapproved Indication; Vomiting | Remdesivir Acetaminophen Amlodipine Ascorbic Acid Finasteride Gabapentin Guaifenesin/Codeine Heparin Lisinopril Ondansetron Pantoprazole Propranolol Saline Nasal Spray Zinc Sulfate Combivent Respimat | | | S C C C C C C C C C C C C C C | Intravenous drip | Other Frequency:Once; | | Gilead Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 14-May-2020 | 17790333 | DIRECT | Y | | | | 71 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Abdominal Pain; Chills; Clinical Trial Participant; | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

Electrocardiogram
Change; Hypotension;
Infusion Related Reaction;
Mental Status Changes;
Nausea; Product Use In
Unapproved Indication;
Pulse Abnormal

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 14-May-2020 | 17790340 | DIRECT | Y | OT | | | 66 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Clinical Trial Participant; Product Use In Unapproved Indication; Therapy Interrupted | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 14-May-2020 | 17790341 | DIRECT | Y | OT | | | 63 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------------|--------------|------------|-------------|-------------------|-----------------------|-----------------|--------------|
| Blood Creatinine Increased; Product Label Confusion; Product Preparation Error | Remdesivir | | | S | Intravenous drip | Other Frequency:Once; | | Gilead |
| | Furosemide | | | S | Intravenous bolus | | | Not Reported |
| | Bumetanide | | | C | | | | Not Reported |
| | Calcium Gluconate | | | C | | | | Not Reported |
| | Docusate | | | C | | | | Not Reported |
| | Epoprostenol Inhalation | | | C | | | | Not Reported |
| | Etomidate | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Gabapentin | | | C | | | | Not Reported |
| | Lorazepam | | | C | | | | Not Reported |
| | Maraviroc | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| Propofol | | | C | | | | Not Reported | |
| Vasopressin | | | C | | | | Not Reported | |

Vecuronium

C

Not Reported

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 14-May-2020 | 17791132 | DIRECT | Y | DE | | | 61 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------------------|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Cardio-Respiratory Arrest; Clinical Trial Participant; Product Use In Unapproved Indication | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Ascorbic Acid 500mg | | | C | | | | Not Reported |
| | Atorvastatin 20mg Tab | | | C | | | | Not Reported |
| | Azithromycin 500mg Iv | | | C | | | | Not Reported |
| | Ceftriaxone 1gm Iv Daily | | | C | | | | Not Reported |
| | Cholecalciferol 4,000 Units Daily | | | C | | | | Not Reported |
| | Doxycycline 100mg Iv Q12h | | | C | | | | Not Reported |
| | Enoxaparin 40mg Daily | | | C | | | | Not Reported |
| | Furosemide 20mg Once | | | C | | | | Not Reported |
| | Hydroxychloroquine 400mg | | | C | | | | Not Reported |
| | Irbesartan 75mg Daily | | | C | | | | Not Reported |
| | Potassium 20meq Once | | | C | | | | Not Reported |
| | Zinc Sulfate 440mg Daily | | | C | | | | Not Reported |
| | Acetaminophen 650mg Q4h Prn | | | C | | | | Not Reported |
| | Fentanyl 50mcg Q2h Prn | | | C | | | | Not Reported |
| | Dexmedetomidine Infusion | | | C | | | | Not Reported |
| | Heparin Infusion | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 15-May-2020 | 17792090 | EXPEDITED (15-DAY) | | OT | CH-SA-2020SA124099 | | 61 YR | Female | CHE |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Dermatitis Exfoliative | Ceftriaxone | | | S | | | | Not Reported |
| Generalised; Eosinophilia; Rash Erythematous | Clarithromycin | | | S | | Unk | | Not Reported |
| | Azithromycin | | | S | | Unk | | Not Reported |
| | Amlodipine (Salt Not Specified) | | | S | | 5 Mg | | Not Reported |
| | Oxazepam | | | S | | Unk | | Not Reported |
| | Lasix | | | S | | Unk | | Sanofi |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|------------------------------------|---|-------|--------------|
| Lasix | S | Unk | Sanofi |
| Lasix | S | Unk | Sanofi |
| Clexane | S | 40 Mg | Sanofi |
| Clexane | S | 40 Mg | Sanofi |
| Lorazepam | S | Unk | Not Reported |
| Paracetamol | S | Unk | Not Reported |
| Paracetamol | S | Unk | Not Reported |
| Quetiapine Fumarate | S | Unk | Not Reported |
| Esomeprazole Magnesium | S | Unk | Not Reported |
| Esomeprazole Magnesium | S | Unk | Not Reported |
| Haldol | S | Unk | Not Reported |
| Remdesivir | S | Unk | Not Reported |
| Diamox [Acetazolamide] | C | Unk | Not Reported |
| Diamox [Acetazolamide] | C | Unk | Not Reported |
| Diamox [Acetazolamide] | C | Unk | Not Reported |
| Distraneurin | C | | Not Reported |
| Heparine | C | Unk | Not Reported |
| Novorapid | C | | Not Reported |
| Ipramol | C | Unk | Not Reported |
| Lexotanil | C | Unk | Not Reported |
| Movicol | C | Unk | Not Reported |
| Morphine | C | Unk | Not Reported |
| Nozinan | C | Unk | Not Reported |
| Antibiotics For Otic And Nasal Use | C | Unk | Not Reported |
| Antibiotics For Otic And Nasal Use | C | Unk | Not Reported |
| Antibiotics For Otic And Nasal Use | C | Unk | Not Reported |
| Solu-Medrol | C | Unk | Not Reported |
| Dexdor | C | Unk | Not Reported |
| Dexdor | C | Unk | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|---------------|---|-----|--------------|
| Dexdor | C | Unk | Not Reported |
| Sintenyl | C | Unk | Not Reported |
| Sintenyl | C | Unk | Not Reported |
| Dormicum | C | Unk | Not Reported |
| Dormicum | C | Unk | Not Reported |
| Dormicum | C | Unk | Not Reported |
| Noradrenaline | C | Unk | Not Reported |
| Noradrenaline | C | Unk | Not Reported |
| Noradrenaline | C | Unk | Not Reported |
| Propofol | C | Unk | Not Reported |
| Propofol | C | Unk | Not Reported |
| Propofol | C | Unk | Not Reported |
| Propofol | C | Unk | Not Reported |
| Rocuronium | C | Unk | Not Reported |
| Tracrium | C | Unk | Not Reported |
| Tracrium | C | Unk | Not Reported |
| Tracrium | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 15-May-2020 | 17792126 | DIRECT | Y | DE | | | 57 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Death | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Convalescent Plasma | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 15-May-2020 | 17792128 | DIRECT | Y | OT | | | 59 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Chills; Hypotension; Infusion Related Reaction | Remdesivir | | | S | Intravenous drip | Other Frequency:X1 | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

(Loading Dose);

| | | |
|--------------------------------|---|--------------|
| Apap 500 Mg Po Q6hr Prn | C | Not Reported |
| Pain/Fever | | |
| Ascorbic Acid 1500 Mg Po Daily | C | Not Reported |
| Cefepime 1 G Ivpb Q12hr | C | Not Reported |
| L-Thyroxine 175 Mcg Po Daily | C | Not Reported |
| Lorazepam 0.5 Mg Po Tid Prn | C | Not Reported |
| Anxiety | | |
| Ondansetron 4 Mg Iv Push Q6hr | C | Not Reported |
| Prn N/V | | |
| Vancomycin 1.5 G Ivpb Q12hr | C | Not Reported |
| Zinc Sulfate 220 Mg Po Daily | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 15-May-2020 | 17792132 | DIRECT | Y | DE | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|----------------------------------|---------------------|--------------|------------|-------------|-------------------|-----------------------|-----------------|--------------|
| Refusal Of Treatment By Relative | Remdesivir | | | S | Intravenous bolus | Other Frequency:Once; | | Gilead |
| | Convalescent Plasma | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 15-May-2020 | 17792142 | DIRECT | Y | HO | | | 67 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Acute Kidney Injury | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 15-May-2020 | 17792175 | DIRECT | Y | HO | | | 73 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Dialysis | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--|--------------------------|--------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|--------------|----------------|
| 15-May-2020 | 17793631 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0466952 | | 65 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Cardiac Arrest; Pulseless Electrical Activity | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Qd | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 15-May-2020 | 17794224 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0467265 | | 74 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acute Respiratory Distress Syndrome; Cardio-Respiratory Arrest; Covid-19 Pneumonia | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 15-May-2020 | 17797263 | DIRECT | Y | OT | | | 66 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Poor Quality Product Administered; Product Storage Error | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | 6 DAY | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 15-May-2020 | 17797264 | DIRECT | Y | | | | 57 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acidosis; Blood Creatinine Increased; Fluid Overload | Remdesivir | | | S | Intravenous drip | | | Gilead | |
| | Cefepime | | | C | | | | Not Reported | |
| | Lactobacillus | | | C | | | | Not Reported | |
| | Aspirin | | | C | | | | Not Reported | |
| | Fentanyl Continuous Drip | | | C | | | | Not Reported | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|----------------------|---|--------------|
| Dextometomedine | C | Not Reported |
| Propofol | C | Not Reported |
| Heparin Subcutaneous | C | Not Reported |
| Famotidine | C | Not Reported |
| Methylprednisolone | C | Not Reported |
| Humalog | C | Not Reported |
| Humulin Nph | C | Not Reported |
| Venelex | C | Not Reported |
| Ocean Mist | C | Not Reported |
| Refresh | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 15-May-2020 | 17797623 | DIRECT | Y | OT | | | 66 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Blood Creatinine Increased; Hypotension | Remdesivir | | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 15-May-2020 | 17797878 | DIRECT | Y | OT | | | 71 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Hypotension | Remdesivir | | | S | | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17797266 | DIRECT | Y | OT | | | 46 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Seizure | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Insulin | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|----------------|---|--------------|
| Zinc | C | Not Reported |
| Fentanyl | C | Not Reported |
| Norepinephrine | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17797267 | DIRECT | Y | OT | | | 41 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--|--------------|------------|-------------|--------------|--------------------|-----------------|--|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir Convalescent Plasma For Covid-19 Tocilizumab Or Placebo/Covacta Study | | | S C C | | | | Gilead Not Reported Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17797268 | DIRECT | Y | OT | | | 72 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|-------------|--|-----------------------|-----------------|----------------------------------|
| Blood Creatinine Increased; Coronary Artery Stenosis; Depressed Level Of Consciousness; Hemiparesis; Mental Status Changes; Renal Ischaemia | Remdesivir Remdesivir Convalescent Plasma For Covid-19 | | | S S C | Intravenous bolus Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead Gilead Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17797269 | DIRECT | Y | OT | | | 57 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------|--------------------------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--|
| Renal Function Test Abnormal | Remdesivir Cefepime Vancomycin | | | S C C | Intravenous drip | | | Gilead Not Reported Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17797270 | DIRECT | Y | | | | 46 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Liver Function Test Increased; Therapy Interrupted | Remdesivir | | | S | | | | Not Reported |
| | Benzonatate | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Clonazepam | | | C | | | | Not Reported |
| | Doxycycline | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Omeprazole | | | C | | | | Not Reported |
| | Ropinirole | | | C | | | | Not Reported |
| Topiramate | | | C | | | | Not Reported | |
| Ziprasidone | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17797271 | DIRECT | Y | | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------------|----------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|------------|
| Alanine Aminotransferase Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17797281 | DIRECT | Y | | | | 57 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|------------------|-----------------------|-----------------|------------|
| Liver Function Test Increased; Therapy Interrupted | Remdesivir | Y | | S | Intravenous drip | Other Frequency:Once; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17797285 | DIRECT | Y | | | | 52 YR | Female | USA |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--------------------|--------------|------------|-------------|------------------|-----------------------|-----------------|--------------|
| Blood Pressure Systolic Increased; Hypertension; Therapy Change | Remdesivir | | | S | Intravenous drip | Other Frequency:Once; | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Digoxin | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Hydralazine | | | C | | | | Not Reported |
| | Losartan | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Nebivolol | | | C | | | | Not Reported |
| Hydroxychloroquine | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17797292 | DIRECT | Y | OT | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|------------------------------------|--------------|------------|-------------|------------------|-----------------------------------|-----------------|--------------|
| Blood Creatinine Increased; Protein Total Increased; Renal Tubular Necrosis; Sepsis | Remdesivir | | | S | Intravenous drip | Other Frequency:Once, Then 100mg; | | Gilead |
| | Heparin/Enoxaparin Subcutaneous | | | C | | | | Not Reported |
| | Aspirin 81 Mg | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Ondansetron | | | C | | | | Not Reported |
| | Levothyroxine 150 Mcg | | | C | | | | Not Reported |
| | Tocilizumab 400 Mg | | | C | | | | Not Reported |
| | Ethacrynic Acid | | | C | | | | Not Reported |
| | Metoprolol | | | C | | | | Not Reported |
| | Tradipitant | | | C | | | | Not Reported |
| | Trimethobenzamide 200 Mg Injection | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17798027 | DIRECT | Y | RI | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | | |
|------------------------------------|----------------------|---|---|---------------------------------------|--------|
| Alanine Aminotransferase Increased | Remdesivir (Gs-5734) | Y | S | Intravenous (not otherwise specified) | Gilead |
| | Remdesivir (Gs-5734) | Y | S | Intravenous (not otherwise specified) | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17798044 | DIRECT | Y | HO | | | 60 DAY | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Cardiac Failure; Coagulopathy; Organ Failure; Transaminases Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 17-May-2020 | 17801712 | DIRECT | Y | OT | | | 32 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Transaminases Increased | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17798196 | DIRECT | Y | OT | | | 23 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Drug Ineffective; Liver Function Test Increased; Therapy Cessation | Remdesivir 200 Mg | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Dextromethorphan | | | C | | | | Not Reported |
| | Benzonatate | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--------------------|---|--------------|
| Aspirin | C | Not Reported |
| Ibuprofen | C | Not Reported |
| Vitamin C | C | Not Reported |
| Zinc Sulfate | C | Not Reported |
| Hydroxychloroquine | C | Not Reported |
| Prednisone | C | Not Reported |
| Albuterol Hfa | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17798574 | DIRECT | Y | OT | | | 23 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Drug Ineffective; Liver Function Test Increased; Therapy Cessation | Remdesivir 200 Mg | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Acetaminophen | | | C | | Not Reported | | |
| | Dextromethorphan | | | C | | Not Reported | | |
| | Benzonatate | | | C | | Not Reported | | |
| | Enoxaparin | | | C | | Not Reported | | |
| | Aspirin | | | C | | Not Reported | | |
| | Ibuprofen | | | C | | Not Reported | | |
| | Vitamin C | | | C | | Not Reported | | |
| | Zinc Sulfate | | | C | | Not Reported | | |
| | Hydroxychloroquine | | | C | | Not Reported | | |
| | Prednisone | | | C | | Not Reported | | |
| | Albuterol Hfa | | | C | | Not Reported | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17800831 | EXPEDITED (15-DAY) | | DE | US-GILEAD-2020-0467444 | | 69 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Dyspnoea; Hypoxia | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |
| | | | | | | | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801700 | DIRECT | Y | OT | | | 53 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Liver Function Test Abnormal | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801703 | DIRECT | Y | | | | 60 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Incorrect Dose Administered | Remdesivir | | | S | | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801706 | DIRECT | Y | DE, LT | | | 77 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Condition Aggravated; General Physical Health Deterioration; Oxygen Saturation Decreased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | 3 DAY | Gilead |
| | Cefepime 2g Iv Q12h | | | C | | | | Not Reported |
| | Ascorbic Acid 1500mg Iv Q6h | | | C | | | | Not Reported |
| | Thiamine 200mg Iv Q12h | | | C | | | | Not Reported |
| | Doxycycline 100mg Po Bid | | | C | | | | Not Reported |
| | Methylprednisolone 60mg Iv Q12h | | | C | | | | Not Reported |
| | Pantoprazole 20mg Po Q24h | | | C | | | | Not Reported |
| | Sertraline 100mg Po Q24h | | | C | | | | Not Reported |
| | Methylprednisolone 60mg Iv Q24h | | | C | | | | Not Reported |
| | Tamsulosin 0.4mg Po Q24h | | | C | | | | Not Reported |
| | Zinc Capsule 50mg Po Q24h | | | C | | | | Not Reported |
| | Ipratropium Inh 2 Puffs Po Q6h | | | C | | | | Not Reported |
| | Enoxaparin 30mg Sc Q12h | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801710 | DIRECT | Y | OT | | | 43 YR | Female | USA |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Coronavirus Test Positive; Vomiting | Remdesivir | | | S | Intravenous drip | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Insulin Aspart | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Ondansetron | | | C | | | | Not Reported |
| | Oxycodone | | | C | | | | Not Reported |
| | Prochloroperazine | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| Doxycycline | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801711 | DIRECT | Y | OT | | | 70 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--|-----------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Therapy Cessation | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| | Atorvastatin | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801746 | DIRECT | Y | OT | | | 84 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatinine Increased; Hypotension; Respiratory Failure; Tachypnoea; Urine Output Decreased; White Blood Cell Disorder | Remdesivir | | | S | | | | Gilead |
| | Vancomycin | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801755 | DIRECT | Y | OT | | | 77 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | | | | |
|---|------------|---|------------------|--|--------------|
| Clinical Trial Participant; Liver Function Test Increased; Product Use In Unapproved Indication; Renal Replacement Therapy | Remdesivir | S | Intravenous drip | | Not Reported |
|---|------------|---|------------------|--|--------------|

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801760 | DIRECT | Y | | | | 53 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|-------------|--|--------------------|-----------------|------------------------------|
| Clinical Trial Participant; Differential White Blood Cell Count Abnormal; Leukopenia; Lymphocyte Percentage Increased; Neutrophil Percentage Decreased; Product Use In Unapproved Indication | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Ascorbic Acid 1500mg Po Bid | | | C | | | | Not Reported |
| | Cholecalciferol 50mcg Po Q24h | | | C | | | | Not Reported |
| | Zinc Capsule 50mg Po Q24h | | | C | | | | Not Reported |
| | Magnesium Oxide 420mg Po Bid | | | C | | | | Not Reported |
| | Insulin Glargine 12 Units Sc Qhs | | | C | | | | Not Reported |
| | Insulin Aspart Sliding Scale Tid Ac | | | C | | | | Not Reported |
| | Senna 17.2mg Po Daily Enoxaparin 30mg Sc Q12h | | | C C | | | | Not Reported Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801796 | DIRECT | Y | OT | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Acute Kidney Injury; Clinical Trial Participant; Product Use In Unapproved Indication; Renal Impairment | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Hydroxychloroquine Or Matching Placebo | | | C | | | | Not Reported |
| | Convalescent Plasma | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801801 | DIRECT | Y | OT | | | 55 YR | Female | USA |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Hypovolaemia; Renal Tubular Necrosis | Remdesivir Injection (For Use Under Eua) | | | S | Intravenous drip | | | Gilead |
| | Remdesivir Injection (For Use Under Eua) | | | S | Intravenous drip | | | Gilead |
| | Vancomycin 2g Iv Q12 | | | C | | | | Not Reported |
| | Vancomycin 1g Iv Q12 | | | C | | | | Not Reported |
| | Vancomycin 1g Iv X 1 | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Pregabalin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801805 | DIRECT | Y | OT | | | 80 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|-------------------|--|-----------------|--------------|
| Renal Impairment | Remdesivir | | | S | Intravenous bolus | Other Frequency:200mg X 1 100mg X4; | | Gilead |
| | Cefepime | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Hydroxychloroquine | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Carvedilol | | | C | | | | Not Reported |
| | Docusate | | | C | | | | Not Reported |
| | Folic Acid | | | C | | | | Not Reported |
| | Neurontin | | | C | | | | Not Reported |
| | Clopidogrel | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Mvi | | | C | | | | Not Reported |
| | Heparin Drip | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801809 | DIRECT | Y | HO | | | 72 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|------------|
| Acute Kidney Injury | Remdesivir | | | S | Intravenous bolus | | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--------------------------|---|--------------|
| Aspirin | C | Not Reported |
| Azithromycin | C | Not Reported |
| Enoxaparin | C | Not Reported |
| Hydrocortisone | C | Not Reported |
| Hydroxychloroquine | C | Not Reported |
| Insulin Glargine | C | Not Reported |
| Insulin Lispro | C | Not Reported |
| Piperacillin-Tazobactam | C | Not Reported |
| Polyethylene Glycol 3350 | C | Not Reported |
| Vancomycin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801815 | DIRECT | Y | OT | | | 67 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Dysphagia; Swelling; Throat Irritation | Remdesivir | Y | | S | | | | Not Reported |
| | Amlopidine | | | C | | | | Not Reported |
| | Albuterol Hfa | | | C | | | | Not Reported |
| | Lisinopril | | | C | | | | Not Reported |
| | Nystatin Oral Susp | | | C | | | | Not Reported |
| | Percocet | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Sitagliptin | | | C | | | | Not Reported |
| | Zinc | | | C | | | | Not Reported |
| | Vitamin D | | | C | | | | Not Reported |
| | Vitamin C | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Metformin | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Dipridamole | | | C | | | | Not Reported |
| | Empagliflozin | | | C | | | | Not Reported |
| Insulin Lispro | | | C | | | | Not Reported | |
| Letrozole | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801819 | DIRECT | Y | HO | | | 75 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | | | | | |
|--|--|--|------------------|-----------------------|--------|--|
| Abdominal Pain; Discomfort; Infusion Related Reaction; Nausea; Vomiting | Remdesivir Albuterol Inhaler Atorvastatin Enoxaparin Hydroxychloroquine Lisinopril Pantoprazole Tiotropium Norco 5 Tussionex Ondansetron Prochlorperazine | S C C C C C C C C C C C | Intravenous drip | Other Frequency:Once; | 20 MIN | Gilead Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported |
|--|--|--|------------------|-----------------------|--------|--|

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801824 | DIRECT | Y | OT | | | 46 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Seizure | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Tocilizumab | | | C | | | | Not Reported |
| | Zinc | | | C | | | | Not Reported |
| | Quetiapine | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Levetiracetam | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801829 | DIRECT | Y | HO | | | 55 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Glomerular Filtration Rate Decreased; Hypoxia | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Doxycycline | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|--------------------|------------------|--------------------|-----------------|---------------------------------------|-----------------------|-----------------|--------------|----------------|
| 18-May-2020 | 17801885 | DIRECT | Y | OT | | | 34 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Anxiety; Blood Pressure Increased; Body Temperature Increased; Heart Rate Increased; Hyperhidrosis; Nausea; Oxygen Saturation Decreased; Respiratory Rate Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 18-May-2020 | 17801892 | DIRECT | Y | OT | | | 38 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Alanine Aminotransferase Increased | Remdesivir | Y | | S | Intravenous drip | | | Gilead | |
| | Ceftriaxone | | | C | | | | Not Reported | |
| | Famotidine | | | C | | | | Not Reported | |
| | Heparin | | | C | | | | Not Reported | |
| | Insulin | | | C | | | | Not Reported | |
| | Midazolam | | | C | | | | Not Reported | |
| | Norepinephrine | | | C | | | | Not Reported | |
| | Azithromycin | | | C | | | | Not Reported | |
| | Tocilizumab | | | C | | | | Not Reported | |
| | Vancomycin | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 18-May-2020 | 17801899 | DIRECT | Y | | | | 52 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Product Administration Error; Product Dose Omission | Remdesivir | | | S | Intravenous bolus | | | Gilead | |
| | Tocilizumab 760mg | | | C | | | | Not Reported | |
| | Convalescent Serum | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801905 | DIRECT | Y | HO | | | 15 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---------------------------------|--------------|------------|-------------|-------------------|-----------------------|-----------------|--------------|
| Hypotension | Remdesivir | Y | | S | Intravenous bolus | Other Frequency:Once; | | Gilead |
| | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |
| | Cosyntropin | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Hydrocortisone Sodium Succinate | | | C | | | | Not Reported |
| | Mercaptopurine | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17801912 | DIRECT | Y | LT | | | 73 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Azotaemia; Continuous Haemodiafiltration; Glomerular Filtration Rate Decreased | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |
| | Enoxaparin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 18-May-2020 | 17802626 | DIRECT | Y | DE | | | 76 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|--------------|
| Chills; Covid-19; Dyspnoea; General Physical Health Deterioration; Hypotension; Liver Function Test Abnormal; Multiple Organ | Convalescent Plasma | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Not Reported |
| | Remdesivir | | | S | | | | Not Reported |
| | Dapsone | | | C | | | | Not Reported |
| | Linezolid | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Piperacillin/Tazobactam | | | C | | | | Not Reported |

Dysfunction Syndrome;
Oxygen Saturation
Decreased; Pneumonia
Staphylococcal; Pyrexia;
Renal Function Test
Abnormal; Sars-Cov-2
Test Positive

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|------------------------------------|----------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|------------|----------------|
| 19-May-2020 | 17802614 | DIRECT | Y | LT | | | 55 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Alanine Aminotransferase Increased | Remdesivir | Y | | S | Intravenous drip | | 5 DAY | Gilead | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|----------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|------------|----------------|
| 19-May-2020 | 17802618 | DIRECT | Y | OT | | | 75 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Continuous Haemodiafiltration; Inadequate Haemodialysis; Renal Impairment | Remdesivir | | | S | Intravenous drip | | 2 DAY | Gilead | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|--|------------------|--------------------|---------------------------------|----------------------|----------------------|-----------------|--|----------------|
| 19-May-2020 | 17802638 | DIRECT | Y | DE | | | 60 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Bacteraemia; Cardiac Arrest; Covid-19; Disease Complication; Pneumonia Pseudomonas; Respiratory Failure | Remdesivir Amiodarone Amlodipine Carvedilol Docusate Enoxaparin Furosemide | | | S C C C C C C | Intravenous bolus | | | Gilead Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|---------------------------|---|--------------|
| Insulin Glargine | C | Not Reported |
| Insulin Lispro | C | Not Reported |
| Lactobacillus Acidophilus | C | Not Reported |
| Lansoprazole | C | Not Reported |
| Lorazepam | C | Not Reported |
| Meropenem | C | Not Reported |
| Metoclopramide | C | Not Reported |
| Multivitamin | C | Not Reported |
| Oxycodone | C | Not Reported |
| Polyethylene Glycol 3350 | C | Not Reported |
| Potassium Chloride | C | Not Reported |
| Neutra-Phos | C | Not Reported |
| Senna | C | Not Reported |
| Vancomycin | C | Not Reported |
| Hydromorphone | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17802944 | DIRECT | Y | DE | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Oxygen Saturation Decreased; Renal Failure | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Hydroxychloroquine Or Matching Placebo (Orchid Trial) | | | C | | | | Not Reported |
| | Convalescent Plasma | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17802952 | DIRECT | Y | DE | | | 53 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|----------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|--------------|
| Pulseless Electrical Activity | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| | Leviteracetam | | | C | | | | Not Reported |
| | Oxcarbazepine | | | C | | | | Not Reported |
| | Amlodipine | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|----------------|--------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|--------------|----------------|
| 19-May-2020 | 17805154 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0466529 | | 71 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Chills; Hypotension; Nausea | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 19-May-2020 | 17805179 | EXPEDITED (15-DAY) | | HO, OT | US-GILEAD-2020-0467261 | | 61 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acute Kidney Injury; Blood Creatinine Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Qd | | Gilead | |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 19-May-2020 | 17805184 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0466961 | | 48 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatinine Increased; Hepatic Function Abnormal | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Qd | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 19-May-2020 | 17806590 | DIRECT | Y | OT | | | 59 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatinine Increased | Remdesivir | Y | | S | Intravenous drip | | | Gilead | |
| | Amolodipine | | | C | | | | Not Reported | |
| | Atracurium | | | C | | | | Not Reported | |
| | Carvedilol | | | C | | | | Not Reported | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|-----------------|---|--------------|
| Famotidine | C | Not Reported |
| Heparin | C | Not Reported |
| Lidocaine Patch | C | Not Reported |
| Midazolam | C | Not Reported |
| Multivitamin | C | Not Reported |
| Acetaminophen | C | Not Reported |
| Atracurium | C | Not Reported |
| Fentanyl | C | Not Reported |
| Midazolam | C | Not Reported |
| Norepinephrine | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806639 | DIRECT | Y | LT | | | 60 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| General Physical Health Deterioration; Haemodynamic Instability; Pneumothorax; Pulmonary Embolism; Sepsis; Shock | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806644 | DIRECT | Y | OT | | | 45 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------------|----------------------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |
| | Bisacodyl Suppository | | | C | | | | Not Reported |
| | Bumetanide 1mg Inj | | | C | | | | Not Reported |
| | Ceftriaxone 2g Inj | | | C | | | | Not Reported |
| | Chlorhexidine 0.12% Swish | | | C | | | | Not Reported |
| | Enoxaparin 100mg | | | C | | | | Not Reported |
| | Fentanyl 100mcg/Hr | | | C | | | | Not Reported |
| | Ipratropium-Albuterol Neb | | | C | | | | Not Reported |
| | Lactated Ringer Infusion | | | C | | | | Not Reported |
| | Potassium Phosphate 15mmol Bolus | | | C | | | | Not Reported |
| | Propfol Infusion 40mcg/Kg/Min | | | C | | | | Not Reported |
| | Rocuronium 10m/MI Infusion | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| Vancomycin | | | C | | | | Not Reported | | |
|--|----------------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|--------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 19-May-2020 | 17806653 | DIRECT | Y | LT | | | 29 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Caesarean Section; Foetal Heart Rate Abnormal; Haemodynamic Instability; Respiratory Failure | Remdesivir | | | S | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 19-May-2020 | 17806658 | DIRECT | Y | OT | | | 55 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatinine Increased; Condition Aggravated; Haemodialysis | Remdesivir Eua | | | S | | | | Not Reported | |
| | Amlodipine 5mg | | | C | | | | Not Reported | |
| | Ascorbic Acid 1000mg | | | C | | | | Not Reported | |
| | Ceftriaxone 1g | | | C | | | | Not Reported | |
| | Doxycycline 100mg | | | C | | | | Not Reported | |
| | Furisemide 40mg | | | C | | | | Not Reported | |
| | Heparin | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 19-May-2020 | 17806695 | DIRECT | Y | OT | | | 75 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Atrial Fibrillation; Blood Creatinine Increased; Body Temperature Increased; Infusion Related Reaction | Remdesivir | | | S | Intravenous drip | | | Gilead | |
| | Acetaminophen | | | C | | | | Not Reported | |
| | Amlodipine | | | C | | | | Not Reported | |
| | Apixaban | | | C | | | | Not Reported | |
| | Doxazosin | | | C | | | | Not Reported | |
| | Hydralazine | | | C | | | | Not Reported | |
| | Lorazepam | | | C | | | | Not Reported | |
| | Combivent Respimat | | | C | | | | Not Reported | |
| | Ascorbic Acid | | | C | | | | Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|-----------------|---|--------------|
| Cholecalciferol | C | Not Reported |
| Levothyroxine | C | Not Reported |
| Zinc Sulfate | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806699 | DIRECT | Y | OT | | | 72 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|--------------|
| Acute Kidney Injury; Acute Respiratory Distress Syndrome; Septic Shock | Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| | Norepinephrine | | | C | | | | Not Reported |
| | Cisatracurium | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| Midazolam | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806709 | DIRECT | Y | RI | | | 54 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Bradycardia | Remdesivir | | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806721 | DIRECT | Y | DE, LT, OT | | | 72 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Fluid Overload; Hypoxia; Respiratory Disorder; Shock | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Bensonatate | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Chlorhexidine | | | C | | | | Not Reported |
| | Cisatracurium | | | C | | | | Not Reported |
| | Dexmedetomidine | | | C | | | | Not Reported |
| | Normosol-R | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|---------------------|---|--------------|
| Epinephrine | C | Not Reported |
| Fentanyl | C | Not Reported |
| Heparin | C | Not Reported |
| Hydroxychloroquine | C | Not Reported |
| Iopamidol | C | Not Reported |
| Lactated Ringers | C | Not Reported |
| Lorazepam | C | Not Reported |
| Magnesium Sulfate | C | Not Reported |
| Melatonin | C | Not Reported |
| Metaclopramide | C | Not Reported |
| Metoprolol Tartrate | C | Not Reported |
| Morphine | C | Not Reported |
| Norepinephrine | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806725 | DIRECT | Y | DE, OT | | | 72 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acidosis; Acute Kidney Injury; Cardiac Arrest; Hypernatraemia; Metabolic Acidosis; Paralysis; Respiratory Acidosis; Respiratory Failure | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Dexmedetomidine Drip | | | C | | | | Not Reported |
| | Enoxaparin 100 Mg Subq Q12h | | | C | | | | Not Reported |
| | Insulin | | | C | | | | Not Reported |
| | Methylprednisolone 60 Mg Iv Q12h | | | C | | | | Not Reported |
| | Lorazepam 2 Mg Iv Q4h Prn | | | C | | | | Not Reported |
| | Levophed Infusion | | | C | | | | Not Reported |
| | Methylprednisolone 40 Mg Iv Q12h | | | C | | | | Not Reported |
| | Dopamine Infusion | | | C | | | | Not Reported |
| | Epinephrine Infusion | | | C | | | | Not Reported |
| | Phenylephrine Infusion | | | C | | | | Not Reported |
| | Epoprostenol For Inhalation | | | C | | | | Not Reported |
| | Sodium Bicarb 150 Meq/Swi 1l At 150 MI/Hr | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Piperacillin/Tazobactam | | | C | | | | Not Reported |
| | Heparin Low Intensity Infusion | | | C | | | | Not Reported |
| | Amiodarone Iv | | | C | | | | Not Reported |
| | Ketamine Infusion | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|-------------------------------|---|--------------|
| Morphine Infusion | C | Not Reported |
| Rocuronium Infusion | C | Not Reported |
| Tocilizumab 800 Mg Iv X1 Dose | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806729 | DIRECT | Y | DE | | | 92 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---------------------|--------------|------------|-------------|-------------------|-----------------------|-----------------|--------------|
| Death | Remdesivir | | | S | Intravenous bolus | Other Frequency:Once; | | Gilead |
| | Convalescent Plasma | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806734 | DIRECT | Y | DE | | | 96 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|------------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Electrocardiogram Abnormal; Renal Failure; Respiratory Failure | Remdesivir Eua | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Ascorbic Acid 500 Mg | | | C | | | | Not Reported |
| | Cefepime 1 Gram | | | C | | | | Not Reported |
| | Ergocalciferol 50,000 Units | | | C | | | | Not Reported |
| | Hydromorphone 0.2 Mg Iv | | | C | | | | Not Reported |
| | Methylprednisolone 40 Mg Injection | | | C | | | | Not Reported |
| | Pantoprazole 40 Mg Tablet | | | C | | | | Not Reported |
| | Senna 17.2 Mg | | | C | | | | Not Reported |
| | Sodium Chloride 0.9% Neb | | | C | | | | Not Reported |
| | Zinc Sulfate 220 Mg | | | C | | | | Not Reported |
| | Mirtazapine 7.5 Mg | | | C | | | | Not Reported |
| | Morphine 4 Mg/MI Injection | | | C | | | | Not Reported |
| | Torseamide 20 Mg | | | C | | | | Not Reported |
| | Norepinephrine 8 Mg / 250 MI | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806736 | DIRECT | Y | DE | | | 54 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Arrhythmia; Clinical Trial Participant; Product Use In Unapproved Indication; Pulseless Electrical Activity; Tachycardia | Remdesivir Eua | Y | | S | | | | Not Reported |
| | Amikacin | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Vasopressin | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Cholecalciferol | | | C | | | | Not Reported |
| | Diphenhydramine | | | C | | | | Not Reported |
| | Docusate | | | C | | | | Not Reported |
| | Doxycycline | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Robitussin Dm | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Tocilizumab | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Montelukast | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| Vancomycin | | | C | | | | Not Reported | |
| Norepinephrine | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806739 | DIRECT | Y | OT | | | 46 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|------------|
| Cholelithiasis; Clinical Trial Participant; Product Use In Unapproved Indication; Sepsis; Shock; Transaminases Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806745 | DIRECT | Y | OT | | | 40 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased Remdesivir S Intravenous (not otherwise specified) Gilead

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17806790 | DIRECT | Y | OT | | | 49 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|--------------|
| Blood Alkaline Phosphatase Increased; Blood Pressure Decreased; Body Temperature Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| | Atorvastatin | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Desvenlafaxine | | | C | | | | Not Reported |
| | Epoetin Alfa | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Hydrocortisone Sodium Succinate | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Methadone | | | C | | | | Not Reported |
| | Metoprolol | | | C | | | | Not Reported |
| | Potassium Chloride | | | C | | | | Not Reported |
| | Pregabalin | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Hydroxychloroquine | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17807091 | DIRECT | Y | DE | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-------------------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Death | Remdesivir (Euc) (Remdesivir (Eau)) | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17807562 | DIRECT | Y | RI | | | 79 YR | Female | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------------------------|--------------|------------|--------------|---------------------------------------|--------------------|-----------------|------------|
| Atrial Fibrillation; Blood Creatinine Increased; Blood Pressure Systolic Increased; Glomerular Filtration Rate Decreased; Increased Bronchial Secretion; Oxygen Saturation Decreased; Po2 Decreased | Remdesivir 100 Mg/20 MI Iv (Eua Drug) | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Cefepime | | | C | | Not Reported | | |
| | Apap | | | C | | Not Reported | | |
| | Ca/Vit D | | | C | | Not Reported | | |
| | Magnesium Sulfate | | | C | | Not Reported | | |
| | Quetiapine | | | C | | Not Reported | | |
| | Morphine | | | C | | Not Reported | | |
| | Pravastatin | | | C | | Not Reported | | |
| | Ezetimibe | | | C | | Not Reported | | |
| | Fluoxetine | | | C | | Not Reported | | |
| | Memantine | | | C | | Not Reported | | |
| | Rivaroxaban | | | C | | Not Reported | | |
| | Docusate | | | C | | Not Reported | | |
| | Famotidine | | | C | | Not Reported | | |
| Calcitonin | | | C | Not Reported | | | | |
| Kcl | | | C | Not Reported | | | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 19-May-2020 | 17807632 | DIRECT | Y | DE | | | 77 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-------------------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Death | Remdesivir (Euc) (Remdesivir (Eua)) | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17807338 | DIRECT | Y | | | | 8 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Incorrect Product Formulation Administered; Product Use Issue | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17807340 | DIRECT | | | | | 62 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Hypoxia; Pneumomediastinum | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17807341 | DIRECT | Y | OT | | | 54 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir | Y | | S | | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17807897 | DIRECT | Y | OT | | | 59 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Aspartate Aminotransferase Increased; Transaminases Increased | Remdesivir 200mg | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Remdesivir 100mg | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Remdesivir 100mg | Y | | S | | | | Gilead |
| | Remdesivir 100mg | Y | | S | | | | Gilead |
| | Hydromorphone | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Zofran | | | C | | | | Not Reported |
| | Vitd3 | | | C | | | | Not Reported |
| | Titrilac | | | C | | | | Not Reported |
| | Seroquel | | | C | | | | Not Reported |
| | Calcium Gluconate | | | C | | | | Not Reported |
| | Lasix | | | C | | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |
| | Miralax | | | C | | | | Not Reported |
| | Benadryl | | | C | | | | Not Reported |
| | Levophed | | | C | | | | Not Reported |
| | Magnesium Sulfate | | | C | | | | Not Reported |
| | Potassium Chloride | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|-----------------------|---|--------------|
| Clozaril | C | Not Reported |
| Propofol | C | Not Reported |
| Amidate | C | Not Reported |
| Quellcin | C | Not Reported |
| Fentanyl | C | Not Reported |
| Versed | C | Not Reported |
| Humulin | C | Not Reported |
| Humalog | C | Not Reported |
| Ancef | C | Not Reported |
| Protonix | C | Not Reported |
| Flagyl | C | Not Reported |
| Rocephin | C | Not Reported |
| Vancomycin | C | Not Reported |
| Zenpep | C | Not Reported |
| Prilosec | C | Not Reported |
| Potassium Bicarbonate | C | Not Reported |
| Zemuron | C | Not Reported |
| Convalescent Plasm | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810056 | EXPEDITED (15-DAY) | | HO, OT | US-GILEAD-2020-0467380 | | 69 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatinine Increased; Oliguria | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, 5 Mg/MI Qd | | Gilead |
| | Potassium Chloride | | | C | | Unk | | Not Reported |
| | Etomidate | | | C | | Unk | | Not Reported |
| | Succinylcholine Bromide | | | C | | Unk | | Not Reported |
| | Fentanyl | | | C | | Unk | | Not Reported |
| | Naloxone | | | C | | Unk | | Not Reported |
| | Piperacillin/Tazobactam | | | C | | Unk | | Not Reported |
| | Norepinephrine | | | C | | Unk | | Not Reported |
| | Epoprostenol | | | C | | Unk | | Not Reported |
| | Famotidine | | | C | | Unk | | Not Reported |
| Aspirin (E.C.) | | | C | | Unk | | Not Reported | |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | | | |
|--------------------------------|---|---------------------------------------|--------------|--------------|
| Bisacodyl Sandoz | C | Unk | Not Reported | |
| Gabapentin | C | Unk | Not Reported | |
| Insulin Lispro | C | | Not Reported | |
| Propofol | C | Unk | Not Reported | |
| Senna Acutifolia | C | Unk | Not Reported | |
| Furosemide [Furosemide Sodium] | C | Intravenous (not otherwise specified) | 40 Mg, Once | Not Reported |
| Hydroxychloroquine | C | Unk | Not Reported | |
| Enoxaparin | C | Unk | Not Reported | |
| Heparin | C | Unk | Not Reported | |
| Metolazone | C | 10 Mg | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810951 | DIRECT | Y | | | | 58 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Vomiting | Remdesivir | Y | | S | Intravenous drip | | 5 DAY | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810957 | DIRECT | Y | OT | | | 74 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|------------|
| Burning Sensation | Remdesivir | | | S | Intravenous bolus | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810962 | DIRECT | Y | OT | | | 69 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|------------------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatinine Increased; Blood Urea Increased | Remdesivir Iv | Y | | S | Intravenous drip | | | Gilead |
| | Insulin Aspart Sliding Scale | | | C | | | | Not Reported |
| | Metoprolol Injection | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--------------------------|---|--------------|
| Cisatracurium Injection | C | Not Reported |
| Norepinephrine Injection | C | Not Reported |
| Propofol Injection | C | Not Reported |
| Fentanyl Injection | C | Not Reported |
| Vasopressin Injection | C | Not Reported |
| Vancomycin Injection | C | Not Reported |
| Cefepime Injection | C | Not Reported |
| Enoxaparin Injection | C | Not Reported |
| Pantoprazole Injection | C | Not Reported |
| Tocilizumab Injection | C | Not Reported |
| Digoxin Injection | C | Not Reported |
| Melatonin Tablet | C | Not Reported |
| Aspirin 325mg Tablet | C | Not Reported |
| Furosemide Injection | C | Not Reported |
| Metolazone Tablet | C | Not Reported |
| Insulin Glargine | C | Not Reported |
| Atorvastatin Tablet | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810969 | DIRECT | Y | OT | | | 57 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Blood Bilirubin Increased | Remdesivir | | | S | | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810975 | DIRECT | Y | HO, OT | | | 73 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Blood Creatinine Increased; Glomerular Filtration Rate Decreased | Remdesivir Remdesivir | | | S C | | | | Gilead Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810977 | DIRECT | Y | OT | | | 21 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|----------------------------|-----------------|------------|
| Haemofiltration | Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:Stat Dose; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810978 | DIRECT | Y | | | | 77 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|--------------|------------------|--------------------|-----------------|------------|
| Blood Creatine Increased; Haemofiltration | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Tocilizumab | | | C | | Not Reported | | |
| | Linezolid | | | C | | Not Reported | | |
| | Enoxaparin | | | C | | Not Reported | | |
| | Vitamin C | | | C | | Not Reported | | |
| | Thiamine | | | C | | Not Reported | | |
| | Pepcid | | | C | | Not Reported | | |
| | Zinc | | | C | | Not Reported | | |
| | Precedex | | | C | | Not Reported | | |
| | Fentanyl | | | C | | Not Reported | | |
| | Propofol | | | C | | Not Reported | | |
| Rocuronium | | | C | Not Reported | | | | |
| Cisatracurium | | | C | Not Reported | | | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810988 | DIRECT | Y | | | | 60 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Renal Impairment; Renal Injury | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17810994 | DIRECT | Y | OT | | | 55 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Hypotension; Infusion Related Reaction | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811012 | DIRECT | Y | OT | | | 35 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Blood Creatinine Increased; Renal Impairment; Respiratory Failure | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Amlodipine 10 Mg Daily | | | C | | | | Not Reported |
| | Ascorbic Acid 500 Mg Po Bid | | | C | | | | Not Reported |
| | Aspirin 81 Mg Po Daily | | | C | | | | Not Reported |
| | Ceftriaxone 1g Iv Daily | | | C | | | | Not Reported |
| | Dextrose 5% Iv, 100 Ml/Hr | | | C | | | | Not Reported |
| | Diphenhydramine 25 Mg Iv X 1 | | | C | | | | Not Reported |
| | Doxycycline 100 Mg Po Bid | | | C | | | | Not Reported |
| | Doxycycline Suspension 100 Mg Po Bid | | | C | | | | Not Reported |
| | Enoxaparin 40 Mg Sq Bid | | | C | | | | Not Reported |
| | Famotidine 20 Mg Bid | | | C | | | | Not Reported |
| | Fentanyl Iv Infusion | | | C | | | | Not Reported |
| | Furosemide Iv 20 Mg X1 Then 40 Mg Bid | | | C | | | | Not Reported |
| | Hydralazine 10 Mg Iv Q4h Prn | | | C | | | | Not Reported |
| | Regular Insulin Infusion | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Ketamine Infusion | | | C | | | | Not Reported |
| | Methylprednisolone Iv | | | C | | | | Not Reported |
| | Montelukast | | | C | | | | Not Reported |
| Ondansetron | | | C | | | | Not Reported | |
| Tocilizumab Iv | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811020 | DIRECT | Y | DE | | | 72 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Aspirin | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Cefazolin | | | C | | | | Not Reported |
| | Cisatricurium | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Hydrocortisone | | | C | | | | Not Reported |
| | Hydroxychloroquine | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Lansoprazole | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Rocuronium | | | C | | | | Not Reported |
| | Sodium Bicarbonate | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Vecuronium | | | C | | | | Not Reported |
| | Angiotensin li | | | C | | | | Not Reported |
| | Hydromorphone | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Vasopressin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811029 | DIRECT | Y | OT | | | 72 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir Injection | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Benzonatate | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Guaifenesin | | | C | | | | Not Reported |
| | Potassium Chloride | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Nebivolol | | | C | | | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

Valsartan C Not Reported
Vancomycin C Not Reported

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811036 | DIRECT | Y | | | | 66 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--|--------------------|-----------------|------------|
| Acute Respiratory Failure; Blood Creatinine Increased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811043 | DIRECT | Y | OT | | | 56 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Glomerular Filtration Rate Decreased; Therapy Interrupted | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Amlodipine | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Insulin Aspart | | | C | | | | Not Reported |
| | Insulin Detemir | | | C | | | | Not Reported |
| | Duo-Neb | | | C | | | | Not Reported |
| | Linezolid | | | C | | | | Not Reported |
| | Morphine | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| Fentanyl | | | C | | | | Not Reported | |
| Midazolam | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811050 | DIRECT | Y | DE | | | 76 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|------------|
| General Physical Health Deterioration; Respiratory Failure; Septic Shock; | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

Therapy Cessation

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811056 | DIRECT | Y | OT | | | 71 YR | Male | AFG |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|--------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Platelet Count Decreased | Remdesivir | Y | | S | Intravenous drip | | | Gilead |
| | Flomax | | | C | | | | Not Reported |
| | Vitamin C 1000mg | | | C | | | | Not Reported |
| | Zinc 220 | | | C | | | | Not Reported |
| | Allopurinol 300mg | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Benzonatate | | | C | | | | Not Reported |
| | Ceftriazone 1gm | | | C | | | | Not Reported |
| | Dipyridamole | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Zestoretic | | | C | | | | Not Reported |
| | Meropenem | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| Prednisone | | | C | | | Not Reported | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811063 | DIRECT | Y | | | | 49 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased | Remdesivir | Y | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811080 | DIRECT | Y | DE | | | 70 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Ventricular Fibrillation | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |
| | Albumin 5% 25g | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--|---|--------------|
| Bumetanide 1mg Q12h | C | Not Reported |
| Calcium 500mg With Vit D 5mcg 2 Daily | C | Not Reported |
| Ceftriaxone 2g Iv Daily | C | Not Reported |
| Enoxaparin 80mg Bid | C | Not Reported |
| Furosemide 20mg Once | C | Not Reported |
| Norepinephrine 4mg/250ml Infusion | C | Not Reported |
| Oxycodone 5mg Q6h | C | Not Reported |
| Pantoprazole 40mg Q12h | C | Not Reported |
| Propofol Infusion 25mcg/Kg/Min | C | Not Reported |
| Psyllium 58.6% Packet | C | Not Reported |
| Ribavirin 600mg Q8h | C | Not Reported |
| Sertraline 150mg Daily | C | Not Reported |
| Vitamin D 2000 Units Daily | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811088 | DIRECT | Y | OT | | | 27 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Blood Alkaline Phosphatase Increased; Haemofiltration; Liver Function Test Increased; Renal Impairment; Right Ventricular Dysfunction | Remdesivir Via Emergency Use Authorization Covid-19 Convalescent Plasma Tocilizumab 400 Mg Iv In 100 MI Nacl Tocilizumab 400 Mg Iv In 100 MI Nacl | | | S | Intravenous drip | | | Not Reported |
| | | | | C | | | | Not Reported |
| | | | | C | | | | Not Reported |
| | | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811092 | DIRECT | Y | HO, LT, OT | | | 34 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------------|---|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Blister; Erythema; Rash Macular | Remdesivir Acetaminophen Morphine Vancomycin | | | S | | | | Gilead |
| | | | | C | | | | Not Reported |
| | | | | C | | | | Not Reported |
| | | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|------------------------|---|--------------|
| Potassium Chloride | C | Not Reported |
| Tocilizumab Or Placebo | C | Not Reported |
| Furosemide | C | Not Reported |
| Famotidine | C | Not Reported |
| Enoxaparin | C | Not Reported |
| Ceftriaxone | C | Not Reported |
| Albuterol | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811136 | DIRECT | Y | DS, HO, LT, OT | | | 42 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|----------------------------|------------------|--------------------|-----------------|--|
| Eye Movement Disorder; Hypoxia; Lung Infiltration; Miosis; Pyrexia; Respiratory Distress; Tachycardia; Unresponsive To Stimuli; Unresponsive To Stimuli | Remdesivir Acetaminophen 650mg Po Q4h Prn Azithromycin 500mg Po Daily Enoxaparin 40mg Subq Daily Famotidine 20mg Po Daily Ondansetron 4mg Iv Q6h Prn | | | S C C C C C | Intravenous drip | | | Gilead Not Reported Not Reported Not Reported Not Reported Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 20-May-2020 | 17811139 | DIRECT | Y | HO, LT | | | 53 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|--|--------------|--------------------|-----------------|--|
| Oxygen Saturation Decreased; Respiratory Distress | Remdesivir Albuterol Cyclobenzaprine Aspirin Ec Doxycycline Atorvastatin Pyridostigmine Calcium Carbonate Ceftriaxone Acetaminophen Zinc Ondansetron Diphenhydramine Amiodarone | | | S C C C C C C C C C C C C C | | | | Gilead Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| Famotidine | | | C | | | | Not Reported | | |
|---|--|------------------|--------------------|-----------------|--|----------------------------------|-----------------|--------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 20-May-2020 | 17811147 | DIRECT | Y | DS, HO, LT | | | 60 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Carotid Artery Occlusion; Ischaemic Stroke | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Acetaminophen | | | C | | | | Not Reported | |
| | Aspirin | | | C | | | | Not Reported | |
| | Azithromycin | | | C | | | | Not Reported | |
| | Ceftriaxone | | | C | | | | Not Reported | |
| | Furosemide | | | C | | | | Not Reported | |
| | Hydroxychloroquine Or Placebo | | | C | | | | Not Reported | |
| | Magnesium Sulfate | | | C | | | | Not Reported | |
| | Potassium Bicarbonate | | | C | | | | Not Reported | |
| | Enoxaparin | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 20-May-2020 | 17811158 | DIRECT | Y | DE | | | 60 YR | Male | ALB |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Bradycardia; Oxygen Saturation Decreased | Remdesivir | | | S | | Other Frequency:Loading Dose; | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 20-May-2020 | 17812033 | DIRECT | Y | | | | 63 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Hypotension; Rash; Tachycardia | Remdesivir (Eua) (Remdesivir (Eua)) | | | S | Intravenous (not otherwise specified) | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 21-May-2020 | 17812217 | DIRECT | Y | DE | | | 71 YR | Female | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--|--------------------|-----------------|------------|
| Hepatic Failure; Hypertension; Hypotension; Multiple Organ Dysfunction Syndrome; Oxygen Saturation Decreased | Remdesivir | | | S | Intravenous (not otherwise specified) | | 1 DAY | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812224 | DIRECT | Y | DE | | | 41 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Condition Aggravated; Lung Disorder; Pulmonary Embolism; Sudden Death | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Remdesivir | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812243 | DIRECT | Y | DE | | | 73 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---------------------|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Death | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Sarilumab | | | C | | | | Not Reported |
| | Apixaban | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Polyethylene Glycol | | | C | | | | Not Reported |
| | Sennosides | | | C | | | | Not Reported |
| | Bisacodyl | | | C | | | | Not Reported |
| | Zinc Sulfate | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Hydralazine | | | C | | | | Not Reported |
| | Ferrous Sulfate | | | C | | | | Not Reported |
| | Docusate | | | C | | | | Not Reported |
| | Metoprolol | | | C | | | | Not Reported |
| | Ropinorole | | | C | | | | Not Reported |
| | Tamsulosin | | | C | | | | Not Reported |
| Carbidopa/Levodopa | | | C | | | | Not Reported | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|--------------|---|--------------|
| Losartan | C | Not Reported |
| Paroxetine | C | Not Reported |
| Finasteride | C | Not Reported |
| Pantoprazole | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812244 | DIRECT | Y | DE | | | 79 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Death | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Morphine Pca | | | C | | | | Not Reported |
| | Levetiracetam | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Cyanocobalamin | | | C | | | | Not Reported |
| | Folic Acid | | | C | | | | Not Reported |
| | Finasteride | | | C | | | | Not Reported |
| | Terazosin | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812245 | DIRECT | Y | OT | | | 50 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Chills; Hypotension | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812248 | DIRECT | Y | | | | 67 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Poor Quality Product Administered; Product Storage Error | Remdesivir | | | S | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812559 | DIRECT | Y | OT | | | 64 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Hyperhidrosis; Hypotension; Vomiting | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Precedex | | | C | | | | Not Reported |
| | Diltiazem | | | C | | | | Not Reported |
| | Docusate | | | C | | | | Not Reported |
| | Duloxetine | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Ferrous Sulfate | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Haloperidol | | | C | | | | Not Reported |
| | Hydralazine | | | C | | | | Not Reported |
| | Lantus | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Lactobacillus | | | C | | | | Not Reported |
| | Lorazepam | | | C | | | | Not Reported |
| | Magnesium Oxide | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Potassium Chloride | | | C | | | | Not Reported |
| | Lyrica | | | C | | | | Not Reported |
| Seroquel | | | C | | | | Not Reported | |
| Terazosin | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812562 | DIRECT | Y | OT | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Infusion Site Extravasation | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Remdesivir | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812592 | DIRECT | Y | | | | 69 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|--------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Liver Function Test Increased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Propofol | | | C | | | | Not Reported |
| | Zosyn | | | C | | | | Not Reported |
| | Levophed | | | C | | | | Not Reported |
| | Sinemet | | | C | | | | Not Reported |
| | Dilaudid | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Actemra | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812596 | DIRECT | Y | OT | | | 74 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Supraventricular Tachycardia | Remdesivir | | | S | | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17812599 | DIRECT | Y | | | | 39 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Dysphagia; Throat Irritation | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17813534 | EXPEDITED (15-DAY) | | | US-GILEAD-2020-0467788 | | 11 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Device Malfunction; Medication Error | Remdesivir | | | S | Intravenous (not otherwise specified) | Unk | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17815405 | DIRECT | Y | OT | | | 53 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Hepatic Enzyme Increased | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17815427 | DIRECT | Y | | | | 69 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------------------------|--------------|------------|-------------|---------------------------------------|------------------------------------|-----------------|--------------|
| Body Temperature Increased; Condition Aggravated | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:X1 Then100mg Q24h; | 5 DAY | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Amlodipine | | | C | | | | Not Reported |
| | Apixaban | | | C | | | | Not Reported |
| | Aspirin (Enteric Coated) 81 Mg Daily | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Benzotropine | | | C | | | | Not Reported |
| | Carvedilol | | | C | | | | Not Reported |
| | Divalproex | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Guaifenesin + Codeine Prn | | | C | | | | Not Reported |
| | Tamsulosin | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin, Regular (Sliding Scale) | | | C | | | | Not Reported |
| | Ipratropium And Albuterol Inhalation | | | C | | | | Not Reported |
| | Loratadine | | | C | | | | Not Reported |
| Methylprednisolone Sodium Succinate | | | C | | | | Not Reported | |
| Montelukast | | | C | | | | Not Reported | |
| Morphine, Intravenous (Prn) | | | C | | | | Not Reported | |
| Ibrutinib | | | C | | | | Not Reported | |
| Pantoprazole | | | C | | | | Not Reported | |
| Quetiapine (And I Ran Out Of | | | C | | | | Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

Room: Zosyn)

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 21-May-2020 | 17815613 | DIRECT | Y | RI | | | 61 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Blood Creatinine Increased; Dialysis | Remdesivir | | | S | | | | Gilead |
| | Remdesivir | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17763474 | EXPEDITED (15-DAY) | | HO | US-ROCHE-2594510 | | 47 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Deep Vein Thrombosis; Intentional Product Use Issue; Off Label Use | Actemra | | | S | Intravenous (not otherwise specified) | | | Not Reported |
| | Remdesivir | | | S | Unknown | | | Not Reported |
| | Hydroxychloroquine | | | S | Unknown | | | Not Reported |
| | Hydroxychloroquine | | | S | Unknown | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Oxygen | | | C | | | | Not Reported |
| | Loperamide | | | C | | | | Not Reported |
| | Lovenox [Enoxaparin Sodium] | | | C | | | | Not Reported |
| | Zosyn | | | C | | | | Not Reported |
| | Tylenol | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Zithromax | | | C | | | | Not Reported |
| | Calcium Gluconate | | | C | | | | Not Reported |
| | Potassium Chloride | | | C | | | | Not Reported |
| | Cholecalciferol | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Multivitamin And Mineral | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17815622 | DIRECT | Y | DE | | | 67 YR | Female | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------------------------|--------------|------------|--------------|---------------------------------------|--------------------|-----------------|------------|
| Acute Respiratory Distress Syndrome; Cardiac Arrest; Pulseless Electrical Activity; Respiratory Failure | Remdesivir Injection | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Cefepime | | | C | | Not Reported | | |
| | Azithromycin | | | C | | Not Reported | | |
| | Diltiazem | | | C | | Not Reported | | |
| | Enoxaparin | | | C | | Not Reported | | |
| | Lorazepam | | | C | | Not Reported | | |
| | Magnesium Sulfate | | | C | | Not Reported | | |
| | Metoprolol Tartrate | | | C | | Not Reported | | |
| | Potassium Chloride | | | C | | Not Reported | | |
| | Sodium Chloride 0.9% Iv Solution | | | C | | Not Reported | | |
| | Hydralazine | | | C | | Not Reported | | |
| | Morphine | | | C | | Not Reported | | |
| | Vecuronium | | | C | | Not Reported | | |
| | Epinephrine Drip | | | C | | Not Reported | | |
| | Phenylephrine Drip | | | C | | Not Reported | | |
| Propofol Drip | | | C | Not Reported | | | | |
| Sodium Bicarbonate Drip | | | C | Not Reported | | | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17815629 | DIRECT | Y | OT | | | 77 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Blood Creatinine Increased; Dialysis | Remdesivir Injection | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Cefepime | | | C | | Not Reported | | |
| | Enoxaparin | | | C | | Not Reported | | |
| | Duoneb | | | C | | Not Reported | | |
| | Pantoprazole | | | C | | Not Reported | | |
| | Sodium Chloride 0.9% Iv Solution | | | C | | Not Reported | | |
| | Propofol | | | C | | Not Reported | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17815634 | DIRECT | Y | OT | | | 78 YR | Female | USA |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Disseminated Intravascular Coagulation; General Physical Health Deterioration; Hypotension; Hypothermia; Infusion Related Reaction | Remdesivir Injection | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Aspirin | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Duoneb | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Valacyclovir | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17815658 | DIRECT | Y | DE | | | 59 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|------------|
| Acidosis; Acute Kidney Injury; Blood Lactic Acid Increased; Cardio-Respiratory Arrest; Haemoglobin Decreased; Hypotension; White Blood Cell Count Increased | Remdesivir | | | S | Intravenous bolus | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17815906 | DIRECT | | DE, HO | | | 69 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Acidosis; Disseminated Intravascular Coagulation; Hypoxia; Paralysis; Renal Failure; Shock | Remdesivir | | | S | | | | Not Reported |
| | Naloxone | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Inhaled Epoprostenol | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Aspirin Chewable | | | C | | | | Not Reported |
| | Gabapentin | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|-----------------|---|--------------|
| Fentanyl | C | Not Reported |
| Propofol | C | Not Reported |
| Lasix | C | Not Reported |
| Enoxaparin | C | Not Reported |
| Heparin | C | Not Reported |
| Metolazone | C | Not Reported |
| Etomidate | C | Not Reported |
| Succinylcholine | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816199 | DIRECT | Y | | | | 44 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Incorrect Dose Administered; Product Dispensing Error | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Albuterol Nebulizer | | | C | | | | Not Reported |
| | Carvedilol | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Hydrocortisone | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816200 | DIRECT | Y | DE | | | 66 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Blood Alkaline Phosphatase Increased; Blood Prolactin Increased; Cardiac Failure Congestive; Lung Disorder; Oxygen Saturation Decreased | Remdesivir Under Emergency Use Authorization (Eua) | | | S | Intravenous (not otherwise specified) | | 4 DAY | Gilead |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|--|------------------|--------------------|-----------------|---------------------------------------|-----------------------|-----------------|--------------|----------------|
| 22-May-2020 | 17816201 | DIRECT | Y | DE | | | 80 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Dialysis; Metabolic Acidosis; Pneumonia Viral | Remdesivir Under Emergency Use Authorization (Eua) | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | 1 DAY | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 22-May-2020 | 17816202 | DIRECT | Y | OT | | | 67 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Liver Function Test Increased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Cefepime | | | C | | | | Not Reported | |
| | Doxycycline | | | C | | | | Not Reported | |
| | Enoxaparin 40 Mg Bid | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 22-May-2020 | 17816203 | DIRECT | Y | OT | | | 68 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Bilirubin Increased | Remdesivir Eua | | | S | | | | Not Reported | |
| | Doxycycline | | | C | | | | Not Reported | |
| | Zosyn | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 22-May-2020 | 17816204 | DIRECT | Y | HO | | | 82 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Covid-19 Pneumonia; | Remdesivir | | | S | | | | Not Reported | |

Disease Progression

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816205 | DIRECT | Y | OT | | | 56 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Blood Creatinine Increased; Renal Impairment | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Acetaminophen-Hydrocodone | | | C | | | | Not Reported |
| | Albuterol-Ipratropium | | | C | | | | Not Reported |
| | Apixaban | | | C | | | | Not Reported |
| | Dexmedetomidine | | | C | | | | Not Reported |
| | Baclofen | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Doxycycline | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Ferrous Sulfate | | | C | | | | Not Reported |
| | Fluconazole | | | C | | | | Not Reported |
| | Fluconazole | | | C | | | | Not Reported |
| | Folic Acid | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Meropenem | | | C | | | | Not Reported |
| Tocilizumab | | | C | | | | Not Reported | |
| Vancomycin | | | C | | | | Not Reported | |
| Norepinephrine | | | C | | | | Not Reported | |
| Propofol | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816206 | DIRECT | Y | LT, OT | | | 66 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|---------------------------------|-----------------|------------|
| Atrial Fibrillation | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once Once Load; | 5 DAY | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816207 | DIRECT | Y | DE | | | 75 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------------------|--------------------------|--------------|------------|--------------|--|--------------------|-----------------|------------|
| Condition Aggravated; Covid-19 | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Metoprolol | | | C | | Not Reported | | |
| | Albuterol 2 Mg/5ml Syrup | | | C | | Not Reported | | |
| | Cholecalciferol | | | C | | Not Reported | | |
| | Zinc Sulfate | | | C | | Not Reported | | |
| | Ascorbic Acid | | | C | | Not Reported | | |
| | Acetaminophen | | | C | | Not Reported | | |
| | Risperidone | | | C | | Not Reported | | |
| | Mirtazipine | | | C | | Not Reported | | |
| | Trazodone | | | C | | Not Reported | | |
| | Risperidone | | | C | | Not Reported | | |
| | Rosuvastatin | | | C | | Not Reported | | |
| Rivaroxaban | | | C | Not Reported | | | | |
| Folic Acid | | | C | Not Reported | | | | |
| Pantoprazole | | | C | Not Reported | | | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816208 | DIRECT | | HO | | | 62 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Hypotension | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816211 | DIRECT | Y | | | | 78 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------------|--------------|------------|-------------|------------------|-----------------------|-----------------|------------|
| Agitation; Anxiety; Hallucination, Visual; Intensive Care Unit Delirium | Remdesivir | | | S | Intravenous drip | Other Frequency:Once; | | Gilead |
| | Lorazepam Iv 0.25 Mg | | | C | | | Not Reported | |
| | Gabapentin 100 Mg | | | C | | | Not Reported | |
| | Requip 1 Mg | | | C | | | Not Reported | |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|----------------------|------------------|--------------------|-----------------|----------------------|---------------------------------------|------------------------------------|-----------------|----------------|
| 22-May-2020 | 17816477 | DIRECT | Y | OT | | | 75 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Transaminases Increased | Remdesivir Injection | | | | S | Intravenous (not otherwise specified) | Other F | | Gilead |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 22-May-2020 | 17816490 | DIRECT | Y | OT | | | 59 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Transaminases Increased | Remdesivir Injection | | | | S | Intravenous (not otherwise specified) | Other Frequency:Dosing Event Desc; | | Gilead |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 22-May-2020 | 17816502 | DIRECT | Y | OT | | | 87 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Liver Function Test Increased; Sars-Cov-2 Test Positive | Remdesivir | | Y | | S | Intravenous drip | Other Frequency:Once; | | Gilead |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 22-May-2020 | 17816556 | DIRECT | Y | HO, OT | | | 84 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Blood Creatinine Increased; Covid-19 | Remdesivir | | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Atorvastatin | | | | C | | | | Not Reported |
| | Diltiazem | | | | C | | | | Not Reported |
| | Enoxaparin | | | | C | | | | Not Reported |
| | Furosemide | | | | C | | | | Not Reported |
| | Insulin | | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--------------|---|--------------|
| Metoprolol | C | Not Reported |
| Pantoprazole | C | Not Reported |
| Lorazepam | C | Not Reported |
| Fentanyl | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816562 | DIRECT | Y | OT | | | 53 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Transaminases Increased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816575 | DIRECT | Y | HO | | | 43 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Aspartate Aminotransferase Increased; Blood Creatinine Increased; Renal Impairment; Septic Shock | Remdesivir | Y | | S | Intravenous drip | | | Gilead |
| | Furosemide 40 Mg Iv | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17816997 | DIRECT | Y | HO | | | 65 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatinine Increased; Haemodialysis | Remdesivir Solution For Injection | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Enoxaparin | | | C | | | | Not Reported |
| | Dexmedetomidine | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Nicotine Patch | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17817002 | DIRECT | Y | OT | | | 69 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Clinical Trial Participant; Product Use In Unapproved Indication; Renal Replacement Therapy; Respiratory Failure; Shock | Remdesivir Under Emergency Use Authorization (Eua). | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Fentanyl Infusion | | | C | | | | Not Reported |
| | Insulin Regular (Humulin R) | | | C | | | | Not Reported |
| | Sliding Scale | | | | | | | |
| | Propofol Infusion | | | C | | | | Not Reported |
| | Enoxaparin (Lovenox) | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| Norepinephrine (Levophed) | | | C | | | | Not Reported | |
| Vasopressin | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17817004 | DIRECT | Y | OT | | | 39 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Clinical Trial Participant; Hepatic Enzyme Increased; Product Use In Unapproved Indication | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17818496 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0468321 | | 72 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acidosis; Acute Kidney Injury; Acute Respiratory Distress Syndrome; Covid-19 Pneumonia; Hypernatraemia; Renal Impairment | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Enoxaparin [Enoxaparin Sodium] | | | C | | 100 Mg | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|-----------------------------------|---|--|--------------|
| Insulin | C | Unk | Not Reported |
| Methylprednisolone | C | Unk | Not Reported |
| Lorazepam A | C | Unk | Not Reported |
| Levophed | C | Unk | Not Reported |
| Dopamine | C | Unk | Not Reported |
| Epinephrine Hydrochloride | C | Unk | Not Reported |
| Phenylephrine | C | Unk | Not Reported |
| Epoprostenol | C | Unk | Not Reported |
| Vancomycin | C | Unk | Not Reported |
| Piperacillin/Tazobactam | C | Unk | Not Reported |
| Heparin | C | Unk | Not Reported |
| Amiodarone | C | Unk | Not Reported |
| Ketamine [Ketamine Hydrochloride] | C | Unk | Not Reported |
| Morphine | C | Unk | Not Reported |
| Rocuronium | C | Unk | Not Reported |
| Tocilizumab | C | Intravenous (not otherwise specified) 800 Mg | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17818529 | EXPEDITED (15-DAY) | | DE, LT, OT | US-GILEAD-2020-0468184 | | 77 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Death | Remdesivir | | | S | Intravenous (not otherwise specified) | Unk | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Cefepime | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Thiamine | | | C | | | | Not Reported |
| | Doxycycline | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--------------|---|--------------|
| Sertraline A | C | Not Reported |
| Tamsulosin | C | Not Reported |
| Zinc | C | Not Reported |
| Ipratropium | C | Not Reported |
| Enoxaparin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17818539 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0468282 | | 53 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Bradycardia; Pulseless Electrical Activity | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |
| | Oxcarbazepine | | | C | | Unk | | Not Reported |
| | Amlodipine | | | C | | Unk | | Not Reported |
| | Enoxaparin | | | C | | Unk | | Not Reported |
| | Famotidine | | | C | | Unk | | Not Reported |
| | Insulin Lispro | | | C | | Unk | | Not Reported |
| | Levetiracetam | | | C | | Unk | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17818552 | EXPEDITED (15-DAY) | | DE, LT, OT | US-GILEAD-2020-0468312 | | 72 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Hypoxia; Respiratory Failure; Shock | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Convalescent Plasma | | | C | | Unk | | Not Reported |
| | Ondansetron | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Phenylephrine | | | C | | | | Not Reported |
| | Potassium Phosphate Dibasic | | | C | | | | Not Reported |
| | Potassium Chloride | | | C | | | | Not Reported |
| | Primasate Bk0/3.5 | | | C | | | | Not Reported |
| | Primasol | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |

| | | | |
|-----------------------|---|-----|--------------|
| Scopolamine Aminoxide | C | | Not Reported |
| Sodium Chloride | C | | Not Reported |
| Vancomycin | C | Unk | Not Reported |
| Vasopressin | C | | Not Reported |
| Vitamin B12 Aaa | C | | Not Reported |
| Zinc Sulfate | C | | Not Reported |
| Cefepime | C | | Not Reported |
| Chlorhexidine | C | | Not Reported |
| Cisatracurium | C | | Not Reported |
| Dexmedetomidine | C | | Not Reported |
| Normosol | C | | Not Reported |
| Enoxaparin | C | | Not Reported |
| Epinephrine | C | | Not Reported |
| Fentanyl | C | | Not Reported |
| Heparin | C | | Not Reported |
| Hydroxychloroquine | C | | Not Reported |
| Iopamidol | C | | Not Reported |
| Lactated Ringers | C | | Not Reported |
| Lorazepam | C | | Not Reported |
| Magnesium Sulfate | C | | Not Reported |
| Melatonin | C | | Not Reported |
| Metoprolol Tartrate | C | | Not Reported |
| Morphine | C | | Not Reported |
| Norepinephrine | C | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17818827 | EXPEDITED (15-DAY) | | HO, LT, OT | US-GILEAD-2020-0468514 | | 52 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Respiratory Distress | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg | | Gilead |
| | Convalescent Plasma | | | C | | | | Not Reported |
| | Cyclobenzaprine | | | C | | Unk | | Not Reported |
| | Aspirin Ec | | | C | | Unk | | Not Reported |
| | Doxycycline | | | C | | Unk | | Not Reported |
| | Pyridostigmine | | | C | | Unk | | Not Reported |
| | Atorvastatin | | | C | | Unk | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|------------------------|---|-----|--------------|
| Calcium Carbonate | C | Unk | Not Reported |
| Zinc | C | Unk | Not Reported |
| Ondansetron | C | Unk | Not Reported |
| Diphenhydramine | C | Unk | Not Reported |
| Amiodarone | C | Unk | Not Reported |
| Famotidine | C | Unk | Not Reported |
| Ceftriaxone | C | Unk | Not Reported |
| Acetaminophen | C | Unk | Not Reported |
| Albuterol [Salbutamol] | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17818831 | EXPEDITED (15-DAY) | | DE | US-GILEAD-2020-0468218 | | 96 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Covid-19 | Remdesivir | | | S | Unknown | 200 Mg, Once | | Gilead |
| | Remdesivir | | | S | Unknown | 100 Mg, Qd | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17818858 | EXPEDITED (15-DAY) | | HO, LT, OT | US-GILEAD-2020-0468531 | | 34 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Blister; Erythema; Rash Macular; Rash Vesicular | Remdesivir | | | S | Unknown | Unk Mg | | Gilead |
| | Remdesivir | | | S | Unknown | Unk Mg | | Gilead |
| | Acetaminophen | | | C | | Unk | | Not Reported |
| | Morphine | | | C | | | | Not Reported |
| | Vancomycin | | | C | | Unk | | Not Reported |
| | Potassium Chloride | | | C | | Unk | | Not Reported |
| | Tocilizumab | | | C | | Unk | | Not Reported |
| | Furosemide | | | C | | Unk | | Not Reported |
| | Famotidine | | | C | | Unk | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | | |
|------------------------|---|-----|--------------|
| Enoxaparin | C | Unk | Not Reported |
| Ceftriaxone | C | Unk | Not Reported |
| Albuterol [Salbutamol] | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17818878 | EXPEDITED (15-DAY) | | DS, HO, LT, OT | US-GILEAD-2020-0468569 | | 60 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|--------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Cerebrovascular Accident | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Remdesivir | | | S | | | | Gilead |
| | Acetaminophen | | | C | | Unk | | Not Reported |
| | Aspirin [Acetylsalicylic Acid] | | | C | | Unk | | Not Reported |
| | Azithromycin | | | C | | Unk | | Not Reported |
| | Ceftriaxone | | | C | | Unk | | Not Reported |
| | Furosemide | | | C | | Unk | | Not Reported |
| | Hydroxychloroquine | | | C | | Unk | | Not Reported |
| | Magnesium Sulfate | | | C | | Unk | | Not Reported |
| | Potassium Bicarbonate | | | C | | Unk | | Not Reported |
| | Enoxaparin | | | C | | Unk | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17819757 | DIRECT | Y | RI | | | 56 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Clinical Trial Participant; Product Use In Unapproved Indication; Renal Replacement Therapy | Remdesivir (Eua) 100mg Vial | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Remdesivir (Eua) 100 Mgvial | Y | | S | Intravenous (not otherwise specified) | Every 24 Hr | | Gilead |
| | Norepinephrine | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Albumin | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|---------------|---|--------------|
| Azithromycin | C | Not Reported |
| Bumetanide | C | Not Reported |
| Ceftriaxone | C | Not Reported |
| Clonazepam | C | Not Reported |
| Desmopressin | C | Not Reported |
| Docusate | C | Not Reported |
| Dopamine | C | Not Reported |
| Enoxaparin | C | Not Reported |
| Epoprostenol | C | Not Reported |
| Famotidine | C | Not Reported |
| Fentanyl | C | Not Reported |
| Furosemide | C | Not Reported |
| Heparin | C | Not Reported |
| Hydromorphone | C | Not Reported |
| Ketamine | C | Not Reported |
| Insulin | C | Not Reported |
| Midodrine | C | Not Reported |
| Phenylephrine | C | Not Reported |
| Propofol | C | Not Reported |
| Rocuronium | C | Not Reported |
| Sennosides | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17822985 | DIRECT | Y | OT | | | 61 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Atrial Fibrillation | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Norepinephrine | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17822988 | DIRECT | Y | | | | 44 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | | | | |
|---------------------------|----------------------|---|---|---------------------------------------|--------|
| Product Preparation Error | Remdesivir Injection | Y | S | Intravenous (not otherwise specified) | Gilead |
|---------------------------|----------------------|---|---|---------------------------------------|--------|

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17822990 | DIRECT | Y | OT | | | 35 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Blood Creatinine Increased; Therapy Cessation | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17822997 | DIRECT | Y | OT | | | 74 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--|--------------|------------|-------------|---------------------------------------|-----------------------------|-----------------|--------------|
| Continuous Haemodiafiltration; Respiratory Failure; Thrombosis In Device; Urine Output Decreased | Remdesivir | | | S | Intravenous bolus | Other Frequency:Once, Then; | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Convalescent Plasma Tocilizumab Or Placebo Trial | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 22-May-2020 | 17823220 | DIRECT | Y | RI | | | 60 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acidosis; Acute Kidney Injury | Remdesivir (Eua) 100 Mg Vial | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Remdesivir (Eua) 100 Mg Vial | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Albumin | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|-------------------------|---|--------------|
| Albuterol | C | Not Reported |
| Bumetanide | C | Not Reported |
| Caffeine Citrate | C | Not Reported |
| Chlorothiazide | C | Not Reported |
| Enoxaparin | C | Not Reported |
| Famotidine | C | Not Reported |
| Furosemide | C | Not Reported |
| Gabapentin | C | Not Reported |
| Insulin Glargine | C | Not Reported |
| Insulin Lispro | C | Not Reported |
| Insulin Regular | C | Not Reported |
| Lactulose | C | Not Reported |
| Magnesium Sulfate | C | Not Reported |
| Methylprednisolone | C | Not Reported |
| Metolazone | C | Not Reported |
| Midazolam | C | Not Reported |
| Midodrine | C | Not Reported |
| Oxycodone | C | Not Reported |
| Piperacillin/Tazobactam | C | Not Reported |
| Potassium Chloride | C | Not Reported |
| Quetiapine | C | Not Reported |
| Rocuronium | C | Not Reported |
| Vancomycin | C | Not Reported |
| Dexmedetomidine | C | Not Reported |
| Epoprostenol | C | Not Reported |
| Heparin | C | Not Reported |
| Hydromorphone | C | Not Reported |
| Ketamine | C | Not Reported |
| Norepinephrine | C | Not Reported |
| Propofol | C | Not Reported |
| Vasopressin | C | Not Reported |
| Acetaminophen | C | Not Reported |
| Fentanyl | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 23-May-2020 | 17822998 | DIRECT | Y | | | | 50 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------------------|------------------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Cough; Hypoaesthesia; Pruritus | Remdesivir Eua | Y | | S | Intravenous drip | | | Gilead |
| | Ceftriaxone (Rocephin) 1,000 | | | C | | | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | | | | | | | | |
|--|--|--|--|---|--|--|--|--|--------------|
| Mg In 0.9 % Sodium Chloride (Ns) 50 MI Ad | | | | | | | | | |
| Enoxaparin (Lovenox) (Conc: 40 Mg/ 0.4 MI) Injection 40 Mg | | | | C | | | | | Not Reported |
| Benzonatate (Tessalon Perles) Capsule 100 Mg | | | | C | | | | | Not Reported |
| Dextromethorphan-Guaifenesin (Conc: 10-100 Mg/5 MI) (Robitussin Dm) Sy | | | | C | | | | | Not Reported |
| Ondansetron (Zofran) (Conc: 2 Mg/MI) Injection 4 Mg | | | | C | | | | | Not Reported |
| Polyethylene Glycol 3350 (Miralax) Packet 17 G | | | | C | | | | | Not Reported |
| Promethazine (Phenergan) 6.25 Mg In 0.9 % Sodium Chloride (Ns) 50 MI I | | | | C | | | | | Not Reported |
| Sennosides-Docusate Sodium (8.6-50 Mg/Tab) (Senna Plus) Tablet 2 Table | | | | C | | | | | Not Reported |
| Simvastatin (Zocor) Tablet 40 Mg | | | | C | | | | | Not Reported |
| Tramadol (Ultram) Tablet 50 Mg | | | | C | | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 23-May-2020 | 17823000 | DIRECT | Y | OT | | | 85 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Erythema; Pain | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 23-May-2020 | 17823003 | DIRECT | Y | DE | | | 74 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Hospice Care | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|----------------------|------------------|--------------------|-----------------|---------------------------------------|-----------------------|-----------------|--------------|----------------|
| 23-May-2020 | 17823009 | DIRECT | Y | OT | | | 39 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Malaise; Renal Impairment | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Atracurium | | | C | | | | Not Reported | |
| | Midazolam | | | C | | | | Not Reported | |
| | Furosemide | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 23-May-2020 | 17823018 | DIRECT | Y | HO, OT | | | 49 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatinine Increased | Remdesivir Injection | | | S | Intravenous drip | | | Gilead | |
| | Remdesivir | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 23-May-2020 | 17823020 | DIRECT | Y | LT | | | 64 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatinine Increased; Hyperkalaemia | Remdesivir | Y | | S | Intravenous drip | | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 23-May-2020 | 17823021 | DIRECT | Y | DE, DS | | | 68 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Renal Failure | Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead | |
| | Tocilizumab | | | C | | | | Not Reported | |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|--|------------------|--------------------|-----------------|---------------------------------------|-----------------------|-----------------|--------------|----------------|
| 23-May-2020 | 17823024 | DIRECT | Y | | | | 64 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir (5 Mg/MI Injection Concentrate) | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead | |
| | Ascorbic Acid 500 Mg Tab | | | C | | | | Not Reported | |
| | Azithromycin 500 Mg Ivpb | | | C | | | | Not Reported | |
| | Benzonatate 100 Mg Cap | | | C | | | | Not Reported | |
| | Ceftriaxone 1 Gm Ivpb | | | C | | | | Not Reported | |
| | Enoxaparin Inj | | | C | | | | Not Reported | |
| | Methylprednisolone 40 Mg Iv | | | C | | | | Not Reported | |
| | Zinc Sulfate 220 Mg Cap | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 23-May-2020 | 17823028 | DIRECT | Y | OT | | | 42 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatine Increased; Nephropathy Toxic | Remdesivir | Y | | S | Intravenous bolus | Other Frequency:X1; | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 23-May-2020 | 17823098 | DIRECT | Y | LT | | | 66 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatine Increased; Dialysis; Gastrointestinal Haemorrhage; Glomerular Filtration Rate Decreased; Hepatic Failure; Hyperkalaemia; Hypovolaemic Shock; Metabolic Acidosis; Renal Failure; Shock Haemorrhagic | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Aspirin | | | C | | | | Not Reported | |
| | Diltiazem | | | C | | | | Not Reported | |
| | Insulin Lispro | | | C | | | | Not Reported | |
| | Methylprednisolone | | | C | | | | Not Reported | |
| | Protonix | | | C | | | | Not Reported | |
| | Atarax | | | C | | | | Not Reported | |
| | Lovenox | | | C | | | | Not Reported | |
| | Ativan | | | C | | | | Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|----------|---|--------------|
| Fentanyl | C | Not Reported |
| Versed | C | Not Reported |
| Ketamine | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 23-May-2020 | 17823103 | DIRECT | Y | LT | | | 66 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatine Increased; Dialysis; Gastrointestinal Haemorrhage; Glomerular Filtration Rate Decreased; Hepatic Failure; Hypovolaemic Shock; Liver Function Test Increased; Shock Haemorrhagic | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Aspirin | | | C | | | | Not Reported |
| | Diltiazem | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Protonix | | | C | | | | Not Reported |
| | Atarax | | | C | | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |
| | Ativan | | | C | | | | Not Reported |
| | Ketamine | | | C | | | | Not Reported |
| | Versed | | | C | | | | Not Reported |
| | Ativan | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823031 | DIRECT | Y | | | | 62 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Blood Creatinine Increased; Liver Function Test Increased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Plavix | | | C | | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Hydralazine | | | C | | | | Not Reported |
| | Humalog | | | C | | | | Not Reported |
| | Levophed | | | C | | | | Not Reported |
| | Omeprazole | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Humulin | | | C | | | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|--------------------|---|--------------|
| Ativan | C | Not Reported |
| Versed | C | Not Reported |
| Sodium Bicarbonate | C | Not Reported |
| Vecuronium | C | Not Reported |
| Keppra | C | Not Reported |
| Solumedrol | C | Not Reported |
| Tylenol | C | Not Reported |
| Melatonin | C | Not Reported |
| Nitroglycerin | C | Not Reported |
| Crestor | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823035 | DIRECT | Y | | | | 31 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Hepatic Enzyme Increased | Eua Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823037 | DIRECT | Y | OT | | | 64 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Vomiting | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Remdesivir | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823040 | DIRECT | Y | OT | | | 79 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Aspirin | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|-----------------|---|--------------|
| Hydrocortisone | C | Not Reported |
| Insulin Regular | C | Not Reported |
| Lactulose | C | Not Reported |
| Levothyroxine | C | Not Reported |
| Norepinephrine | C | Not Reported |
| Pantoprazole | C | Not Reported |
| Propofol | C | Not Reported |
| Quetiapine | C | Not Reported |
| Senna | C | Not Reported |
| Vasopressin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823060 | DIRECT | Y | OT | | | 81 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|------------------|--|-----------------|--------------|
| Hypotension | Remdesivir | | | S | Intravenous drip | Other Frequency:Once Then 100 Mgx4; | 30 MIN | Gilead |
| | Bisoprolol 5 Mg | | | C | | | | Not Reported |
| | Diltiazem Er 30 Mg | | | C | | | | Not Reported |
| | Hydralazine 25 Mg | | | C | | | | Not Reported |
| | Losartan 100 Mg | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823067 | DIRECT | Y | DE | | | 86 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---------------------|--------------|------------|-------------|--|--|-----------------|-----------------------|
| Respiratory Disorder | Convalescent Plasma | | | S | Intravenous (not otherwise specified) | Other Frequency:2 Units Given Once; | | Versiti Blood Centers |
| | Remdesivir (Eua) | | | S | | | | Not Reported |
| | Tocilizumab | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823073 | DIRECT | Y | HO | | | 68 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Blood Creatinine | Remdesivir | | | S | | | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

Increased

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823078 | DIRECT | Y | DE | | | 68 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---------------------------------------|--------------------|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Acute Kidney Injury; Haemodialysis | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Not Reported |
| | Lorazepam | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Insulin Regular | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Daptomycin | | | C | | | | Not Reported |
| | Labetalol | | | C | | | | Not Reported |
| | Duoneb Nebulizer | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Bupropion | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Cisatracurium | | | C | | | | Not Reported |
| Dexmedetomidine | | | C | | | Not Reported | | |
| Enoxaparin | | | C | | | Not Reported | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823118 | DIRECT | Y | OT | | | 54 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-------------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Heparin | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Piperacillin/Tazobactam | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Selinexor | | | C | | | | Not Reported |
| | Senna | | | C | | | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | |
|-----------|---|--------------|
| Trazodone | C | Not Reported |
| Zinc | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 24-May-2020 | 17823125 | DIRECT | Y | OT | | | 71 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------------------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|--------------|
| Blood Lactic Acid Decreased; Renal Injury; Respiratory Rate Increased; Septic Shock; Tachypnoea; Urinary Casts | Remdesivir Injection | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| | Apixaban 5 Mg | | | C | | | | Not Reported |
| | Aspirin 81 Mg | | | C | | | | Not Reported |
| | Insulin Lispro Sliding Scale | | | C | | | | Not Reported |
| | Norepinephrine Infusion | | | C | | | | Not Reported |
| | Vasopressin Infusion | | | C | | | | Not Reported |
| | Cisatracurium Infusion | | | C | | | | Not Reported |
| | Propofol Infusion | | | C | | | | Not Reported |
| | Fentanyl Infusion | | | C | | | | Not Reported |
| | Tocilizumab 400 Mg | | | C | | | | Not Reported |
| | Unfractionated Intravenous Heparin | | | C | | | | Not Reported |
| | Piperacillin/Tazobactam 4.5 Grams Q6h | | | C | | | | Not Reported |
| | Vancomycin 1250 Mg Q12h | | | C | | | | Not Reported |
| | Tradipitant/Placebo | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17820923 | EXPEDITED (15-DAY) | | DE, OT | US-SA-2020SA130868 | | | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Disseminated Intravascular Coagulation; Intra-Abdominal Haemorrhage; Retroperitoneal Haemorrhage; Septic Shock; Shock Haemorrhagic | Lovenox | | | S | Subcutaneous | 40 Mg, Qd | | Sanofi |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | Unk | | Not Reported |
| | Ascorbic Acid | | | C | | Unk | | Not Reported |
| | Fenofibrate | | | C | | Unk | | Not Reported |
| | Heparin | | | C | | Unk | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|---|---|-----|--------------|
| Methylprednisolone | C | Unk | Not Reported |
| Nph Insulin | C | Unk | Not Reported |
| Insulin Human;Insulin Human Injection, Isophane Sodium Chloride | C | Unk | Not Reported |
| Sitagliptin | C | Unk | Not Reported |
| Midazolam | C | Unk | Not Reported |
| Pantoprazole | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17823157 | DIRECT | Y | OT | | | 32 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|--------------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Hepatic Enzyme Increased | Remdesivir | Y | | S | Intravenous drip | | | Gilead |
| | Albuterol Hfa 90mcg/Puff | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17823162 | DIRECT | Y | OT | | | 56 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Acute Kidney Injury | Remdesivir | | | S | | | | Not Reported |
| | Zosyn | | | C | | | | Not Reported |
| | Doxycyline | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17823167 | DIRECT | Y | OT | | | 72 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Bradycardia | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Hydroxychloroquine | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Hydromorphone | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17823171 | DIRECT | Y | | | | 59 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Infusion Site Extravasation | Remdesivir | Y | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17823177 | DIRECT | Y | OT | | | 57 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Burning Sensation | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17823181 | DIRECT | Y | OT | | | 75 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|----------------------------|------------------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Hypopnoea; Infusion | Remdesivir | | | S | | | | Not Reported |
| Related Reaction; Rash; | Allopurinol 100 Mg Tablet | | | C | | | | Not Reported |
| Rash Pruritic; Respiratory | Carvedilol 12.5 Mg Tablet | | | C | | | | Not Reported |
| Distress; Wheezing | Enoxaparin 40 Mg Subcutaneous | | | C | | | | Not Reported |
| | Famotidine 20mg Tablets | | | C | | | | Not Reported |
| | Insulin Glargine Subcutaneous | | | C | | | | Not Reported |
| | Insulin Lispro Subcutaneous | | | C | | | | Not Reported |
| | Multivitamin Oral Tablet | | | C | | | | Not Reported |
| | Polyethylene Glycol 17 G Packet | | | C | | | | Not Reported |
| | Senna-Docusate 8.6 Mg-50 Mg Tablet | | | C | | | | Not Reported |
| | Tamoxifen 20 Mg Tablets | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17823188 | DIRECT | Y | | | | 60 YR | Female | USA |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir | | | S | | | | Not Reported |
| | Albuterol Inhaler | | | C | | | | Not Reported |
| | Amlodipine 5 Mg Tablet | | | C | | | | Not Reported |
| | Benzonatate 200mg Capsules | | | C | | | | Not Reported |
| | Docusate 100 Mg Capsule | | | C | | | | Not Reported |
| | Senna Tablets | | | C | | | | Not Reported |
| | Enoxaparin 40 Mg Subcutaneous | | | C | | | | Not Reported |
| | Famotidine 20mg Tablets | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin Lispro Subcutaneous | | | C | | | | Not Reported |
| | Levothyroxine 50mcg Tablet | | | C | | | | Not Reported |
| | Rosuvastatin 20 Mg Tablet | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17823195 | DIRECT | Y | DE | | | 68 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Anxiety; Encephalopathy; Hypoxia; Respiratory Distress; Respiratory Failure; Unresponsive To Stimuli | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Zosyn | | | C | | | | Not Reported |
| | Insulin Lispro & Insulin Glargine | | | C | | | | Not Reported |
| | Albuterol | | | C | | | | Not Reported |
| | Combivent | | | C | | | | Not Reported |
| | Amlodipine | | | C | | | | Not Reported |
| | Precedex | | | C | | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |
| | Gabapentin | | | C | | | | Not Reported |
| | Seebri | | | C | | | | Not Reported |
| | Levothyroxine | | | C | | | | Not Reported |
| | Ativan | | | C | | | | Not Reported |
| | Lopressor | | | C | | | | Not Reported |
| | Dulera | | | C | | | | Not Reported |
| | Percocet | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 25-May-2020 | 17823212 | DIRECT | Y | OT | | | 73 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
|---|---------------------------|--------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|--------------|----------------|
| Glomerular Filtration Rate Decreased; Renal Impairment | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 25-May-2020 | 17823217 | DIRECT | Y | | | | 89 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Administration Site Extravasation | Remdesivir | | | S | Intravenous drip | | 5 DAY | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17792758 | EXPEDITED (15-DAY) | | OT | CH-PFIZER INC-2020191603 | | 61 YR | Female | CHE |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Dermatitis Exfoliative Generalised; Eosinophilia; Rash Erythematous | Nexium | | | S | Unknown | Unk | | Unknown | |
| | Nexium | | | S | Unknown | Unk | | Unknown | |
| | Temesta (Lorazepam) | | | S | Unknown | Unk | | Pfizer | |
| | Zithromax | | | S | Unknown | Unk | | Pfizer | |
| | Amlodipine Besilate | | | S | Unknown | Unk | | Pfizer | |
| | Haldol | | | S | Unknown | Unk | | Not Reported | |
| | Quetiapine | | | S | Unknown | Unk | | Not Reported | |
| | Lasix [Furosemide Sodium] | | | S | Unknown | Unk | | Not Reported | |
| | Lasix [Furosemide Sodium] | | | S | Unknown | Unk | | Not Reported | |
| | Lasix [Furosemide Sodium] | | | S | Unknown | Unk | | Not Reported | |
| | Ceftriaxone | | | S | Unknown | Unk | | Not Reported | |
| | Clarithromycine | | | S | Unknown | Unk | | Not Reported | |
| | Remdesivir | | | S | Unknown | Unk | | Not Reported | |
| Anxiolit | | | S | Unknown | Unk | | Not Reported | | |
| Clexane | | | S | Unknown | 40 Mg | | Not Reported | | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | |
|---|---|---------|-------|--------------|
| Clexane | S | Unknown | 40 Mg | Not Reported |
| Dafalgan | S | Unknown | Unk | Not Reported |
| Dafalgan | S | Unknown | Unk | Not Reported |
| Solu-Medrol | C | Unknown | Unk | Not Reported |
| Diamox [Acetazolamide] | C | Unknown | Unk | Not Reported |
| Diamox [Acetazolamide] | C | Unknown | Unk | Not Reported |
| Diamox [Acetazolamide] | C | Unknown | Unk | Not Reported |
| Distraneurin [Clomethiazole] | C | Unknown | Unk | Not Reported |
| Novorapid | C | Unknown | Unk | Not Reported |
| Ipramol | C | Unknown | Unk | Not Reported |
| Heparine [Heparin Sodium] | C | Unknown | Unk | Not Reported |
| Lexotanil | C | Unknown | Unk | Not Reported |
| Movicol [Macrogol 3350;Potassium Chloride;Sodium Bicarbonate;Sodium Ch Morphine | C | Unknown | Unk | Not Reported |
| Nozinan [Levomepromazine Hydrochloride] | C | Unknown | Unk | Not Reported |
| Dexdor | C | Unknown | Unk | Not Reported |
| Dexdor | C | Unknown | Unk | Not Reported |
| Dexdor | C | Unknown | Unk | Not Reported |
| Sinteny | C | Unknown | Unk | Not Reported |
| Sinteny | C | Unknown | Unk | Not Reported |
| Dormicum [Midazolam Maleate] | C | Unknown | Unk | Not Reported |
| Dormicum [Midazolam Maleate] | C | Unknown | Unk | Not Reported |
| Dormicum [Midazolam Maleate] | C | Unknown | Unk | Not Reported |
| Noradrenaline [Norepinephrine] | C | Unknown | Unk | Not Reported |
| Noradrenaline [Norepinephrine] | C | Unknown | Unk | Not Reported |
| Noradrenaline [Norepinephrine] | C | Unknown | Unk | Not Reported |
| Propofol | C | Unknown | Unk | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | |
|---------------------------------|---|---------|-----|--------------|
| Propofol | C | Unknown | Unk | Not Reported |
| Propofol | C | Unknown | Unk | Not Reported |
| Propofol | C | Unknown | Unk | Not Reported |
| Rocuronium [Rocuronium Bromide] | C | Unknown | Unk | Not Reported |
| Tracrium | C | Unknown | Unk | Not Reported |
| Tracrium | C | Unknown | Unk | Not Reported |
| Tracrium | C | Unknown | Unk | Not Reported |
| Colistin | C | Unknown | Unk | Not Reported |
| Colistin | C | Unknown | Unk | Not Reported |
| Colistin | C | Unknown | Unk | Not Reported |
| Tobramycin | C | | Unk | Not Reported |
| Tobramycin | C | | Unk | Not Reported |
| Tobramycin | C | | Unk | Not Reported |
| Amphotericin B | C | | Unk | Not Reported |
| Amphotericin B | C | | Unk | Not Reported |
| Amphotericin B | C | | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17822479 | EXPEDITED (15-DAY) | | OT | DE-ABBVIE-20K-062-3416492-00 | | | Unknown | DEU |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Adverse Drug Reaction; Liver Disorder; Multiple Organ Dysfunction Syndrome; Renal Failure | Kaletra | | | S | Oral | | | Not Reported |
| | Remdesivir | | | S | Unknown | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17823907 | DIRECT | Y | OT | | | 76 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | | |
|--|------------|---|---|--|--------|
| Condition Aggravated; Diarrhoea; Dyspnoea | Remdesivir | Y | S | Intravenous (not otherwise specified) | Gilead |
|--|------------|---|---|--|--------|

| | | | | | | | | | |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17823998 | DIRECT | Y | DE | | | 71 YR | Female | USA |

| | | | | | | | | |
|----------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Liver Function Test Increased | Remdesivir | | | S | | | | Not Reported |

| | | | | | | | | | |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17824003 | DIRECT | Y | OT | | | 43 YR | Male | USA |

| | | | | | | | | |
|----------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Liver Function Test Increased | Remdesivir | | | S | | | | Not Reported |

| | | | | | | | | | |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17824009 | DIRECT | Y | OT | | | 73 YR | Female | USA |

| | | | | | | | | |
|---|--|--------------|------------|----------------------|--------------|--|-----------------|--|
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir Amiodarone 360 Mg/200 MI Milrinone 20 Mg/100 MI Norepinephrine | Y | | S C C C | | Intravenous (not otherwise specified) | | Gilead Not Reported Not Reported Not Reported |

| | | | | | | | | | |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17824025 | DIRECT | Y | DE | | | 73 YR | Male | USA |

| | | | | | | | | |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Acute Respiratory Distress Syndrome; Pneumonia; Renal Failure | Remdesivir | | | S | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824060 | DIRECT | Y | DE | | | 76 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---------------------------|---------------------------|--------------|------------|-------------|---------------------------------------|------------------------|-----------------|--------------|
| Cardio-Respiratory Arrest | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Total; | | Gilead |
| | Cefepime | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Methocarbamol | | | C | | | | Not Reported |
| | Methylprednisolone Sodium | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Pregabalin | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Vasopressin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824081 | DIRECT | Y | | | | 38 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Heart Rate Decreased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Acetylcysteine | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Ceftaroline | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Insulin Regular | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Polyethylene Glycol | | | C | | | | Not Reported |
| | Senna | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| Propofol | | C | | Not Reported | | | | | |
|--------------------------------------|-----------------------|------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17824084 | DIRECT | Y | | | | 59 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Bradycardia | Remdesivir | | | S | Intravenous (not otherwise specified) | | 5 DAY | Gilead | |
| | Acetylcysteine | | | C | | | | | Not Reported |
| | Atorvastatin | | | C | | | | | Not Reported |
| | Citalopram | | | C | | | | | Not Reported |
| | Enoxaparin | | | C | | | | | Not Reported |
| | Famotidine | | | C | | | | | Not Reported |
| | Gabapentin | | | C | | | | | Not Reported |
| | Protonix | | | C | | | | | Not Reported |
| | Tiotropium | | | C | | | | | Not Reported |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17824086 | DIRECT | Y | OT | | | 69 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Aspartate Aminotransferase Increased | Remdesivir | | | S | Intravenous drip | | | Gilead | |
| | Albuterol Ipratropium | | | C | | | | | Not Reported |
| | Famotidine | | | C | | | | | Not Reported |
| | Sennosides | | | C | | | | | Not Reported |
| | Docusate | | | C | | | | | Not Reported |
| | Insulin Lispro | | | C | | | | | Not Reported |
| | Epoprostenol | | | C | | | | | Not Reported |
| | Asprin | | | C | | | | | Not Reported |
| | Acetaminophen | | | C | | | | | Not Reported |
| | Norepinephrine | | | C | | | | | Not Reported |
| | Heparin Drip | | | C | | | | | Not Reported |
| | Methylprednisone | | | C | | | | | Not Reported |
| | Midodrine | | | C | | | | | Not Reported |
| | Ampicillin Sulbactam | | | C | | | | | Not Reported |
| | Metolazone | | | C | | | | | Not Reported |
| | Ketamine Drip | | | C | | | | | Not Reported |
| | Hydromorphone Drip | | | C | | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--------------------|---|--------------|
| Cisatracurium Drip | C | Not Reported |
| Furosemide | C | Not Reported |
| Potassium | C | Not Reported |
| Acetazolamide | C | Not Reported |
| Oxycodone | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824087 | DIRECT | Y | HO, OT | | | 80 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Burning Sensation; Clinical Trial Participant; Condition Aggravated; Covid-19 Pneumonia; Product Use In Unapproved Indication; Respiratory Disorder | Remdesivir | | | S | | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824088 | DIRECT | Y | | | | 85 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-------------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Clinical Trial Participant; Decreased Appetite; Product Use In Unapproved Indication | Remdesivir (Eua) (Remdesivir (Eua)) | | | S | Intravenous (not otherwise specified) | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824089 | DIRECT | Y | DE | | | 82 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Cardiac Arrest; Clinical Trial Participant; Product Use In Unapproved Indication | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Famotidine | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--------------------|---|--------------|
| Miralax | C | Not Reported |
| Lorazepam | C | Not Reported |
| Ceftriaxone | C | Not Reported |
| Dilaudid | C | Not Reported |
| Guiafenesin | C | Not Reported |
| Aspirin | C | Not Reported |
| Acetaminophen | C | Not Reported |
| Mylanta Suspension | C | Not Reported |
| Methylprednisolone | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824090 | DIRECT | Y | OT | | | 65 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Clinical Trial Participant; Ischaemic Stroke; Product Use In Unapproved Indication; Vertebral Artery Occlusion | Remdesivir | Y | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824149 | DIRECT | Y | RI | | | 68 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Acute Kidney Injury; Clinical Trial Participant; Product Use In Unapproved Indication | Remdesivir (Eua) (Remdesivir (Eua)) | | | S | Intravenous (not otherwise specified) | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824205 | DIRECT | Y | | | | 67 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Procedural Hypotension | Remdesivir | | | S | | | | Gilead |
| | Azithromycin | | | C | | | | Not Reported |
| | Insulin Aspart | | | C | | | | Not Reported |
| | Amlodipine | | | C | | | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | |
|------------------|---|--------------|
| Ascorbic Acid | C | Not Reported |
| Bumetanide | C | Not Reported |
| Ceftriaxone | C | Not Reported |
| D5/Ns | C | Not Reported |
| Fentanyl | C | Not Reported |
| Gemfibrozil | C | Not Reported |
| Heparin | C | Not Reported |
| Midazolam | C | Not Reported |
| Norepinephrine | C | Not Reported |
| Pantoprazole | C | Not Reported |
| Sodium Phosphate | C | Not Reported |
| Zinc Sulfate | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824219 | DIRECT | Y | HO, OT | | | 43 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------------------|----------------|--------------|------------|-------------|-------------------|---------------------------|-----------------|------------|
| Blood Creatinine Increased; Dyspnoea | Remdesivir | Y | | S | Intravenous bolus | Other Frequency:One Time; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824509 | DIRECT | Y | HO, OT | | | 73 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Pneumonia; Sepsis | Remdesivir (Eua) (Remdesivir (Eua)) | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824895 | DIRECT | Y | OT | | | 62 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------------|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Renal Impairment; Therapy Cessation | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Albumin | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Bumetanide | | | C | | | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|-----------------|---|--------------|
| Chlorothiazide | C | Not Reported |
| Enoxaparin | C | Not Reported |
| Fentanyl | C | Not Reported |
| Heparin | C | Not Reported |
| Lidocaine Patch | C | Not Reported |
| Metronidazole | C | Not Reported |
| Norepinephrine | C | Not Reported |
| Pantoprazole | C | Not Reported |
| Propofol | C | Not Reported |
| Vecuronium | C | Not Reported |
| Zinc Sulfate | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824899 | DIRECT | Y | HO | | | 62 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|------------------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Blood Creatinine Increased; Therapy Cessation | Remdesivir Eua | Y | | S | Intravenous bolus | | | Gilead |
| | Chlorhexidine 0.12% Solution | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Ipratropium-Albuterol | | | C | | | | Not Reported |
| | Multivitamin | | | C | | | | Not Reported |
| | Rocuronium | | | C | | | | Not Reported |
| | Sennosides-Docusate | | | C | | | | Not Reported |
| | Hydromorphone | | | C | | | | Not Reported |
| | Lorazepam | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824926 | DIRECT | Y | OT | | | 52 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Inflammatory Marker Increased; | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Acetaminophen Tab | | | C | | | | Not Reported |
| | Azithromycin Iv | | | C | | | | Not Reported |
| | Ceftriaxone Iv | | | C | | | | Not Reported |
| | Benzonatate | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|-------------------|--------------------------------------|---|--------------|
| Therapy Cessation | Enoxaparin | C | Not Reported |
| | Famotidine Iv | C | Not Reported |
| | Metoprolol Iv | C | Not Reported |
| | Potassium & Sodium Phosphates Packet | C | Not Reported |
| | Potassium Chloride Tab | C | Not Reported |
| | Vancomycin Iv | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824932 | DIRECT | Y | OT | | | 69 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|--------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Hepatic Enzyme Increased | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Diphenhydramine | | | C | | | | Not Reported |
| | Doxycycline | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Etomidate | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Levothyroxine | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Potassium Chloride | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| Succinylcholine | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824939 | DIRECT | Y | DE | | | 39 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Hepatic Enzyme Increased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824944 | DIRECT | Y | DE | | | 76 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Cardiac Arrest; Dyspnoea; Emphysema; Interstitial Lung Disease; Respiratory Failure; Tachycardia | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Enoxaparin | | | C | | | | Not Reported |
| | Albuterol | | | C | | | | Not Reported |
| | Brovana | | | C | | | | Not Reported |
| | Anoro Ellipta | | | C | | | | Not Reported |
| | Lasix | | | C | | | | Not Reported |
| | Prednisone | | | C | | | | Not Reported |
| | Insulin | | | C | | | | Not Reported |
| | Protonix | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| Metformin | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824950 | DIRECT | Y | OT | | | 46 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|----------------------------|------------------------------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|--------------|
| Blood Creatinine Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| | Voriconazole Iv | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Fluconazole | | | C | | | | Not Reported |
| | Fluticasone Nasal Spray | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Levothyroxine | | | C | | | | Not Reported |
| | Senna | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Zinc Sulfate | | | C | | | | Not Reported |
| | Sodium Chloride 0.9% W/ 20 Meq Kcl | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Benzonatate | | | C | | | | Not Reported |
| | Iopamidol | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|-------------------------|---|--------------|
| Ondansetron | C | Not Reported |
| Promethazine W/ Codeine | C | Not Reported |
| Vancomycin | C | Not Reported |
| Piperacillin-Tazobactam | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824956 | DIRECT | Y | OT | | | 72 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatinine Increased; Dose Calculation Error; Glomerular Filtration Rate Decreased; Incorrect Dose Administered By Product; Sepsis | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Ascorbic Acid Po | | | C | | | | Not Reported |
| | Azithromycin Iv | | | C | | | | Not Reported |
| | Ceftriaxone Iv | | | C | | | | Not Reported |
| | Cholecalciferol | | | C | | | | Not Reported |
| | Cimetidine Po | | | C | | | | Not Reported |
| | Furosemide Ivp And Gtt | | | C | | | | Not Reported |
| | Zinc Gluconate Po | | | C | | | | Not Reported |
| | Cisatracurium | | | C | | | | Not Reported |
| | Epoprostenol Inhaled | | | C | | | | Not Reported |
| | Fentanyl Infusion Vent Sedation | | | C | | | | Not Reported |
| Propofol | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824960 | DIRECT | Y | HO | | | 46 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Liver Function Test Increased; Therapy Interrupted | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | 2 DAY | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824966 | DIRECT | Y | LT, OT | | | 79 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Blood Creatinine Increased; Blood Urea | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | 5 DAY | Gilead |

| | | | |
|---------------------|------------------------------|---|--------------|
| Increased; Dialysis | Tocilizumab | C | Not Reported |
| | Cefepime | C | Not Reported |
| | Azithromycin | C | Not Reported |
| | Fentanyl Continuous Infusion | C | Not Reported |
| | Midazolam Infusion | C | Not Reported |
| | Propofol Infusion | C | Not Reported |
| | Albumin 25 Gm Infusion | C | Not Reported |
| | Famotidine 20 Mg Po | C | Not Reported |
| | Aspirin 81 Mg | C | Not Reported |
| | Furosemide 40 Mg Iv | C | Not Reported |
| | Enoxaparin 40 Mg Sq | C | Not Reported |
| | Insulin Infusion | C | Not Reported |
| | Cisatracurium Infusion | C | Not Reported |
| | Meropenem | C | Not Reported |
| | Simvastatin 20 Mg | C | Not Reported |
| | Vitamin D 2000 Units | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824970 | DIRECT | Y | OT | | | 56 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|----------------------------|--|--------------|------------|-------------|---------------------------------------|------------------------------------|-----------------|--------------|
| Blood Creatinine Increased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:Daily After 200mg; | | Gilead |
| | Ascorbic Acid Po 1000mg Bid | | | C | | | | Not Reported |
| | Atorvastatin 10mg Po Daily | | | C | | | | Not Reported |
| | Ceftriaxone 1gm Iiv Daily | | | C | | | | Not Reported |
| | Clopidogrel 75mg Po Daily | | | C | | | | Not Reported |
| | Enoxaparin 90mg Sq Q12hrs | | | C | | | | Not Reported |
| | Famotidine 20mg Iv Daily | | | C | | | | Not Reported |
| | Insulin Lispro Sq Sliding Scale | | | C | | | | Not Reported |
| | Loratadine 10mg Po Daily | | | C | | | | Not Reported |
| | Methylprednisolone 125mg Iv Q12hrs | | | C | | | | Not Reported |
| | Zinc 220mg Oral Bid | | | C | | | | Not Reported |
| | Norco 5/325mg Po Q6hrs Prn | | | C | | | | Not Reported |
| | Fentanyl Variable Rate Continuous Iv | | | C | | | | Not Reported |
| | Norepinephrine Variable Rate Continuous Iv | | | C | | | | Not Reported |
| | Propofol Variable Rate | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

Continuous Iv

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824973 | DIRECT | Y | OT | | | 41 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|-------------|--------------|--------------------|-----------------|--|
| Asthenia; Chromaturia; Fatigue; Therapy Cessation | Remdesivir Azithromycin Cefepime | Y | | S C C | | | | Not Reported Not Reported Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824977 | DIRECT | Y | | | | 55 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|----------------|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Rash; Rash Maculo- Papular | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Not Reported |
| | Stribild | | | C | | | | Not Reported |
| | Prezista | | | C | | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |
| | Solumedrol | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824979 | DIRECT | Y | DE | | | 52 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-------------------------------------|--------------|------------|-------------|--|-----------------------|-----------------|--------------|
| Death | Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Azithromycin 250mg Iv | | | C | | | | Not Reported |
| | Potassium Chloride Er 40meq Oral | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824984 | DIRECT | Y | OT | | | 51 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Hepatic Enzyme Increased; Therapy Interrupted | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Tocilizumab | | | C | | | | Not Reported |
| | Acetaminophen 325 Mg | | | C | | | | Not Reported |
| | Aspirin 81mg Ec | | | C | | | | Not Reported |
| | Enoxaparin 40mg Sc Bid | | | C | | | | Not Reported |
| | Pantoprazole 40mg Po Qday | | | C | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824989 | DIRECT | Y | DE | | | 85 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Arrhythmia; Creatinine Renal Clearance Decreased; Encephalopathy; Respiratory Failure; Sudden Cardiac Death | Remdesivir Solution | | | S | | | | Gilead |
| | Modafinil | | | C | | | | Not Reported |
| | Trazodone | | | C | | | | Not Reported |
| | Quetiapine | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824990 | DIRECT | Y | | | | 60 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Aspartate Aminotransferase Increased | Remdesivir | Y | | S | Intravenous drip | | | Gilead |
| | Tocilizumab | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824991 | DIRECT | Y | OT | | | 69 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| | | | | | | | | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | | |
|---|---------------------|---|---|-------------------|--------------|
| Aspartate | Remdesivir | Y | S | Intravenous bolus | Gilead |
| Aminotransferase Increased; Blood Alkaline Phosphatase Increased; Liver Function Test Increased | Bisacodyl | | C | | Not Reported |
| | Lansoprazole | | C | | Not Reported |
| | Metoclopramide | | C | | Not Reported |
| | Polyethylene Glycol | | C | | Not Reported |
| | Sennosides-Docusate | | C | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824992 | DIRECT | Y | HO | | | 45 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury | Remdesivir Injection | | | S | Intravenous drip | | | Gilead |
| | Remdesivir For Injection, Lyophilized Powder, 100 Mg Vial | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17824993 | DIRECT | Y | | | | 79 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Administration Site Extravasation | Remdesivir | | | S | Intravenous drip | | 5 DAY | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17825230 | EXPEDITED (15-DAY) | | DE, OT | US-SA-2020SA135575 | | | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Covid-19; Disseminated Intravascular Coagulation; Intra-Abdominal Haemorrhage; Retroperitoneal Haemorrhage; Septic Shock; Shock Haemorrhagic | Lovenox | | | S | Subcutaneous | 40 Mg, Qd | | Sanofi |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | Unk | | Not Reported |
| | Ascorbic Acid | | | C | Unknown | Unk | | Not Reported |
| | Heparin | | | C | Unknown | Unk | | Not Reported |
| | Fenofibrate | | | C | Unknown | Unk | | Not Reported |
| | Methylprednisolone | | | C | Unknown | Unk | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | | | |
|---|---|---------|-----|--------------|
| Sodium Chloride | C | Unknown | Unk | Not Reported |
| Sitagliptin | C | Unknown | Unk | Not Reported |
| Midazolam | C | Unknown | Unk | Not Reported |
| Pantoprazole | C | Unknown | Unk | Not Reported |
| Nph Insulin | C | Unknown | Unk | Not Reported |
| Insulin Human;Insulin Human Injection, Isophane | C | Unknown | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17826568 | EXPEDITED (15-DAY) | | HO, OT | US-GILEAD-2020-0467857 | | 73 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Acute Kidney Injury | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17826572 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0467950 | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------|-------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Renal Tubular Necrosis | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Qd | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Tocilizumab | | | C | | 400 Mg | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Trimethobenzamide | | | C | | 200 Mg, Once | | Not Reported |
| | Asa | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Ondansetron | | | C | | | | Not Reported |
| | Levothyroxine | | | C | | | | Not Reported |
| | Ethacrynic Acid | | | C | | | | Not Reported |
| | Metoprolol | | | C | | Unk | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | Tradipitant | | C | | Unk | | Not Reported | | |
|---|---|--------------------|--------------------|--------------------------------------|--|----------------------|-----------------|--|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17826584 | EXPEDITED (15-DAY) | | | US-GILEAD-2020-0467774 | | | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Product Storage Error | Remdesivir | | | S | Unknown | Unk | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17827902 | DIRECT | Y | DS, HO, LT | | | 67 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Crystal Nephropathy; Hydronephrosis; Renal Tubular Necrosis; Respiratory Disorder; Urine Analysis Abnormal | Remdesivir Acetaminophen Duonebs Amiodarone 150mg Iv Bolus Once Azithromycin 500mg Iv Once Cefepime 2gm Iv Potassium Chloride 20meq Iv Tocilizumab 400mg Iv | | | S C C C C C C C | Intravenous drip | | | Gilead Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 26-May-2020 | 17827908 | DIRECT | Y | OT | | | 59 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Blood Alkaline Phosphatase Increased; Condition Aggravated; Enteritis | Remdesivir Atorvastatin Lovenox Imodium Losartan Pantoprazole Phosphorus Toradol | | | S C C C C C C | Intravenous (not otherwise specified) | | | Gilead Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|------------|---|--------------|
| Lopressor | C | Not Reported |
| Metoprolol | C | Not Reported |
| Aspirin | C | Not Reported |
| Diltiazem | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17827943 | DIRECT | Y | DE | | | 53 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Atrial Fibrillation; Bradycardia; Cardio- Respiratory Arrest; Hypotension; Respiratory Failure | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17827959 | DIRECT | Y | OT | | | 72 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------------------------|
| Acute Kidney Injury; Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir Remdesivir | | | S C | | | | Not Reported Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17828102 | DIRECT | Y | | | | 85 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------------|--------------|------------|-------------|--|--------------------|-----------------|------------|
| Gallbladder Disorder; Hepatic Enzyme Increased | Remdesivir 100 Mg/20 MI | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 26-May-2020 | 17828289 | DIRECT | Y | | | | 81 YR | Female | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|------------------------------|--------------|------------|-------------|---------------------------------------|---------------------------------------|---------------------------------------|--------------|
| Blood Creatine Phosphokinase Increased | Remdesivir (Eua) 100 Mg Vial | | | S | Intravenous (not otherwise specified) | Intravenous (not otherwise specified) | | Gilead |
| | Remicade Inj 100mg Vial | | | S | | | Intravenous (not otherwise specified) | |
| | Acetaminophen | | | C | | | | Not Reported |
| | Acetazolamide | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Cellralxone | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin Nph | | | C | | | | Not Reported |
| | Lansoprazole | | | C | | | | Not Reported |
| | Linolid | | | C | | | | Not Reported |
| | Meropenem | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| Polyethylene Glycol | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17828748 | DIRECT | Y | OT | | | 63 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Blood Creatinine Increased; Glomerular Filtration Rate Decreased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17828807 | DIRECT | Y | OT | | | 66 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Cardiac Arrest | Remdesivir | Y | | S | Intravenous drip | | | Gilead |
| | Azithromycin | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------------------|----------------|
| 27-May-2020 | 17829752 | DIRECT | Y | OT | | | 49 YR | Prefer not to disclose | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------|--|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Transaminases Increased | Remdesivir Injection | Y | | S | Intravenous drip | | 3 DAY | Gilead |
| | Acetaminophen 500 Mg | | | C | | | | Not Reported |
| | Albuterol 90 Mcg Hfa | | | C | | | | Not Reported |
| | Ascorbic Acid 500 Mg | | | C | | | | Not Reported |
| | Benzonatate 100 Mg | | | C | | | | Not Reported |
| | Dexamethasone 20 Mg | | | C | | | | Not Reported |
| | Dextromethorphan-Guaifenesin Cr 30-600 | | | C | | | | Not Reported |
| | Docusate 100 Mg | | | C | | | | Not Reported |
| | Docusate-Senna 50/8.6 Mg | | | C | | | | Not Reported |
| | Enoxaparin 40 Mg | | | C | | | | Not Reported |
| | Famotidine 20 Mg | | | C | | | | Not Reported |
| | Guaifenesin 100/5 | | | C | | | | Not Reported |
| | Loperamide 2mg/15ml | | | C | | | | Not Reported |
| | Ondansetron 4mg/2ml | | | C | | | | Not Reported |
| | Zinc Sulfate 220mg | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17829758 | DIRECT | Y | OT | | | 48 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Ischaemic Hepatitis; Multi-Organ Disorder; Therapy Interrupted | Remdesivir | | | S | Intravenous bolus | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17829764 | DIRECT | Y | | | | 46 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------------|--------------|------------|-------------|------------------|-----------------------|-----------------|------------|
| Blood Creatine | Remdesivir Injection | | | S | Intravenous (not | Other Frequency:Once; | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | | |
|---|-------------------------------------|---|--|-------|--------------|
| Phosphokinase Increased; Therapy Cessation | Remdesivir | S | otherwise specified) Intravenous (not otherwise specified) | 6 DAY | Gilead |
| | Atorvastatin 40 Mg Tablet | C | | | Not Reported |
| | Ceftriaxone 1 Gm Injection | C | | | Not Reported |
| | Enoxaparin 100 Mg Injection | C | | | Not Reported |
| | Furosemide 40 Mg Injection | C | | | Not Reported |
| | Hydromorphone 1 Mg Injection | C | | | Not Reported |
| | Hydroxychloroquine 200 Mg Tablet | C | | | Not Reported |
| | Lorazepam 2 Mg Injection | C | | | Not Reported |
| | Meropenem 1 Gm Injection | C | | | Not Reported |
| | Pantoprazole 40 Mg Injection | C | | | Not Reported |
| | Potassium Chloride Injection | C | | | Not Reported |
| | Topiramate 100 Mg Tablet | C | | | Not Reported |
| | Vancomycin 1 Gm Injection | C | | | Not Reported |
| | Propofol 10 Mg/ML Injection | C | | | Not Reported |
| | Sodium Bicarbonate Injection | C | | | Not Reported |
| | Vecuronium Injection | C | | | Not Reported |
| | Acetaminophen Tablet | C | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17830125 | EXPEDITED (15-DAY) | | | US-GILEAD-2020-0468001 | | 52 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Product Dose Omission | Remdesivir | | | S | Unknown | 200 Mg | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|-----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17830843 | EXPEDITED (15-DAY) | | OT | CH-JNJFOC-20200514694 | | 61 YR | Female | CHE |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Rash Erythematous | Haldol | | | S | Unknown | | | Janssen |
| | Ceftriaxone | | | S | Unknown | | | Not Reported |
| | Clarithromycine | | | S | Unknown | | | Not Reported |
| | Zithromax | | | S | Unknown | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|--------------------------|---|---------|--------------|
| Remdesivir | S | Unknown | Not Reported |
| Amlodipine | S | Unknown | Not Reported |
| Anxiolit | S | Unknown | Not Reported |
| Clexane | S | Unknown | Not Reported |
| Clexane | S | Unknown | Not Reported |
| Dafalgan | S | Unknown | Not Reported |
| Dafalgan | S | Unknown | Not Reported |
| Lasix /00032601/ | S | Unknown | Not Reported |
| Lasix /00032601/ | S | Unknown | Not Reported |
| Lasix /00032601/ | S | | Not Reported |
| Nexium /01479302/ | S | Unknown | Not Reported |
| Nexium /01479302/ | S | Unknown | Not Reported |
| Quetiapine | S | Unknown | Not Reported |
| Temesta /00273201/ | S | Unknown | Not Reported |
| Diamox /00016901/ | C | | Not Reported |
| Diamox /00016901/ | C | | Not Reported |
| Diamox /00016901/ | C | | Not Reported |
| Distraneurin /00027501/ | C | | Not Reported |
| Novorapid | C | | Not Reported |
| Ipramol | C | | Not Reported |
| Heparine /00027701/ | C | | Not Reported |
| Lexotanil | C | | Not Reported |
| Movicol | C | | Not Reported |
| Morphine | C | | Not Reported |
| Nozinan /00038601/ | C | | Not Reported |
| Solu-Medrol | C | | Not Reported |
| Dexdor | C | | Not Reported |
| Dexdor | C | | Not Reported |
| Dexdor | C | | Not Reported |
| Sintenyl | C | | Not Reported |
| Sintenyl | C | | Not Reported |
| Dormicum /00036201/ | C | | Not Reported |
| Dormicum /00036201/ | C | | Not Reported |
| Dormicum /00036201/ | C | | Not Reported |
| Noradrenaline /00127501/ | C | | Not Reported |
| Noradrenaline /00127501/ | C | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|--------------------------|---|--------------|
| Noradrenaline /00127501/ | C | Not Reported |
| Propofol | C | Not Reported |
| Propofol | C | Not Reported |
| Propofol | C | Not Reported |
| Propofol | C | Not Reported |
| Rocuronium | C | Not Reported |
| Tracrium | C | Not Reported |
| Tracrium | C | Not Reported |
| Tracrium | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17831674 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468136 | | 52 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Hypertension | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Qd | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Digoxin | | | C | | Unk | | Not Reported |
| | Enoxaparin | | | C | | Unk | | Not Reported |
| | Furosemide | | | C | | Unk | | Not Reported |
| | Hydralazine | | | C | | Unk | | Not Reported |
| | Losartan | | | C | | Unk | | Not Reported |
| | Methylprednisolon [Methylprednisolone] | | | C | | Unk | | Not Reported |
| | Nebivolol | | | C | | Unk | | Not Reported |
| | Hydroxychloroquine | | | C | | Unk | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17831684 | EXPEDITED (15-DAY) | | DE, HO, OT | US-GILEAD-2020-0468502 | | 73 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Acute Respiratory Distress Syndrome; Alanine | Remdesivir | | | S | Unknown | 200 Mg | | Gilead |

Aminotransferase
Increased; Aspartate
Aminotransferase
Increased; Blood
Creatinine Increased;
Glomerular Filtration Rate
Decreased; Pneumonia
Viral; Renal Failure

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833395 | DIRECT | Y | DE | | | 63 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Death | Remdesivir | Y | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833398 | DIRECT | Y | | | | 41 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|----------------------------------|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|------------|
| Liver Function Test Increased | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833410 | DIRECT | Y | OT | | | 67 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Therapy Cessation | Remdesivir Injection | Y | | S | Intravenous drip | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Dexamethasone | | | C | | | | Not Reported |
| | Doxycycline | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Hydralazine | | | C | | | | Not Reported |
| | Loperamide | | | C | | | | Not Reported |
| | Potassium Chloride | | | C | | | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | |
|------------------------------|---|--------------|
| Sodium Chloride | C | Not Reported |
| Multivitamin | C | Not Reported |
| Ondansetron | C | Not Reported |
| Dextromethorphan-Guaifenesin | C | Not Reported |
| Zinc Sulfate | C | Not Reported |
| Docusate-Senna | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833414 | DIRECT | Y | OT | | | 53 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-----------------------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|--------------|
| Acute Respiratory Distress Syndrome; Acute Respiratory Failure; | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Blood Alkaline Phosphatase Increased; Blood Bilirubin Increased; Blood Creatinine Increased; Hypoxia; Shock; Viral Cardiomyopathy | Amiodarone Infusion | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Dobutamine Infusion | | | C | | | | Not Reported |
| | Doxycycline Iv | | | C | | | | Not Reported |
| | Enoxaparin 40mg Q12 | | | C | | | | Not Reported |
| | Famotidine 20mg Iv Q12 | | | C | | | | Not Reported |
| | Fentanyl Infusion | | | C | | | | Not Reported |
| | Hydrocortisone 50mg Iv Q6hr | | | C | | | | Not Reported |
| | Midazolam Infusion | | | C | | | | Not Reported |
| | Norepinephrine Infusion | | | C | | | | Not Reported |
| | Phenylephrine Infusion | | | C | | | | Not Reported |
| | Propofol Infusion | | | C | | | | Not Reported |
| | Sodium Bicarbonate Inusion | | | C | | | | Not Reported |
| | Vasopressin Infusion | | | C | | | | Not Reported |
| | Digoxin Bolus Iv | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833420 | DIRECT | Y | DE | | | 64 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Hypotension | Remdesivir | | | S | | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833421 | DIRECT | Y | OT | | | 24 YR | Female | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|----------------------------------|----------------|--------------|------------|-------------|--|-----------------------|-----------------|--------------|
| Epigastric Discomfort; Nausea | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| Iohexol | | | C | | | Not Reported | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833426 | DIRECT | Y | DE | | | 51 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------|--------------|------------|-------------|--|--------------------|-----------------|------------|
| Blood Pressure Decreased; Cardiac Arrest; Lethargy; Pneumothorax; Respiratory Failure | Remdesivir Solution | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Remdesivir | | | S | | | Gilead | |
| | Albuterol | | | C | | | Not Reported | |
| | Ascorbic Acid | | | C | | | Not Reported | |
| | Atorvastatin | | | C | | | Not Reported | |
| | Aztreonam | | | C | | | Not Reported | |
| | Bisacodyl | | | C | | | Not Reported | |
| | Buspirone | | | C | | | Not Reported | |
| | Carbidopa-Levodopa | | | C | | | Not Reported | |
| | Celebrex | | | C | | | Not Reported | |
| | Clonazepam | | | C | | | Not Reported | |
| | Digoxin | | | C | | | Not Reported | |
| | Depakote | | | C | | | Not Reported | |
| | Lovenox | | | C | | | Not Reported | |
| | Fentanyl | | | C | | | Not Reported | |
| | Guaifenesin Er | | | C | | | Not Reported | |
| | Metoprolol | | | C | | | Not Reported | |
| Propofol | | | C | | Not Reported | | | |
| Risperidone | | | C | | Not Reported | | | |
| Dexmedetomidine Additive | | | C | | Not Reported | | | |
| Epinephrine | | | C | | Not Reported | | | |
| Fentanyl | | | C | | Not Reported | | | |

Vancomycin

C

Not Reported

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833433 | DIRECT | Y | OT | | | 57 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir Injection | Y | | S | Intravenous drip | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Albuterol Hfa | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Budesonide-Formoterol | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Cholecalciferol | | | C | | | | Not Reported |
| | Dexamethasone | | | C | | | | Not Reported |
| | Docusate-Senna | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Linagliptin | | | C | | | | Not Reported |
| | Lisinopril | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Polyethylene Glycol | | | C | | | | Not Reported |
| | Selinexor | | | C | | | | Not Reported |
| | Tramadol | | | C | | | | Not Reported |
| | Zinc Sulfate | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833438 | DIRECT | Y | | | | 43 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Hypokalaemia | Remdesivir | | | S | Intravenous bolus | | 10 DAY | Gilead |
| | Cefepime | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Acetylcysteine Inh. Solution 20% | | | C | | | | Not Reported |
| | Albuterol-Ipratropium Inh. | | | C | | | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | | |
|------------------------------|---|--|--------------|
| Solution | | | |
| Amlodipine | C | | Not Reported |
| Enteral Nutrition (Vital Hp) | C | | Not Reported |
| Famotidine | C | | Not Reported |
| Piperacillin/Tazobactam | C | | Not Reported |
| Vancomycin | C | | Not Reported |
| Fentanyl | C | | Not Reported |
| Insulin Lispro | C | | Not Reported |
| Propofol | C | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833450 | DIRECT | Y | | | | 52 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833453 | DIRECT | Y | OT | | | 49 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------------|---|--------------|------------|-------------|-------------------|-----------------------|-----------------|--------------|
| Alanine Aminotransferase Increased | Remdesivir | Y | | S | Intravenous bolus | Other Frequency:Once; | 1 DAY | Gilead |
| | Remdesivir | Y | | S | Intravenous bolus | | 1 DAY | Gilead |
| | Acetaminophen Prn | | | C | | | | Not Reported |
| | Albuterol Hfa Mdi | | | C | | | | Not Reported |
| | Ascorbic Acid (Vitamin C) 1000mg Po Tid | | | C | | | | Not Reported |
| | Bisacodyl Supp Daily Prn | | | C | | | | Not Reported |
| | Enoxaparin 40mg Subq Q12hr | | | C | | | | Not Reported |
| | Guaifenesin/Codeine Prn Cough | | | C | | | | Not Reported |
| | Tussionex Po Bid | | | C | | | | Not Reported |
| | Solu-Medrol 40mg Iv Q12hr | | | C | | | | Not Reported |
| | Morphine Iv Prn | | | C | | | | Not Reported |
| | Sodium Chloride Iv Solution | | | C | | | | Not Reported |
| | Thiamine 100mg Tablet Po Daily | | | C | | | | Not Reported |
| | Zinc Sulfate 220mg Po Daily | | | C | | | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | |
|---------------------------------|---|--------------|
| Chlorhexidine Swish/Spit Bid | C | Not Reported |
| Famotidine 20mg Po Bid | C | Not Reported |
| Mupirocin 2% Ointment Nasal Bid | C | Not Reported |
| Thiamine 100mg Iv Daily | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833459 | DIRECT | Y | OT | | | 45 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Glomerular Filtration Rate Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833468 | DIRECT | Y | OT | | | 71 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Pyrexia | Remdesivir | | | S | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Bumetanide | | | C | | | | Not Reported |
| | Carvedilol | | | C | | | | Not Reported |
| | Dexamethasone | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Insulin Aspart | | | C | | | | Not Reported |
| | Insulin Detemir | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Meropenem | | | C | | | | Not Reported |
| | Warfarin | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833473 | DIRECT | Y | | | | 44 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Hepatic Enzyme Increased | Remdesivir | | | S | Intravenous (not | | | Gilead |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

otherwise specified)

| | | | |
|-------------|---|--|--------------|
| Tocilizumab | C | | Not Reported |
| Aztreonam | C | | Not Reported |
| Levaquin | C | | Not Reported |
| Pravastatin | C | | Not Reported |
| Sirolimus | C | | Not Reported |
| Prednisone | C | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833477 | DIRECT | | OT | | | 71 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Pulmonary Embolism | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833483 | DIRECT | Y | DE | | | 61 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|------------------------------|--------------|------------|-------------|------------------|-----------------------|-----------------|--------------|
| Respiratory Arrest | Remdesivir | Y | | S | Intravenous drip | Other Frequency:Once; | | Gilead |
| | Covid-19 Convalescent Plasma | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833489 | DIRECT | Y | DE | | | 83 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Acute Hepatic Failure; Diarrhoea; Malaise; Pyrexia | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Apixaban | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Chlorhexidine Oral Solution | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Gabapentin | | | C | | | | Not Reported |
| | Insulin (Lispro, Regular) | | | C | | | | Not Reported |

| | | |
|-------------------------------|---|--------------|
| Lactated Ringers | C | Not Reported |
| Latanoprost Drops | C | Not Reported |
| Magnesium Sulfate | C | Not Reported |
| Metoprolol Tartrate | C | Not Reported |
| Metronidazole | C | Not Reported |
| Modafinil | C | Not Reported |
| Mometasone/Formoterol | C | Not Reported |
| Montelukast | C | Not Reported |
| Morphine | C | Not Reported |
| Potassium Chloride | C | Not Reported |
| Sertraline | C | Not Reported |
| Sodium Chloride 0.9% Infusion | C | Not Reported |
| Vancomycin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833490 | DIRECT | Y | DE | | | 76 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-----------------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Acidosis; Acute Respiratory Failure; Cough; Dyspnoea; Hypoxia; Renal Impairment; Sepsis | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Albuterol | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Chlorhexidine Oral Solution | | | C | | | | Not Reported |
| | Normosol-R | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Hydrocortisone Iv | | | C | | | | Not Reported |
| | Triad Paste Wound Dressing | | | C | | | | Not Reported |
| | Insulin (Glargine, Regular) | | | C | | | | Not Reported |
| | Lactated Ringers | | | C | | | | Not Reported |
| | Lactulose | | | C | | | | Not Reported |
| | Magnesium Sulfate Iv | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Metronidazole | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Midodrine | | | C | | | | Not Reported |
| | Morphine Sulfate | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--|----------------|------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|--------------|----------------|
| 27-May-2020 | 17833492 | DIRECT | | OT | | | 57 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatinine Increased; Creatinine Renal Clearance Decreased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--|---------------------------------|------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|--------------|----------------|
| 27-May-2020 | 17833505 | DIRECT | Y | OT | | | 56 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Abdominal Distension; General Physical Health Deterioration; | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead | |
| Haemoglobin Decreased; Intestinal Dilatation; Intestinal Ischaemia; | Amiodarone | | | C | | | | Not Reported | |
| Lactic Acidosis; Neutrophil Count Decreased; Platelet Count Decreased; Septic Shock; Supraventricular Tachycardia; Tissue Infiltration | Albumin | | | C | | | | Not Reported | |
| | Cyanocobalamin | | | C | | | | Not Reported | |
| | Folic Acid | | | C | | | | Not Reported | |
| | Heparin Sq | | | C | | | | Not Reported | |
| | Enoxaparin Sq | | | C | | | | Not Reported | |
| | Famotidine | | | C | | | | Not Reported | |
| | Hydrocortisone Sodium Succinate | | | C | | | | Not Reported | |
| | Midodrine | | | C | | | | Not Reported | |
| | Multivitamin | | | C | | | | Not Reported | |
| | Nicotine Transdermal | | | C | | | | Not Reported | |
| | Thiamine | | | C | | | | Not Reported | |
| | Dobutamine Infusion | | | C | | | | Not Reported | |
| | Epinephrine Infusion | | | C | | | | Not Reported | |
| | Fentanyl Infusion | | | C | | | | Not Reported | |
| | Ketamine Infusion | | | C | | | | Not Reported | |
| | Norepinephrine Infusion | | | C | | | | Not Reported | |
| | Phenylephrine Infusion | | | C | | | | Not Reported | |
| | Vasopressin Infusion | | | C | | | | Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833510 | DIRECT | Y | OT | | | 50 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|------------------|-----------------------|-----------------|--------------|
| Acute Kidney Injury | Remdesivir | | | S | Intravenous drip | Other Frequency:Once; | 1 DAY | Gilead |
| | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Albumin | | | C | | | | Not Reported |
| | Calcium Gluconate | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Levofloxacin | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Sertraline | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| Midazolam | | | C | | | | Not Reported | |
| Norepinephrine | | | C | | | | Not Reported | |
| Propofol | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833527 | DIRECT | Y | OT | | | 69 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Rhabdomyolysis | Remdesivir | | | S | Intravenous (not otherwise specified) | | 4 DAY | Not Reported |
| | Sinemet | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Reglan | | | C | | | | Not Reported |
| | Midodrine | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Pepcid | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|------------|---|--------------|
| Lovenox | C | Not Reported |
| Solumedrol | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833532 | DIRECT | Y | OT | | | 68 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased | Remdesivir | Y | | S | | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833533 | DIRECT | Y | | | | 64 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Liver Function Test Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | 1 DAY | Not Reported |
| | Zithromax | | | C | | | | Not Reported |
| | Rocephin | | | C | | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |
| | Solumedrol | | | C | | | | Not Reported |
| | Humalog | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833539 | DIRECT | Y | HO | | | 82 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------------|--------------|------------|-------------|---------------|-----------------------|-----------------|------------|
| Blood Pressure Increased; Headache; Heart Rate Increased; Migraine; Myalgia; Pain; Pruritus; Rash Papular | Remdesivir Injection | Y | | S | Iontophoresis | Other Frequency:Once; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833545 | DIRECT | Y | OT | | | 65 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|--|--------------------|-----------------|------------|
| Blood Creatine Increased; Glomerular Filtration Rate Decreased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833603 | DIRECT | Y | HO, LT | | | 48 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Bacterial Infection; White Blood Cell Count Increased | Remdesivir | | | S | | | | Not Reported |
| | Aspirin 81mg | | | C | | | | Not Reported |
| | Atorvastatin 10mg | | | C | | | | Not Reported |
| | Famotidine 20mg | | | C | | | | Not Reported |
| | Furosemide 20mg | | | C | | | | Not Reported |
| | Lorazepam 2mg | | | C | | | | Not Reported |
| | Sodium Chloride | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Insulin Aspart | | | C | | | | Not Reported |
| | Insulin Detemir | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833610 | DIRECT | Y | OT | | | 69 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Condition Aggravated; Pyrexia; Ventricular Tachycardia | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Amlodipine | | | C | | | | Not Reported |
| | Apixaban | | | C | | | | Not Reported |
| | Aspirin Ec | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Benzotropine | | | C | | | | Not Reported |
| | Carvedilol | | | C | | | | Not Reported |
| | Divalproex | | | C | | | | Not Reported |
| | Donepezil | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|---|---|--------------|
| Furosemide | C | Not Reported |
| Guaifenesin | C | Not Reported |
| Insulin Glargine | C | Not Reported |
| Insulin Regular Human | C | Not Reported |
| Ipratropium/Albuterol Inhalation | C | Not Reported |
| Loratadine | C | Not Reported |
| Methylprednisolone Sodium Succinate | C | Not Reported |
| Montelukast | C | Not Reported |
| Ibrutinib | C | Not Reported |
| Pantoprazole | C | Not Reported |
| Also: Quetiapine, Tamsulosin, Zinc Sulfate, & Zosyn | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833630 | DIRECT | Y | | | | 66 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Liver Function Test Increased | Remdesivir | | | S | Intravenous drip | | | Not Reported |
| | Remdesivir | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833637 | DIRECT | Y | DE | | | 73 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Death | Remdesivir For Eua | Y | | S | | | | Gilead |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Insulin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833642 | DIRECT | Y | LT | | | 26 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Pulseless Electrical | Remdesivir | | | S | Intravenous (not otherwise specified) | | 1 DAY | Gilead |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | | |
|-----------------------------------|--------------------|---|--------------|
| Activity; Transaminases Increased | Azithromycin | C | Not Reported |
| | Cefepime | C | Not Reported |
| | Calcium Gluconate | C | Not Reported |
| | Enoxaparin | C | Not Reported |
| | Methylprednisolone | C | Not Reported |
| | Pantoprazole | C | Not Reported |
| | Zinc Sulfate | C | Not Reported |
| | Acetaminophen | C | Not Reported |
| | Ondansetron | C | Not Reported |
| | Fentanyl | C | Not Reported |
| | Midazolam | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833647 | DIRECT | Y | | | | 42 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---------------------------|--------------|------------|-------------|------------------|-----------------------|-----------------|--------------|
| Chills; Tremor | Remdesivir | | | S | Intravenous drip | Other Frequency:Once; | | Gilead |
| | Enoxaparin | | | C | | | | Not Reported |
| | Insulin Glargine (Lantus) | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 27-May-2020 | 17833652 | DIRECT | Y | HO, OT | | | 80 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; International Normalised Ratio Increased; Liver Disorder; Prothrombin Time Prolonged | Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Unknown |
| | Actemra | | | C | | | | Not Reported |
| | Plaquinil | | | C | | | | Not Reported |
| | Ceftiraxone | | | C | | | | Not Reported |
| | Doxycycline | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Vit C | | | C | | | | Not Reported |
| | Torse mide | | | C | | | | Not Reported |
| | Cardizem | | | C | | | | Not Reported |
| | Lipitor | | | C | | | | Not Reported |
| | Protonix | | | C | | | | Not Reported |
| | Metoprolol XI | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| Prednisone | | | C | | | Not Reported | | | |
|--|----------------|------------------|--------------------|-----------------|---------------------------------------|-----------------------|-----------------|------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 27-May-2020 | 17833668 | DIRECT | Y | | | | 40 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Liver Function Test Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 27-May-2020 | 17833677 | DIRECT | Y | DE | | | 77 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Condition Aggravated; Dyspnoea; Hypoxia; Lethargy; Respiratory Disorder | Remdesivir | | | S | | | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 27-May-2020 | 17833720 | DIRECT | Y | | | | 57 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Infusion Site Extravasation | Remdesivir | Y | | S | Intravenous drip | Other Frequency:Once; | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 27-May-2020 | 17833738 | DIRECT | Y | | | | 1 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Incorrect Product Formulation Administered; Product Dispensing Error; Product Use Issue; Therapy Interrupted | Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--|--------------------------|--------------------|--------------------|-----------------|--|-------------------------------|-----------------|------------------------------|----------------|
| 27-May-2020 | 17833753 | DIRECT | | DE | | | 80 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Covid-19 | Remdesivir Remdesivir | | | S C | | | | Gilead Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 27-May-2020 | 17833766 | DIRECT | | OT | | | 62 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Liver Function Test Increased | Remdesivir Remdesivir | | | S C | | | | Not Reported Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 27-May-2020 | 17839011 | DIRECT | Y | | | | | Unknown | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Liver Function Test Increased | Remdesivir Remdesivir | | | S C | Intravenous drip | | | Not Reported Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 28-May-2020 | 17812574 | EXPEDITED (15-DAY) | | DE, OT | GB-PFIZER INC- 2020198894 | | | Male | GBR |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acute Kidney Injury; Multiple Organ Dysfunction Syndrome | Spirolonactone | | | S | Oral | 50 Mg, Bid (100mg Per Day) | | Pfizer | |
| | Furosemide | | | S | Intravenous (not otherwise specified) | 40 Mg, Bid (80 Mg Per Day) | | Not Reported | |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Not Reported | |
| | Atorvastatin | | | C | | Unk | | Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|--|---|-----|--------------|
| Ipratropium | C | | Not Reported |
| Azithromycin | C | Unk | Not Reported |
| Co-Amoxiclav [Amoxicillin;Clavulanate Potassium] | C | Unk | Not Reported |
| Lansoprazole | C | Unk | Not Reported |
| Paracetamol | C | Unk | Not Reported |
| Midazolam | C | Unk | Not Reported |
| Metoclopramide | C | Unk | Not Reported |
| Morphine | C | Unk | Not Reported |
| Salbutamol | C | Unk | Not Reported |
| Noradrenaline [Norepinephrine] | C | Unk | Not Reported |
| Rocuronium | C | Unk | Not Reported |
| Piperacilin/Tazobactam | C | Unk | Not Reported |
| Erythromycin | C | Unk | Not Reported |
| Heparin | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17833859 | DIRECT | Y | OT | | | 78 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|--|--|-----------------|------------|
| Disturbance In Attention; Lethargy; Oxygen Saturation Decreased; Palpitations; Tremor; Ventricular Tachycardia | Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:Once (Loading Dose; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834192 | DIRECT | Y | OT | | | 92 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; | Remdesivir | | | S | | | | Gilead |
| Alanine Aminotransferase | Remdesivir | | | C | | | | Not Reported |

Increased; Aspartate
Aminotransferase
Increased; Blood
Creatinine Increased;
Glomerular Filtration Rate
Decreased

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834582 | DIRECT | Y | DE | | | 78 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Hypoxia | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Cefepime | | | C | | | | Not Reported |
| | Ipratropium | | | C | | | | Not Reported |
| | Metoprolol | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Insulin | | | C | | | | Not Reported |
| | Diltiazem | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Morphine | | | C | | | | Not Reported |
| | Allopurinol | | | C | | | | Not Reported |
| | Dexmedetomidine | | | C | | | | Not Reported |
| | Lorazepam | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834588 | DIRECT | Y | DE, OT | | | 61 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Febrile Neutropenia; Respiratory Failure | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Tocilizumab | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|----------------------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|------------------------|----------------|
| 28-May-2020 | 17834593 | DIRECT | Y | LT | | | 86 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Therapy Interrupted | Remdesivir Atorvastatin | Y | | S C | Intravenous bolus | | | Gilead Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|---|------------------|--------------------|---|----------------------|----------------------|-----------------|--|----------------|
| 28-May-2020 | 17834597 | DIRECT | Y | DE | | | 38 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Bradycardia; Condition Aggravated; Hypotension; Inflammatory Marker Increased; Ventricular Fibrillation | Remdesivir Acetaminophen 650mg Tablet Cefepime 2g Ivpb Dexmedetomidine 1.4mg/Kg/Hr Infusion Enoxaparin 40mg Bid Etomidate 20mg Once Fentanyl 100mcg Once Insulin Glargine 5 Units Bid Insulin Lispro Sliding Scale Lorazepam 1mg Inj Once Insulin Regular Sliding Scale Midazolam 5mg Inj Once Propofol Infusion Rocuronium Infusion Vancomycin 1250mg Q6h Magnesium Oxide 400mg Bid Potassium Chloride 40meq Daily | Y | | S C C C C C C C C C C C C C C C C C C | Intravenous bolus | | | Gilead Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834603 | DIRECT | Y | DS | | | 51 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------|--------------|------------|-------------|-------------------|-------------------------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatinine Increased; Blood Pressure Decreased; Blood Urea Increased | Remdesivir | Y | | S | Intravenous bolus | Other Frequency:1 Time & 100 Daily; | | Gilead |
| | Lovenox 40mg | | | C | | | | Not Reported |
| | Docusate With Senna | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Lantus | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Lisinopril | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Fentanyl Drip | | | C | | | | Not Reported |
| | Lactated Ringers | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| Rocuronium | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834607 | DIRECT | | DE | | | 92 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Acute Kidney Injury | Remdesivir | | | S | | | | Gilead |
| | Remdesivir | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834613 | DIRECT | Y | DE | | | 86 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| General Physical Health Deterioration; Hypoxia | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |
| | Convalescent Plasma | | | C | | | | Not Reported |
| | Tocilizumab | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834623 | DIRECT | Y | OT | | | 70 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | | |
|-------------------------|---------------|---|---|---------------------------------------|--------------|
| Transaminases Increased | Remdesivir | Y | S | Intravenous (not otherwise specified) | Gilead |
| | Acetaminophen | | C | | Not Reported |
| | Enoxaparin | | C | | Not Reported |
| | Fentanyl | | C | | Not Reported |
| | Furosemide | | C | | Not Reported |
| | Insulin | | C | | Not Reported |
| | Linezolid | | C | | Not Reported |
| | Meropenem | | C | | Not Reported |
| | Lorazepam | | C | | Not Reported |
| | Phenylephrine | | C | | Not Reported |
| | Propofol | | C | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834646 | DIRECT | Y | OT | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Atrial Fibrillation; Clinical Trial Participant; Product Use In Unapproved Indication | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834651 | DIRECT | Y | DE | | | 61 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Clinical Trial Participant; Liver Function Test Increased; Multiple Organ Dysfunction Syndrome; Product Use In Unapproved Indication; Shock | Remdesivir | | | S | Intravenous (not otherwise specified) | | 2 DAY | Gilead |
| | Norepinephrine Infusion | | | C | | | | Not Reported |
| | Phenylephrine Infusion | | | C | | | | Not Reported |
| | Vasopressin Infusion | | | C | | | | Not Reported |
| | Epinephrine Infusion | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834885 | DIRECT | Y | DE | | | 83 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---|--------------|------------|-------------|--|--------------------|-----------------|------------------------------|
| Clinical Trial Participant; Product Use In | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| Unapproved Indication; Respiratory Failure | Azithromycin Piperacillin/Tazobactam | | | C C | | | | Not Reported Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834887 | DIRECT | Y | DE | | | 66 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------------------|--------------|------------|-------------|--|--------------------|-----------------|------------------------|
| Clinical Trial Participant; Palliative Care; Product Use In Unapproved Indication; Therapy Cessation | Remdesivir Convalescent Plasma | | | S C | Intravenous (not otherwise specified) | | | Gilead Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834892 | DIRECT | Y | OT | | | 56 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------------------------|
| Clinical Trial Participant; Dysphagia; Headache; Product Use In Unapproved Indication | Remdesivir Convalescent Plasma | | | S C | | | | Not Reported Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834894 | DIRECT | Y | OT | | | 74 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--|
| Acute Kidney Injury; Clinical Trial Participant; Product Use In Unapproved Indication | Remdesivir Amlodipine Ibuprofen | | | S C C | | | | Not Reported Not Reported Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|----------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|------------|----------------|
| 28-May-2020 | 17834895 | DIRECT | Y | OT | | | 73 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Hepatic Enzyme Increased; Therapy Cessation | Remdesivir | | | S | Intravenous drip | | | Gilead | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|-------------------------------|--------------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|--------------|----------------|
| 28-May-2020 | 17834911 | DIRECT | Y | | | | 54 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Liver Function Test Increased | Remdesivir | Y | | S | Intravenous bolus | | | Gilead | |
| | Valproic Acid | | | C | | | | Not Reported | |
| | Hydroxychloroquine | | | C | | | | Not Reported | |
| | Azithromycin | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|------------------------|------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|--------------|----------------|
| 28-May-2020 | 17834946 | DIRECT | Y | OT | | | 65 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acute Kidney Injury; Renal Tubular Necrosis | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Morphine | | | C | | | | Not Reported | |
| | Duoneb | | | C | | | | Not Reported | |
| | Dextrose 50% | | | C | | | | Not Reported | |
| | Sodium Chloride Flush | | | C | | | | Not Reported | |
| | Sodium Chloride 250 MI | | | C | | | | Not Reported | |
| | Potassium Chloride | | | C | | | | Not Reported | |
| | Magnesium Sulfate | | | C | | | | Not Reported | |
| | Dexmedetomidine | | | C | | | | Not Reported | |
| | Zinc Sulfate | | | C | | | | Not Reported | |
| | Cefepime | | | C | | | | Not Reported | |
| | Enoxaparin | | | C | | | | Not Reported | |
| | Metoprolol | | | C | | | | Not Reported | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|--------------------|---|--------------|
| Pantoprazole | C | Not Reported |
| Bumetanide | C | Not Reported |
| Methylprednisolone | C | Not Reported |
| Insulin Lispro | C | Not Reported |
| Chlorothiazide | C | Not Reported |
| Vancomycin | C | Not Reported |
| Insulin Detemir | C | Not Reported |
| Tocilizumab | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834965 | DIRECT | Y | OT | | | 49 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Therapy Interrupted | Remdesivir | | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834973 | DIRECT | Y | OT | | | 53 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Liver Function Test Increased; Therapy Interrupted | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17834979 | DIRECT | Y | | | | 84 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-------------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Anaemia; Platelet Count Increased; White Blood Cell Count Decreased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Acyclovir 400 Mg Po Bid | | | C | | | | Not Reported |
| | Allopurinol 300 Mg Po Daily | | | C | | | | Not Reported |
| | Aspirin 325 Mg Po Daily | | | C | | | | Not Reported |
| | Cholecalciferol 2000 Units Po Daily | | | C | | | | Not Reported |
| | Furosemide 20 Mg Po Bid | | | C | | | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| | | |
|-------------------------------|---|--------------|
| Levothyroxine 88 Mcg Po Daily | C | Not Reported |
| Meropenem 1 Gram Iv Q12h | C | Not Reported |
| Ruxolitinib | C | Not Reported |
| Heparin Iv Infusion | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17835864 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468283 | | 38 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Aspartate Aminotransferase Increased; Aspartate Aminotransferase Increased; Septic Shock | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Qd | | Gilead |
| | Ceftriaxone | | | C | | Unk | | Not Reported |
| | Heparin | | | C | | Unk | | Not Reported |
| | Insulin | | | C | | Unk | | Not Reported |
| | Midazolam | | | C | | Unk | | Not Reported |
| | Norepinephrine | | | C | | Unk | | Not Reported |
| | Azithromycin | | | C | | Unk | | Not Reported |
| | Tocilizumab | | | C | | Unk | | Not Reported |
| | Vancomycin | | | C | | Unk | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17835865 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468246 | | 70 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Abnormal; Aspartate Aminotransferase Abnormal | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |
| | Atorvastatin | | | C | | Unk | | Not Reported |
| | Propofol | | | C | | Unk | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17835872 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468272 | | 46 YR | Female | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Seizure | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Tocilizumab | | | C | | Unk | | Not Reported |
| | Zinc | | | C | | Unk | | Not Reported |
| | Quetiapine | | | C | | Unk | | Not Reported |
| | Methylprednisolone | | | C | | Unk | | Not Reported |
| | Melatonin | | | C | | Unk | | Not Reported |
| | Levetiracetam | | | C | | Unk | | Not Reported |
| | Atorvastatin | | | C | | Unk | | Not Reported |
| | Ascorbic Acid | | | C | | Unk | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17835873 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468468 | | 75 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Atrial Fibrillation | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Acetaminophen | | | C | | Unk | | Not Reported |
| | Amlodipine | | | C | | Unk | | Not Reported |
| | Apixaban | | | C | | Unk | | Not Reported |
| | Doxazosin | | | C | | Unk | | Not Reported |
| | Hydralazine | | | C | | Unk | | Not Reported |
| | Lorazepam | | | C | | Unk | | Not Reported |
| | Combivent Respimat | | | C | | Unk | | Not Reported |
| | Ascorbic Acid | | | C | | Unk | | Not Reported |
| | Cholecalciferol | | | C | | Unk | | Not Reported |
| | Levothyroxine | | | C | | Unk | | Not Reported |
| | Zinc Sulfate | | | C | | Unk | | Not Reported |
| | Tylenol | | | C | | Unk | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17835874 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468237 | | 23 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|--------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Liver Function Test Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |
| | Acetaminophen | | | C | Oral | 1000 Mg Q5h | | Not Reported |
| | Dextromethorphan | | | C | Oral | 30 Mg | | Not Reported |
| | Benzonate | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Aspirin [Acetylsalicylic Acid] | | | C | | | | Not Reported |
| | Ibuprofen | | | C | | | | Not Reported |
| | Vitamin C [Ascorbic Acid] | | | C | | | | Not Reported |
| | Zinc Sulfate | | | C | | | | Not Reported |
| | Hydroxychloroquine | | | C | | | | Not Reported |
| | Prednisone | | | C | | | | Not Reported |
| Albuterol Hfa | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17835876 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468482 | | 49 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Abnormal; Blood Alkaline Phosphatase Increased; Hypotension | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |
| | Atorvastatin | | | C | | Unk | | Not Reported |
| | Ceftriaxone | | | C | | Unk | | Not Reported |
| | Desvenlafaxine | | | C | | Unk | | Not Reported |
| | Epoetin Alfa | | | C | | Unk | | Not Reported |
| | Famotidine | | | C | | Unk | | Not Reported |
| | Heparin | | | C | | Unk | | Not Reported |
| | Hydrocortisone Sodium Succinate | | | C | | Unk | | Not Reported |
| | Insulin Glargine | | | C | | Unk | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|--------------------|---|-----|--------------|
| Insulin Lispro | C | Unk | Not Reported |
| Methadone | C | Unk | Not Reported |
| Metoprolol | C | Unk | Not Reported |
| Potassium Chloride | C | Unk | Not Reported |
| Pregabalin | C | Unk | Not Reported |
| Azithromycin | C | Unk | Not Reported |
| Hydroxychloroquine | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17835882 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468290 | | 67 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Dysphagia; Swelling; Throat Irritation | Remdesivir | | | S | Unknown | 200 Mg | | Gilead |
| | Albuterol Hfa | | | C | | Unk | | Not Reported |
| | Nystatin | | | C | | Unk | | Not Reported |
| | Percocet [Oxycodone Hydrochloride;Paracetamol] | | | C | | Unk | | Not Reported |
| | Pantoprazole | | | C | | Unk | | Not Reported |
| | Zinc | | | C | | Unk | | Not Reported |
| | Vitamin D [Colecalciferol] | | | C | | Unk | | Not Reported |
| | Vitamin C [Ascorbic Acid] | | | C | | Unk | | Not Reported |
| | Aspirin [Acetylsalicylic Acid] | | | C | | Unk | | Not Reported |
| | Methylprednisolone | | | C | | Unk | | Not Reported |
| | Dipridamole | | | C | | Unk | | Not Reported |
| | Insulin Lispro | | | C | | Unk | | Not Reported |
| | Letrozole | | | C | | Unk | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17837784 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468230 | | 60 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

Acute Kidney Injury; Medication Error; Product Use Issue Remdesivir S Unknown Unk Gilead

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17837791 | EXPEDITED (15-DAY) | | DS, HO, LT, OT | US-GILEAD-2020-0469042 | | 67 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Hydronephrosis; Necrosis; Renal Impairment; Respiratory Disorder | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Acetaminophen | | | C | | Unk | | Not Reported |
| | Duoneb | | | C | | Unk | | Not Reported |
| | Azithromycin | | | C | | Unk | | Not Reported |
| | Amiodarone | | | C | | Unk | | Not Reported |
| | Cefepime | | | C | | Unk | | Not Reported |
| | Potassium Chloride | | | C | | Unk | | Not Reported |
| | Tocilizumab | | | C | | Unk | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17837798 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0468927 | | 76 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Death | Remdesivir | | | S | Intravenous (not otherwise specified) | 300 Mg, Total | | Gilead |
| | Cefepime | | | C | | Unk | | Not Reported |
| | Enoxaparin | | | C | | Unk | | Not Reported |
| | Famotidine | | | C | | Unk | | Not Reported |
| | Fentanyl | | | C | | Unk | | Not Reported |
| | Heparin | | | C | | Unk | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|--------------------|---|-----|--------------|
| Insulin Lispro | C | Unk | Not Reported |
| Methocarbamol | C | Unk | Not Reported |
| Methylprednisolone | C | Unk | Not Reported |
| Midazolam | C | Unk | Not Reported |
| Norepinephrine | C | Unk | Not Reported |
| Pregabalin | C | Unk | Not Reported |
| Propofol | C | Unk | Not Reported |
| Vancomycin | C | Unk | Not Reported |
| Vasopressin | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838503 | DIRECT | Y | OT | | | 57 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Hypotension; Renal Impairment | Remdesivir | | | S | Intravenous drip | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Rocuronium | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838778 | DIRECT | Y | OT | | | 51 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Blood Creatine Phosphokinase Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Atorvastatin Tablet | | | C | | | | Not Reported |
| | Ceftriaxone Injection | | | C | | | | Not Reported |
| | Enoxaparin Injection | | | C | | | | Not Reported |
| | Furosemide Injection | | | C | | | | Not Reported |
| | Guaifenesin Tablet | | | C | | | | Not Reported |
| | Hydroxychloroquine Tablet | | | C | | | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|------------------------------|---|--------------|
| Lansoprazole Capsule | C | Not Reported |
| Levothyroxine Tablet | C | Not Reported |
| Methylprednisolone Injection | C | Not Reported |
| Pantoprazole Tablet | C | Not Reported |
| Vancomycin Injection | C | Not Reported |
| Propofol Injection | C | Not Reported |
| Acetaminophen Tablet | C | Not Reported |
| Alprazolam Tablet | C | Not Reported |
| Lorazepam Injection | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838938 | DIRECT | Y | | | | 33 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir | Y | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838945 | DIRECT | Y | OT | | | 60 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Transaminases Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838949 | DIRECT | Y | | | | 90 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Glomerular Filtration Rate Decreased; Therapy Cessation | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Vancomycin | | | C | | | | Not Reported |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838954 | DIRECT | Y | OT | | | 73 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Renal Failure | Remdesivir | Y | | S | Intravenous drip | | | Gilead |
| | Fenatnyl | | | C | | | | Not Reported |
| | Nimbex | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Cetrixone | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838955 | DIRECT | Y | OT | | | 63 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|-------------------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|--------------|
| Acute Kidney Injury; Ischaemic Hepatitis; Transaminases Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |
| | Azithromycin | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Dexamethasone | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Phenylephrine | | | C | | | | Not Reported |
| | Piperacillin/Tazobactam | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Rocuronium | | | C | | | | Not Reported |
| | Zinc Sulfate | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838959 | DIRECT | Y | HO, LT | | | 63 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

Acute Kidney Injury; Haemodialysis Remdesivir S Intravenous (not otherwise specified) Gilead

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838962 | DIRECT | Y | | | | 73 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------------------|--------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Aspartate Aminotransferase Increased | Remdesivir | | | S | Oral | | | Gilead |
| | Cefepime | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Aripiprazole | | | C | | | | Not Reported |
| | Gabapentin | | | C | | | | Not Reported |
| | Mirtazapine | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Prazosin | | | C | | | | Not Reported |
| | Tamsulosin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838968 | DIRECT | Y | | | | 82 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| International Normalised Ratio Increased | Remdesivir | Y | | S | Intravenous drip | | | Gilead |
| | Eliquis 2.5mg Q12h | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838972 | DIRECT | Y | LT | | | 34 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Ventricular Tachycardia | Remdesivir | Y | | S | Intravenous drip | | | Gilead |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|---|----------------|------------------|--------------------|-----------------|----------------------|--|-----------------------|-----------------|----------------|
| 28-May-2020 | 17838976 | DIRECT | Y | | | | 71 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Chills; Hypotension; Infusion Site Extravasation; Infusion Site Reaction; Nausea | Remdesivir | | | | S | Intravenous drip | | | Gilead |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 28-May-2020 | 17838982 | DIRECT | Y | OT | | | 62 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Acute Kidney Injury; Creatinine Renal Clearance Decreased; Glomerular Filtration Rate Decreased | Remdesivir | | | | S | Intravenous drip | | | Gilead |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 28-May-2020 | 17838987 | DIRECT | Y | | | | 91 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Glomerular Filtration Rate Decreased | Remdesivir | | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Vancomycin | | | | C | | | | Not Reported |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 28-May-2020 | 17838988 | DIRECT | Y | OT | | | 49 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
| Acute Kidney Injury; Creatinine Renal Clearance Decreased; | Remdesivir | | | | S | Intravenous drip | Other Frequency:Once; | | Gilead |

Glomerular Filtration Rate
Decreased

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838991 | DIRECT | Y | OT | | | 74 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Creatinine Renal Clearance Decreased; Glomerular Filtration Rate Decreased; Therapy Cessation | Remdesivir | | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838994 | DIRECT | Y | | | | 77 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Acute Kidney Injury; Blood Creatine Increased; Creatinine Renal Clearance Decreased; Glomerular Filtration Rate Decreased | Remdesivir | | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17838997 | DIRECT | Y | | | | 32 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Hepatotoxicity | Remdesivir | | | S | Intravenous drip | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17839001 | DIRECT | Y | LT, OT | | | 78 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| | | | | | | | | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | | | |
|---------------------|---------------------------|---|------------------|--------------|
| Acute Kidney Injury | Remdesivir | S | Intravenous drip | Gilead |
| | Rocuronium | C | | Not Reported |
| | Sodium Bicarbonate 50 Meq | C | | Not Reported |
| | Fentanyl | C | | Not Reported |
| | Insulin Drip | C | | Not Reported |
| | Morphine | C | | Not Reported |
| | Propofol | C | | Not Reported |
| | Zosyn | C | | Not Reported |
| | Azithromycin | C | | Not Reported |
| | Bumex | C | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17839004 | DIRECT | Y | OT | | | 82 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|----------------------------------|---------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| White Blood Cell Count Decreased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Allopurinol | | | C | | | | Not Reported |
| | Amiodarone | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Cardidopa-Levodopa | | | C | | | | Not Reported |
| | Diltiazem | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Hydrocodone-Acetaminophen | | | C | | | | Not Reported |
| | Insulin Aspart | | | C | | | | Not Reported |
| | Insulin Glargine | | | C | | | | Not Reported |
| | Methylprednisolone | | | C | | | | Not Reported |
| | Metoprolol Tartrate | | | C | | | | Not Reported |
| | Sertraline | | | C | | | | Not Reported |
| | Topiramate | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 28-May-2020 | 17839023 | DIRECT | Y | DE | | | 73 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | | | | | | |
|--|--|------------------|--------------------|-----------------------|---------------------------------------|-----------------------|-----------------|--|----------------|
| Ventricular Fibrillation | Remdesivir | | S | Intravenous drip | Other Frequency:Once; | | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 28-May-2020 | 17839025 | DIRECT | Y | | | | 54 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acute Kidney Injury | Remdesivir | | | S | Intravenous bolus | Other Frequency:Once; | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 28-May-2020 | 17839026 | DIRECT | Y | DE | | | 88 YR | Female | AFG |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Hypotension; Hypoxia; Skin Discolouration | Remdesivir Azithromycin Aztreonam Ceftriaxone Pumozyme | | | S C C C C | Intravenous drip | | | Gilead Not Reported Not Reported Not Reported Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 28-May-2020 | 17839552 | DIRECT | Y | HO, RI, OT | | | 94 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Thrombocytopenia | Remdesivir 100mg/20ml | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 28-May-2020 | 17839768 | DIRECT | Y | | | | 32 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Liver Function Test Increased | Remdesivir | Y | | S | Intravenous drip | | | Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17839763 | DIRECT | Y | | | | 76 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------|----------------------|--------------|------------|-------------|-------------------|---------------------------|-----------------|--------------|
| Ventricular Tachycardia | Remdesivir Injection | | | S | Intravenous bolus | Other Frequency:200mg X1; | | Gilead |
| | Amlodipine | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Metoprolol XI | | | C | | | | Not Reported |
| | Prazosin | | | C | | | | Not Reported |
| | Probenecid | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17839790 | DIRECT | Y | DE | | | 81 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------------|--|--------------|------------|-------------|-------------------|--------------------|-----------------|--------------|
| Dialysis; Renal Failure; Tachypnoea | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Acetaminophen | | | C | | | | Not Reported |
| | Amlodipine | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Benzonatate | | | C | | | | Not Reported |
| | Normosol-R | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Guaifenesin/Codeine | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Hydrochlorothiazide | | | C | | | | Not Reported |
| | Hydromorphone | | | C | | | | Not Reported |
| | Insulin (Glargine, Lispro And Regular) | | | C | | | | Not Reported |
| | Labetolol | | | C | | | | Not Reported |
| | Lactated Ringers | | | C | | | | Not Reported |
| | Levothyroxine | | | C | | | | Not Reported |
| | Lidocaine/Epinephrine | | | C | | | | Not Reported |
| | Lorazepam | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | | | | | | |
|---|---|-------------------------|---------------------------|------------------------|--|--|------------------------|------------------------------|-----------------------|
| | Magnesium Sulfate | | | | | | | | Not Reported |
| | Morphine | | | | | | | | Not Reported |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 29-May-2020 | 17839798 | DIRECT | Y | DE | | | 74 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acute Kidney Injury; Haemodialysis; | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| Pneumothorax; Pseudomonas Bacteraemia | Convalescent Plasma Tocilizumab Or Matching Placebo | | | C C | | | | Not Reported Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 29-May-2020 | 17839805 | DIRECT | Y | DE | | | 75 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Fluid Overload; Hypotension | Remdesivir Solution | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Convalescent Plasma | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 29-May-2020 | 17839841 | DIRECT | Y | OT | | | 48 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Feeling Hot; Flushing; Infusion Related Reaction | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Once Then 100mg X4; | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 29-May-2020 | 17839991 | DIRECT | Y | OT | | | 54 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Alanine Aminotransferase | Remdesivir | | | S | Intravenous drip | | | Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | | | | | | |
|------------------------------|---------------|---|--|--|--|--|--|--|--------------|
| Increased; Therapy Cessation | Acetaminophen | C | | | | | | | Not Reported |
| | Azithromycin | C | | | | | | | Not Reported |
| | Ceftriaxone | C | | | | | | | Not Reported |
| | Enoxaparin | C | | | | | | | Not Reported |
| | Vancomycin | C | | | | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840013 | DIRECT | Y | DE | | | 67 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|-----------------------|-----------------|------------|
| Death | Remdesivir | | | S | Intravenous drip | Other Frequency:Once; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840020 | DIRECT | Y | OT | | | 34 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Blood Alkaline Phosphatase Increased; Hyperhidrosis; Liver Function Test Increased; Therapy Cessation | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840027 | DIRECT | Y | OT | | | 65 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|---------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatinine Increased; Dialysis; Disease Progression | Remdesivir | Y | | S | | | | Gilead |
| | Aspirin | | | C | | | | Not Reported |
| | Atovastatin | | | C | | | | Not Reported |
| | Calcium Citrate/Vitamin D | | | C | | | | Not Reported |
| | Cefazolin | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |

| | | |
|-----------------|---|--------------|
| Furosemide | C | Not Reported |
| Hydrocortisone | C | Not Reported |
| Lansoprazole | C | Not Reported |
| Naloxegol | C | Not Reported |
| Multivitamin | C | Not Reported |
| Tacrolimus | C | Not Reported |
| Tenofovir | C | Not Reported |
| Atracurium | C | Not Reported |
| Dexmedetomidine | C | Not Reported |
| Fentanyl | C | Not Reported |
| Norepinephrine | C | Not Reported |
| Propofol | C | Not Reported |
| Vasopressin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840033 | DIRECT | Y | OT | | | 55 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Continuous Haemodiafiltration; Creatinine Renal Clearance Decreased; Endotracheal Intubation; Renal Impairment; Therapy Cessation | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840034 | DIRECT | Y | DE | | | 71 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|------------------|-----------------------|-----------------|------------|
| Acute Respiratory Distress Syndrome; Cardiac Arrest; Cardio-Respiratory Arrest; Pulse Absent; Shock | Remdesivir | Y | | S | Intravenous drip | Other Frequency:Once; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840052 | DIRECT | Y | OT | | | 55 YR | Male | XQZ |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---------------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Blood Bilirubin Increased | Remdesivir | | | S | Intravenous drip | | | Not Reported |
| | Rocuronium | | | C | | Not Reported | | |
| | Propofol | | | C | | Not Reported | | |
| | Norepinephrine | | | C | | Not Reported | | |
| | Midazolam | | | C | | Not Reported | | |
| | Hydromorphone | | | C | | Not Reported | | |
| | Fluoxetine | | | C | | Not Reported | | |
| | Fentanyl | | | C | | Not Reported | | |
| | Ceftriaxone | | | C | | Not Reported | | |
| | Heparin | | | C | | Not Reported | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840058 | DIRECT | Y | OT | | | 64 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------------------------|--------------|------------|-------------|-------------------|--------------------|-----------------|------------|
| Blood Creatinine Increased; C-Reactive Protein Increased; Fibrin D Dimer Increased; Glomerular Filtration Rate Decreased; Haematuria; Interleukin Level Increased; Seizure | Remdesivir | | | S | Intravenous bolus | | | Gilead |
| | Acetylcysteine 20% Oral Solution | | | C | | Not Reported | | |
| | Aztreonam | | | C | | Not Reported | | |
| | Furosemide | | | C | | Not Reported | | |
| | Levofloxacin | | | C | | Not Reported | | |
| | Tocilizumab | | | C | | Not Reported | | |
| | Acetaminophen | | | C | | Not Reported | | |
| | Albuterol | | | C | | Not Reported | | |
| | Atropine 1% (Orally) | | | C | | Not Reported | | |
| | Clopidogrel | | | C | | Not Reported | | |
| | Docusate | | | C | | Not Reported | | |
| | Heparin Subq | | | C | | Not Reported | | |
| | Levothyroxine | | | C | | Not Reported | | |
| | Midazolam | | | C | | Not Reported | | |
| | Norepinephrine | | | C | | Not Reported | | |
| | Pantoprazole | | | C | | Not Reported | | |
| | Propofol | | | C | | Not Reported | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840084 | DIRECT | Y | | | | 79 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Off Label Use | Remdesivir | Y | | S | | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840087 | DIRECT | Y | DE | | | 73 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|------------------------|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Disease Progression; Hypoxia; Respiratory Failure; Severe Acute Respiratory Syndrome | Remdesivir 100mg/20 MI | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Aspirin | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Carbidopa-Levodopa | | | C | | | | Not Reported |
| | Donepezil | | | C | | | | Not Reported |
| | Enoxaprin | | | C | | | | Not Reported |
| | Etomidate | | | C | | | | Not Reported |
| | Lispro | | | C | | | | Not Reported |
| | Insulin | | | C | | | | Not Reported |
| | Metoprolol | | | C | | | | Not Reported |
| | Montelukast | | | C | | | | Not Reported |
| | Solifenecin | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840213 | DIRECT | Y | DE | | | 68 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------------------|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Distributive Shock; Drug Ineffective | Remdesivir 100mg/20 MI Eua | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | | | | | Intravenous (not otherwise specified) | Frequency 4x | | |
| | Colace | | | C | | | | Not Reported |
| | Eliquis | | | C | | | | Not Reported |
| | Humalog | | | C | | | | Not Reported |
| | Insulin | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|-------------------------|---|--------------|
| Lantus | C | Not Reported |
| Pepcid | C | Not Reported |
| Miralax | C | Not Reported |
| Seroquel | C | Not Reported |
| Singulair | C | Not Reported |
| Zofran | C | Not Reported |
| Acetaminophen | C | Not Reported |
| Piperacillin Tazobactam | C | Not Reported |
| Azithromycin | C | Not Reported |
| Diclofenac | C | Not Reported |
| Propofol | C | Not Reported |
| Norepinephrine | C | Not Reported |
| Fentanyl | C | Not Reported |
| Exmedetomidine | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840266 | DIRECT | Y | OT | | | 67 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Bilirubin Increased; Blood Creatinine Increased; Dehydration; Hypotension; Transaminases Increased | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Fentanyl Drip | | | C | | | | Not Reported |
| | Norepinephrine Drip | | | C | | | | Not Reported |
| | Rocuronium Drip | | | C | | | | Not Reported |
| | Furosemide Ivp X1 | | | C | | | | Not Reported |
| | Gabapentin | | | C | | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Lactated Ringers | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Ketamine | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17840269 | DIRECT | Y | OT | | | 77 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|------------------|--------------------|-----------------|------------|
| Blood Creatinine | Remdesivir | | | S | Intravenous (not | | | Gilead |
| | | | | | | | | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | | | | | | | | |
|-----------|---------------|--|--|---|----------------------|--|--|--|--------------|
| Increased | | | | | otherwise specified) | | | | |
| | Furosemide Iv | | | C | | | | | Not Reported |
| | Furosemide Po | | | C | | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17841424 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468719 | | 56 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Norepinephrine | | | C | | 2-10 Mcg/Min | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Albumin | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Bumetanide | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Clonazepam | | | C | | | | Not Reported |
| | Desmopressin | | | C | | | | Not Reported |
| | Docusate | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Epoprostenol | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Hydromorphone | | | C | | | | Not Reported |
| | Ketamine | | | C | | | | Not Reported |
| | Insulin | | | C | | | | Not Reported |
| | Midodrine | | | C | | | | Not Reported |
| | Phenylephrine | | | C | | 25-50 Mcg/Min | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Rocuronium | | | C | | | | Not Reported |
| | Sennosides | | | C | | | | Not Reported |
| | Dopamine | | | C | | 1-7 Mcg/Kg/Min | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17841427 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468705 | | 69 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|--------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Kidney Injury; Blood Creatinine Increased; Blood Urea Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Insulin Aspart | | | C | | | | Not Reported |
| | Metoprolol | | | C | | | | Not Reported |
| | Cisatracurium | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Vasopressin | | | C | | | | Not Reported |
| | Vancomycin | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Pantoprazole | | | C | | | | Not Reported |
| | Tocilizumab | | | C | | | | Not Reported |
| | Digoxin | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Aspirin [Acetylsalicylic Acid] | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| Metolazone | | | C | | | | Not Reported | |
| Insulin Glargine | | | C | | | | Not Reported | |
| Atorvastatin | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17841756 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0468849 | | 68 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------------------|------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Acute Respiratory Failure; Covid-19 | Remdesivir | | | S | Intravenous (not otherwise specified) | Unk | | Gilead |
| | Zosyn | | | C | | Unk | | Not Reported |
| | Albuterol [Salbutamol] | | | C | | Unk | | Not Reported |
| | Insulin Lispro | | | C | | Unk | | Not Reported |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | | |
|--|---|-----|--------------|
| Insulin Glargine | C | Unk | Not Reported |
| Combivent | C | Unk | Not Reported |
| Amlodipine | C | Unk | Not Reported |
| Precedex | C | Unk | Not Reported |
| Lovenox [Enoxaparin Sodium] | C | Unk | Not Reported |
| Gabapentin | C | Unk | Not Reported |
| Seebri | C | Unk | Not Reported |
| Levothyroxine | C | Unk | Not Reported |
| Ativan | C | Unk | Not Reported |
| Lopressor | C | Unk | Not Reported |
| Dulera | C | Unk | Not Reported |
| Percocet [Oxycodone Hydrochloride;Paracetamol] | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17842483 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468473 | | 59 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------|--|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Transaminases Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Hydromorphone | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |
| | Zofran [Ondansetron] | | | C | | | | Not Reported |
| | Vitamin D3 | | | C | | | | Not Reported |
| | Titralac [Calcium Carbonate] | | | C | | | | Not Reported |
| | Seroquel | | | C | | | | Not Reported |
| | Calcium Gluconate | | | C | | | | Not Reported |
| | Lasix [Furosemide] | | | C | | | | Not Reported |
| | Lovenox [Enoxaparin Sodium] | | | C | | | | Not Reported |
| | Miralax | | | C | | | | Not Reported |
| | Benadryl [Diphenhydramine Hydrochloride] | | | C | | | | Not Reported |
| | Levophed | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--------------------------|---|--------------|
| Magnesium Sulfate | C | Not Reported |
| Potassium Chloride | C | Not Reported |
| Clozaril | C | Not Reported |
| Propofol | C | Not Reported |
| Amidate [Etomidate] | C | Not Reported |
| Quelicin | C | Not Reported |
| Fentanyl | C | Not Reported |
| Versed | C | Not Reported |
| Humuline Regular | C | Not Reported |
| Humalog | C | Not Reported |
| Ancef [Cefazolin Sodium] | C | Not Reported |
| Protonix [Omeprazole] | C | Not Reported |
| Flagyl [Metronidazole] | C | Not Reported |
| Rocephin [Ceftriaxone] | C | Not Reported |
| Vancomycin | C | Not Reported |
| Zenpep | C | Not Reported |
| Prilosec [Omeprazole] | C | Not Reported |
| Potassium Bicarbonate | C | Not Reported |
| Zemuron | C | Not Reported |
| Levaquin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17842534 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468511 | | 54 YR | Unknown | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased | Remdesivir | | | S | Unknown | Unk | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17842537 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0468948 | | 85 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Death | Remdesivir | | | S | Unknown | Unk | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17842544 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468274 | | 34 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Anxiety; Blood Pressure Increased; Body Temperature Abnormal; Erythema; Heart Rate Increased; Hyperhidrosis; Nausea; Oxygen Saturation Decreased; Respiratory Rate Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17844971 | DIRECT | Y | | | | 71 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-------------------------|--------------|------------|-------------|------------------|-----------------------|-----------------|--------------|
| Bradycardia | Remdesivir | | | S | Intravenous drip | Other Frequency:Once; | | Not Reported |
| | Prenisone` | | | C | | | | Not Reported |
| | Augmentin | | | C | | | | Not Reported |
| | Sertraline | | | C | | | | Not Reported |
| | Apixiban | | | C | | | | Not Reported |
| | Apriso | | | C | | | | Not Reported |
| | Divalproex | | | C | | | | Not Reported |
| | Cetirizine | | | C | | | | Not Reported |
| | Ferrous Gluconate | | | C | | | | Not Reported |
| | Guaifenesin | | | C | | | | Not Reported |
| | Hydroxyzine | | | C | | | | Not Reported |
| | Loperamide | | | C | | | | Not Reported |
| | Metoprolol Succinate XI | | | C | | | | Not Reported |
| | Omeprazole | | | C | | | | Not Reported |
| | Polyethylene Glycol | | | C | | | | Not Reported |
| | Spirolactone | | | C | | | | Not Reported |
| | Tamsulosin | | | C | | | | Not Reported |
| | Metoprol Tartrate | | | C | | | | Not Reported |
| | Zosyn | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| Saline | | | C | | | Not Reported | | | |
|---|----------------|------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|--------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 29-May-2020 | 17844976 | DIRECT | Y | HO | | | 27 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Liver Function Test Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Setraline | | | C | | | | Not Reported | |
| | Melatonin | | | C | | | | Not Reported | |
| | Acetaminophen | | | C | | | | Not Reported | |
| | Enoxaparin | | | C | | | | Not Reported | |
| | Ketorolac | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 29-May-2020 | 17844978 | DIRECT | Y | OT | | | 61 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Atrial Fibrillation; Heart Rate Irregular | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 29-May-2020 | 17844983 | DIRECT | Y | | | | 47 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Disease Progression; Hyperhidrosis; Hypotension | Remdesivir | Y | | S | Parenteral | | | Gilead | |
| | Lovenox | | | C | | | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 29-May-2020 | 17844998 | DIRECT | Y | HO | | | 77 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) Detailed Report

Acute Kidney Injury Remdesivir S Intravenous drip Gilead

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17845001 | DIRECT | Y | OT | | | 60 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|-------------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Blood Creatinine Increased; International Normalised Ratio Increased; Therapy Cessation | Remdesivir | Y | | S | Intravenous bolus | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17845002 | DIRECT | Y | DS | | | 33 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------|------------------|--------------|------------|-------------|------------------|----------------------------------|-----------------|--------------|
| Hypoxia; Quadripareisis | Remdesivir | | | S | Intravenous drip | Other Frequency:X1 Loading Dose; | | Gilead |
| | Senna | | | C | | | | Not Reported |
| | Melatonin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Doxycycline Iv | | | C | | | | Not Reported |
| | Clindamycin Iv | | | C | | | | Not Reported |
| | Dexamethasone | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Glycolax | | | C | | | | Not Reported |
| | Peridex | | | C | | | | Not Reported |
| | Acetaminophen Po | | | C | | | | Not Reported |
| | Precedex | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Acyclovir Iv | | | C | | | | Not Reported |
| | Etomidate | | | C | | | | Not Reported |
| | Omnipaque | | | C | | | | Not Reported |
| | Lorazepam | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|------------|---|--------------|
| Rocuronium | C | Not Reported |
| Vancomycin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17845005 | DIRECT | Y | | | | 23 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|------------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased | Remdesivir | | | S | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17845007 | DIRECT | Y | OT | | | 75 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Renal Impairment | Remdesivir | | | S | Intravenous drip | | | Gilead |
| | Osmolite 1.5 Cal Liquid | | | C | | | | Not Reported |
| | Atorvastatin 10mg At Bedtime | | | C | | | | Not Reported |
| | Chlorhexidine Mouthwash | | | C | | | | Not Reported |
| | Doxepin 10mg | | | C | | | | Not Reported |
| | Ensure Clinical Health | | | C | | | | Not Reported |
| | Erythromycin Opth Ointment Twice Daily | | | C | | | | Not Reported |
| | Furosemide 40mg Iv Once | | | C | | | | Not Reported |
| | Heparin In D5w 25000 Unit Bag | | | C | | | | Not Reported |
| | Propofol 1000mg Titration | | | C | | | | Not Reported |
| | Sodium Chloride 0.9% @ 50ml/Hr | | | C | | | | Not Reported |
| | Acetaminophen 325mg Tablet | | | C | | | | Not Reported |
| | Lorazepam 1mg Injection Once | | | C | | | | Not Reported |
| | Noepinephrine 4mg In 500ml | | | C | | | | Not Reported |
| | Dextrose 5% | | | | | | | |
| | Hydroxychloroquine 200mg | | | C | | | | Not Reported |
| | Insulin Lispro Per Sliding Scale | | | C | | | | Not Reported |
| | Levothyroxine 137mcg Per Dose | | | C | | | | Not Reported |
| | Methylprednisolone 125mg Iv Every 6 Hrs | | | C | | | | Not Reported |
| | Omega 3 Fatty Acid 2000mg Twice Daily | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|----------------------------------|---|--------------|
| Pantoprazole 40mg Iv Twice Daily | C | Not Reported |
| Propranolol 40mg Twice Daily | C | Not Reported |
| Sertraline 25mg Daily | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17845012 | DIRECT | Y | HO, OT | | | 44 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|--|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Blood Alkaline Phosphatase Increased; Blood Creatinine Increased; Therapy Interrupted; Transaminases Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Cobicistat/ Elvitegravir/Emtracitabine | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Doxycycline | | | C | | | | Not Reported |
| | Omnipaque | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Norepinephrine | | | C | | | | Not Reported |
| | Cisatracurium | | | C | | | | Not Reported |
| | Cholecalciferol | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Folic Acid | | | C | | | | Not Reported |
| | Multivitamin | | | C | | | | Not Reported |
| | Codeine-Guifenesin | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17845018 | DIRECT | Y | LT | | | 70 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Angioedema; Therapy Interrupted | Remdesivir | Y | | S | | | | Gilead |
| | Azithromycin | | | C | | | | Not Reported |
| | Duoneb | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Budesonide | | | C | | | | Not Reported |
| | Chlorhexadine | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Lasix | | | C | | | | Not Reported |
| | Lantus | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|--------------------|---|--------------|
| Lactobacillus | C | Not Reported |
| Methylprednisolone | C | Not Reported |
| Oxycodone | C | Not Reported |
| Pantoprazole | C | Not Reported |
| Zosyn | C | Not Reported |
| Cisatracurium | C | Not Reported |
| Dexmedetomidine | C | Not Reported |
| Fentanyl | C | Not Reported |
| Propofol | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17845059 | DIRECT | Y | DE | | | 76 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---------------------------|--------------|------------|-------------|---------------------------------------|---------------------|-----------------|--------------|
| Death | Remdesivir | | | S | Intravenous bolus | Other Frequency:X1; | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Kaletra 400/100 Mg Bid Po | | | C | | | | Not Reported |
| | Ivermectin 9mg Po Q48h X2 | | | C | | | | Not Reported |
| | Doses | | | | | | | |
| | Actemra 400mg X1 | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17845065 | DIRECT | N | DE | | | 59 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|---------------------|--------------|------------|-------------|------------------|--------------------|-----------------|--------------|
| Acidosis; Acidosis; Acute | Remdesivir | | | S | Intravenous drip | | | Gilead |
| Kidney Injury; Blood Creatinine Increased; | Remdesivir | | | S | Intravenous drip | | | Gilead |
| Blood Pressure Systolic Decreased; Bronchitis; | Convalescent Plasma | | | C | | | | Not Reported |
| Hypotension; Multiple Organ Dysfunction Syndrome; Oliguria; | Azithromycin | | | C | | | | Not Reported |
| Pneumonia; Renal Impairment; Respiratory Failure; Sepsis | Medrol | | | C | | | | Not Reported |
| | Amlodopine | | | C | | | | Not Reported |
| | Ascorbic Acid | | | C | | | | Not Reported |
| | Ceftriaxone | | | C | | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |
| | Insulin Lispro | | | C | | | | Not Reported |
| | Zosyn | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|----------------|---|--------------|
| Vacomycin | C | Not Reported |
| Versed | C | Not Reported |
| Norepinephrine | C | Not Reported |
| Propofol | C | Not Reported |
| Vasopressin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17845068 | DIRECT | Y | | | | 61 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|-----------------------|-----------------|------------|
| Infusion Site Extravasation; Peripheral Swelling | Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:Once; | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17846418 | DIRECT | Y | RI, OT | | | 63 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-----------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Atrial Fibrillation | Remdesivir 100mg/20ml | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Remdesivir 100mg/20ml | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Remdesivir 100mg/20ml | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 29-May-2020 | 17846473 | DIRECT | Y | RI, OT | | | 76 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------------------|--------------|------------|-------------|--|--------------------|-----------------|------------|
| Aspartate Aminotransferase Increased; Atrial Fibrillation; Blood Creatine Phosphokinase Increased; Blood Lactate | Remdesivir 100mg/20ml Vial | | | S | Intravenous (not otherwise specified) Intravenous (not otherwise specified) | | | Gilead |

Dehydrogenase
Increased; C-Reactive
Protein Increased;
Hypotension; Right
Ventricular Systolic
Pressure Increased;
Serum Ferritin Increased

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|--------------------------|------------------|--------------------|-----------------|---------------------------------------|----------------------------------|-----------------|--------------|----------------|
| 30-May-2020 | 17845070 | DIRECT | Y | DE, HO, LT | | | 68 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Death | Emergency Use Remdesivir | Y | | S | Intravenous (not otherwise specified) | Other Frequency:X1 Loading Dose; | | Gilead | |
| | Emergency Use Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Acetaminopohen | | | C | | | | Not Reported | |
| | Amlopidine | | | C | | | | Not Reported | |
| | Anastrozole | | | C | | | | Not Reported | |
| | Ascorbic Acid | | | C | | | | Not Reported | |
| | Atorvastatin | | | C | | | | Not Reported | |
| | Azithromycin | | | C | | | | Not Reported | |
| | Cefepime | | | C | | | | Not Reported | |
| | Clopidogrel | | | C | | | | Not Reported | |
| | Combivent Respimat | | | C | | | | Not Reported | |
| | Compazine | | | C | | | | Not Reported | |
| | Cholecalciferol | | | C | | | | Not Reported | |
| | Clonidine | | | C | | | | Not Reported | |
| | Coreg | | | C | | | | Not Reported | |
| | Cyanocobalamin | | | C | | | | Not Reported | |
| | Docusate Senna | | | C | | | | Not Reported | |
| | Donepezil | | | C | | | | Not Reported | |
| | Enoxaparin | | | C | | | | Not Reported | |
| | Famotidine | | | C | | | | Not Reported | |
| | Ferrous Sulfate | | | C | | | | Not Reported | |
| | Folic Acid | | | C | | | | Not Reported | |
| | Gabapentin | | | C | | | | Not Reported | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 30-May-2020 | 17845071 | DIRECT | Y | HO | | | 73 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------|--------------|------------|-------------|---------------------------------------|--|-----------------|--------------|
| Acute Kidney Injury; Cerebrovascular Accident; Mental Status Changes | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Loading/Once Daily; | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | Other Frequency:Loading/Once Daily; | | Gilead |
| | Venlafaxine | | | C | | | | Not Reported |
| | Topamax | | | C | | | | Not Reported |
| | Namenda | | | C | | | | Not Reported |
| | Imdur | | | C | | | | Not Reported |
| | Neurontin | | | C | | | | Not Reported |
| | Breo Ellipta | | | C | | | | Not Reported |
| | Pepcid | | | C | | | | Not Reported |
| | Aspirin | | | C | | | | Not Reported |
| | Cardizem | | | C | | | | Not Reported |
| | Levetiracetam | | | C | | | | Not Reported |
| | Combivent | | | C | | | | Not Reported |
| | Heparin | | | C | | | | Not Reported |
| | Dextrose | | | C | | | | Not Reported |
| | Morphine | | | C | | | | Not Reported |
| | Rocephin | | | C | | | | Not Reported |
| | Zithromax | | | C | | | | Not Reported |
| | Nystatin | | | C | | | | Not Reported |
| | Cardizem | | | C | | | | Not Reported |
| | Tylenol | | | C | | | | Not Reported |
| | Eliquis | | | C | | | | Not Reported |
| | Sodium Chloride | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 30-May-2020 | 17845076 | DIRECT | Y | OT | | | 64 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | | | | | | |
|--|----------------|------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|------------|----------------|
| Bradycardia | Remdesivir | Y | | S | Intravenous bolus | | | | Not Reported |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 30-May-2020 | 17845081 | DIRECT | Y | OT | | | 69 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Hypersensitivity; Laryngeal Oedema; Periorbital Swelling; Peripheral Swelling; Peripheral Swelling | Remdesivir | Y | | S | Intravenous bolus | | | | Not Reported |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 30-May-2020 | 17845085 | DIRECT | Y | OT | | | 69 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acute Kidney Injury | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | | Gilead |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 30-May-2020 | 17845113 | DIRECT | Y | OT | | | 57 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Infusion Related Reaction; Nausea | Remdesivir | | | S | Intravenous (not otherwise specified) | | 7 DAY | | Gilead |
| | Remdesivir | | | C | | | | | Not Reported |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 30-May-2020 | 17845123 | DIRECT | Y | OT | | | 55 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acute Kidney Injury | Remdesivir | | | S | Intravenous (not otherwise specified) | | | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--|----------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|--------------|----------------|
| 30-May-2020 | 17845128 | DIRECT | | | | | 48 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Intercepted Product Preparation Error; Product Preparation Error | Remdesivir | | | S | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|--------------------|------------------|--------------------|-----------------|--|----------------------|-----------------|--------------|----------------|
| 30-May-2020 | 17845130 | DIRECT | Y | HO, OT | | | 70 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Bradycardia | Remdesivir | Y | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Methylprednisolone | | | C | | | | Not Reported | |
| | Enoxaparin | | | C | | | | Not Reported | |
| | Lisinopril | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|------------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|--------------|----------------|
| 30-May-2020 | 17846348 | DIRECT | | HO | | | | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Infusion Site Pain | Remdesivir (Eua) | | | S | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|----------------|--------------------|--------------------|-----------------|--|----------------------|-----------------|--------------|----------------|
| 30-May-2020 | 17846639 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020- 0469017 | | 82 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Death; Hypoxia | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead | |
| | Famotidine | | | C | | Unk | | Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--|------------------|------------------|--------------------|-----------------|--|----------------------|-----------------|--------------|----------------|
| 31-May-2020 | 17845136 | DIRECT | Y | | | | 63 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Acute Kidney Injury; Chronic Kidney Disease | Remdesivir (Eua) | Y | | S | Intravenous (not otherwise specified) | | | Gilead | |
| | Remdesivir (Eua) | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|----------------------------------|----------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|--------------|----------------|
| 31-May-2020 | 17845140 | DIRECT | Y | | | | 57 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Haemorrhage; Thrombocytopenia | Remdesivir | | | S | Intravenous drip | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--|--------------------|--------------------|--------------------|-----------------|--|----------------------|-----------------|--------------|----------------|
| 01-Jun-2020 | 17844495 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468824 | | 26 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Liver Function Test Increased; Oxygen Consumption Decreased; Renal Impairment | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead | |
| | Remdesivir | | | S | | 100 Mg, Qd | | Gilead | |
| | Remdesivir | | | S | | Unk | | Gilead | |
| | Covalescent Plasma | | | C | | Unk | | Not Reported | |
| | Tocilizumab | | | C | | Unk | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|----------------|------------------|--------------------|-----------------|----------------------|----------------------|-----------------|------------|----------------|
| 01-Jun-2020 | 17846453 | DIRECT | Y | | | | 61 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | | |
|----------------------------|---------------------|---|---------------------------------------|--------------|
| Blood Creatinine Increased | Remdesivir | S | Intravenous (not otherwise specified) | Gilead |
| | Lopinavir/Ritonavir | C | | Not Reported |
| | Losartan | C | | Not Reported |
| | Metformin Er | C | | Not Reported |
| | Tocilizumab | C | | Not Reported |
| | Aspirin | C | | Not Reported |
| | Cefuroxime | C | | Not Reported |
| | Famotidine | C | | Not Reported |
| | Gabapentin | C | | Not Reported |
| | Guaifenesin | C | | Not Reported |
| | Hydrocholorthiazide | C | | Not Reported |
| | Heparin | C | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17846476 | DIRECT | Y | | | | 39 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Alanine Aminotransferase Increased; Liver Function Test Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |
| | Tocilizumab | | | C | | | | Not Reported |
| | Lovenox | | | C | | | | Not Reported |
| | Ondansetron | | | C | | | | Not Reported |
| | Tramadol | | | C | | | | Not Reported |
| | Acetaminophen | | | C | | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17846480 | DIRECT | Y | | | | 51 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Product Dose Omission | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17846502 | DIRECT | Y | HO | | | 59 YR | Male | USA |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Alanine Aminotransferase Increased; Aspartate Aminotransferase Increased; Therapy Cessation | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17846513 | DIRECT | | OT | | | 57 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-------------------|--------------|------------|--------------|---------------------------------------|--------------------|-----------------|--------------|
| Hyperphosphataemia | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Not Reported |
| | Ceftriaxone | | | C | | Not Reported | | |
| | Docusate Sodium | | | C | | Not Reported | | |
| | Etomidate | | | C | | Not Reported | | |
| | Famotidine | | | C | | Not Reported | | |
| | Furosemide | | | C | | Not Reported | | |
| | Insulin Detemir | | | C | | Not Reported | | |
| | Insulin Humalog | | | C | | Not Reported | | |
| | Magnesium Sulfate | | | C | | Not Reported | | |
| | Metolazone | | | C | | Not Reported | | |
| | Metoprolol | | | C | | Not Reported | | |
| | Senna Liquid | | | C | | Not Reported | | |
| | Bumetanide Drip | | | C | | Not Reported | | |
| | Fentanyl Drip | | | C | | Not Reported | | |
| Heparin Infusion | | | C | Not Reported | | | | |
| Insulin Human Regular | | | C | Not Reported | | | | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17846521 | DIRECT | | OT | | | 57 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|-----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Thrombocytosis | Remdesivir | | | S | Intravenous (not otherwise specified) | | | Not Reported |
| | Ceftriaxone | | | C | | Not Reported | | |
| | Docusate Sodium | | | C | | Not Reported | | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|-----------------------|---|--------------|
| Etomidate | C | Not Reported |
| Famotidine | C | Not Reported |
| Furosemide | C | Not Reported |
| Insulin Detemir | C | Not Reported |
| Insulin Humalog | C | Not Reported |
| Magnesium Sulfate | C | Not Reported |
| Metolazone | C | Not Reported |
| Metoprolol | C | Not Reported |
| Senna Liquid | C | Not Reported |
| Bumetanide Drip | C | Not Reported |
| Fentanyl Drip | C | Not Reported |
| Heparin Infusion | C | Not Reported |
| Insulin Human Regular | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|------------------|--------------------|-----------------|----------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17846712 | DIRECT | N | DE | | | 68 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|---|--------------|------------|-------------|---------------------------------------|--|-----------------|--------------|
| Covid-19 | Remdesivir 5mg/MI Concentrated Solution | Y | | S | Intravenous (not otherwise specified) | Other Dose:200mg/40ml; Frequency: 1 | | Gilead |
| | Convalescent Plasma 213 MI | | | C | Intravenous (not otherwise specified) | Dose Or Amount: 100/Mg/20ml Frequency: 2 | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17847828 | EXPEDITED (15-DAY) | | | US-GILEAD-2020-0468846 | | 67 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|---|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Product Administration Error; Product Storage Error | Remdesivir | | | S | Unknown | Unk | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17847986 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0469172 | | 92 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
|-----------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

Acute Kidney Injury; Death Remdesivir S Unknown Unk Gilead

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17848017 | EXPEDITED (15-DAY) | | LT, OT | US-GILEAD-2020-0469288 | | 79 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Blood Creatinine Increased; Blood Urea Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Tocilizumab | | | C | | | | Not Reported |
| | Cefepime | | | C | | | | Not Reported |
| | Azithromycin | | | C | | | | Not Reported |
| | Fentanyl | | | C | | | | Not Reported |
| | Midazolam | | | C | | | | Not Reported |
| | Propofol | | | C | | | | Not Reported |
| | Albumin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Aspirin 81 | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Enoxaparin | | | C | | | | Not Reported |
| | Insulin | | | C | | | | Not Reported |
| | Cisatracurium | | | C | | | | Not Reported |
| Meropenem | | | C | | | | Not Reported | |
| Simvastatin | | | C | | | | Not Reported | |
| Vitamin D [Colecalciferol] | | | C | | | | Not Reported | |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17848022 | EXPEDITED (15-DAY) | | HO, LT, OT | US-GILEAD-2020-0469201 | | 48 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-------------------------|--------------------------------|--------------|------------|-------------|--------------|--------------------|-----------------|--------------|
| Endotracheal Intubation | Remdesivir | | | S | Unknown | Unk | | Gilead |
| | Aspirin [Acetylsalicylic Acid] | | | C | | | | Not Reported |
| | Atorvastatin | | | C | | | | Not Reported |
| | Famotidine | | | C | | | | Not Reported |
| | Furosemide | | | C | | | | Not Reported |
| | Lorazepam | | | C | | | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | |
|-----------------|---|--------------|
| Sodium Chloride | C | Not Reported |
| Vancomycin | C | Not Reported |
| Heparin | C | Not Reported |
| Insulin Aspart | C | Not Reported |
| Insulin Detemir | C | Not Reported |
| Norepinephrine | C | Not Reported |
| Ceftriaxone | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17848028 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0469174 | | 76 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|--------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Renal Impairment | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Albuterol [Salbutamol] | | | C | | Unk | | Not Reported |
| | Aspirin [Acetylsalicylic Acid] | | | C | | Unk | | Not Reported |
| | Cefepime | | | C | | Unk | | Not Reported |
| | Chlorhexidine | | | C | | Unk | | Not Reported |
| | Normosol R | | | C | | Unk | | Not Reported |
| | Enoxaparin | | | C | | Unk | | Not Reported |
| | Fentanyl | | | C | | Unk | | Not Reported |
| | Heparin | | | C | | Unk | | Not Reported |
| | Hydrocortisone | | | C | | Unk | | Not Reported |
| | Triad | | | C | | Unk | | Not Reported |
| | Insulin Glargine | | | C | | Unk | | Not Reported |
| | Insulin Regular Hm | | | C | | Unk | | Not Reported |
| | Lactated Ringers | | | C | | Unk | | Not Reported |
| | Lactulose | | | C | | Unk | | Not Reported |
| | Magnesium Sulfate | | | C | | Unk | | Not Reported |
| | Melatonin | | | C | | Unk | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|--------------------|---|-----|--------------|
| Metronidazole | C | Unk | Not Reported |
| Midazolam | C | Unk | Not Reported |
| Midodrine | C | Unk | Not Reported |
| Morphine Sulfate | C | Unk | Not Reported |
| Norepinephrine | C | Unk | Not Reported |
| Pantoprazole | C | Unk | Not Reported |
| Phenylephrine | C | Unk | Not Reported |
| Potassium Chloride | C | | Not Reported |
| Primasate Bk0/3.5 | C | | Not Reported |
| Primasol Bgk | C | | Not Reported |
| Propofol | C | | Not Reported |
| Simvastatin | C | | Not Reported |
| Sodium Bicarbonate | C | | Not Reported |
| Vancomycin | C | | Not Reported |
| Zolpidem | C | | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17848032 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468530 | | 57 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------------|----------------|--------------|------------|-------------|--------------|--------------------|-----------------|------------|
| Bilirubin Conjugated Increased | Remdesivir | | | S | Unknown | Unk | | Gilead |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17848037 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468536 | | 55 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|----------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|------------|
| Hypotension; Infusion Related Reaction | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Qd | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg Qd | | Gilead |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17848039 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0469173 | | 82 YR | Female | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|-----------------------|----------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Death | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Acetaminophen | | | C | | Unk | | Not Reported |
| | Apixaban | | | C | | Unk | | Not Reported |
| | Ceftriaxone | | | C | | Unk | | Not Reported |
| | Enoxaparin | | | C | | Unk | | Not Reported |
| | Furosemide | | | C | | Unk | | Not Reported |
| | Gabapentin | | | C | | Unk | | Not Reported |
| | Insulin Lispro | | | C | | Unk | | Not Reported |
| | Insulin Regular Hm | | | C | | Unk | | Not Reported |
| | Lactated Ringers | | | C | | Unk | | Not Reported |
| | Latanoprost | | | C | | Unk | | Not Reported |
| | Magnesium Sulfate | | | C | | Unk | | Not Reported |
| | Metoprolol Tartrate | | | C | | Unk | | Not Reported |
| | Metronidazole | | | C | | Unk | | Not Reported |
| | Modafinil | | | C | | Unk | | Not Reported |
| | Mometasone | | | C | | Unk | | Not Reported |
| | Formoterol | | | C | | Unk | | Not Reported |
| | Montelukast | | | C | | Unk | | Not Reported |
| | Morphine | | | C | | Unk | | Not Reported |
| | Potassium Chloride | | | C | | Unk | | Not Reported |
| | Sertraline | | | C | | Unk | | Not Reported |
| | Sodium Chloride 0.9% | | | C | | Unk | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| Vancomycin | | C | | Unk | | Not Reported | | | |
|---|--------------------------------|--------------------|--------------------|-----------------|---------------------------------------|----------------------|-----------------|--------------|----------------|
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 01-Jun-2020 | 17848043 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0469167 | | 61 YR | Female | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Respiratory Arrest | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead | |
| | Convalescent Plasma | | | C | | Unk | | Not Reported | |
| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
| 01-Jun-2020 | 17848044 | EXPEDITED (15-DAY) | | DE, OT | US-GILEAD-2020-0469503 | | 45 YR | Male | USA |
| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> | |
| Blood Creatinine Increased; Cardiac Arrest; Glomerular Filtration Rate Decreased; Liver Function Test Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Mg, Once | | Gilead | |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead | |
| | Acetaminophen | | | C | | | | Not Reported | |
| | Norco | | | C | | | | Not Reported | |
| | Albuterol [Salbutamol] | | | C | | | | Not Reported | |
| | Amiodarone | | | C | | | | Not Reported | |
| | Amlodipine | | | C | | | | Not Reported | |
| | Aspirin [Acetylsalicylic Acid] | | | C | | | | Not Reported | |
| | Atorvastatin | | | C | | | | Not Reported | |
| | Calcium Carbonate | | | C | | | | Not Reported | |
| | Calcium Gluconate | | | C | | | | Not Reported | |
| | Ceftriaxone | | | C | | | | Not Reported | |
| | Chlorhexidine Gluconate | | | C | | | | Not Reported | |
| | Cholecalciferol | | | C | | | | Not Reported | |
| | Cisatracurium | | | C | | | | Not Reported | |
| | Dexmedetomidine | | | C | | | | Not Reported | |
| | Digoxin | | | C | | | | Not Reported | |
| | Doxycycline | | | C | | | | Not Reported | |
| | Enoxaparin | | | C | | | | Not Reported | |
| | Heparin | | | C | | | | Not Reported | |

FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report

| | | |
|--------------------|---|--------------|
| Insulin Glargine | C | Not Reported |
| Insulin Lispro | C | Not Reported |
| Famotidine | C | Not Reported |
| Fentanyl | C | Not Reported |
| Furosemide | C | Not Reported |
| Losartan | C | Not Reported |
| Meropenem | C | Not Reported |
| Metformin | C | Not Reported |
| Methylprednisolone | C | Not Reported |
| Metoprolol | C | Not Reported |
| Midazolam | C | Not Reported |
| Nitroglycerin | C | Not Reported |
| Norepinephrine | C | Not Reported |
| Nortriptyline | C | Not Reported |
| Phenylephrine | C | Not Reported |
| Propofol | C | Not Reported |
| Tocilizumab | C | Not Reported |
| Warfarin | C | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|------------------------|----------------------|------------|------------|----------------|
| 01-Jun-2020 | 17848077 | EXPEDITED (15-DAY) | | OT | US-GILEAD-2020-0468738 | | 71 YR | Male | USA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--------------------------|-----------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|--------------|
| Platelet Count Increased | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Gilead |
| | Flomax [Tamsulosin Hydrochloride] | | | C | | Unk | | Not Reported |
| | Vitamin C [Ascorbic Acid] | | | C | | Unk | | Not Reported |
| | Zinc | | | C | | Unk | | Not Reported |
| | Allopurinol | | | C | | Unk | | Not Reported |
| | Azithromycin | | | C | | Unk | | Not Reported |
| | Benzonatate | | | C | | Unk | | Not Reported |
| | Ceftriaxone | | | C | | Unk | | Not Reported |
| | Dipyridamole | | | C | | Unk | | Not Reported |
| | Enoxaparin | | | C | | Unk | | Not Reported |
| | Insulin Glargine | | | C | | Unk | | Not Reported |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| | | | |
|--------------------|---|-----|--------------|
| Insulin Lispro | C | Unk | Not Reported |
| Zestoretic | C | Unk | Not Reported |
| Meropenem | C | Unk | Not Reported |
| Methylprednisolone | C | Unk | Not Reported |
| Prednisone | C | Unk | Not Reported |

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|--|----------------------|------------|------------|----------------|
| 02-Jun-2020 | 17794570 | EXPEDITED (15-DAY) | | DE, HO, LT, OT | NL-BRISTOL-MYERS SQUIBB COMPANY- BMS-2020-037224 | | 66 YR | Male | NLD |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-------------------------------------|--------------|------------|-------------|---------------------------------------|--------------------|-----------------|----------------------|
| Covid-19; Haematoma Muscle; Lactic Acidosis; Off Label Use; Renal Failure; Respiratory Failure; Subcutaneous Abscess | Apixaban | | | S | Unknown | Unk | | Bristol Myers Squibb |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 200 Milligram, Qd | | Not Reported |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Milligram, Qd | | Not Reported |
| | Nadroparine | | | S | Unknown | Unk | | Not Reported |
| | Pravastatine [Pravastatin Sodium] | | | C | Unknown | Unk | | Not Reported |
| | Metoclopramide | | | C | Unknown | Unk | | Not Reported |
| | Nifedipine | | | C | Unknown | Unk | | Not Reported |
| | Perindopril | | | C | Unknown | Unk | | Not Reported |
| | Oxycodone [Oxycodone Hydrochloride] | | | C | Unknown | Unk | | Not Reported |
| | Fenoterol;Ipratropium | | | C | Unknown | Unk | | Not Reported |
| | Cotrimaxazol | | | C | Unknown | Unk | | Not Reported |
| | Valaciclovir | | | C | Unknown | Unk | | Not Reported |
| | Allopurinol | | | C | Unknown | Unk | | Not Reported |
| | Paracetamol | | | C | Unknown | Unk | | Not Reported |
| | Pantoprazol [Pantoprazole] | | | C | Unknown | Unk | | Not Reported |
| Flucloxacillin | | | C | Unknown | Unk | | Not Reported | |
| Folic Acid | | | C | Unknown | Unk | | Not Reported | |

**FDA Adverse Event Reporting System
Freedom of Information Act (FOIA)
Detailed Report**

| <u>FDA Received Date</u> | <u>Case #</u> | <u>Case Type</u> | <u>Health Prof</u> | <u>Outcomes</u> | <u>Mfr Control #</u> | <u>503B Facility</u> | <u>Age</u> | <u>Sex</u> | <u>Country</u> |
|--------------------------|---------------|--------------------|--------------------|-----------------|---|----------------------|------------|------------|----------------|
| 02-Jun-2020 | 17852138 | EXPEDITED (15-DAY) | | DE, HO, OT | FR-VALIDUS PHARMACEUTICALS LLC-FR- 2020VAL000437 | | | Unknown | FRA |

| <u>Preferred Term</u> | <u>Product</u> | <u>Comp.</u> | <u>OTC</u> | <u>Role</u> | <u>Route</u> | <u>Dosage Text</u> | <u>Duration</u> | <u>Mfr</u> |
|--|-----------------------|--------------|------------|-------------|--|--------------------|-----------------|--------------|
| Coronavirus Infection; Pancreatitis | Furosemide | | | S | Intravenous (not otherwise specified) | Unk | | Validus |
| | Remdesivir | | | S | Intravenous (not otherwise specified) | 100 Mg, Qd | | Not Reported |
| | Kardegic | | | C | | Unk | | Not Reported |
| | Coumadine | | | C | | Unk | | Not Reported |
| | Perfalgan | | | C | | Unk | | Not Reported |
| | Triatec /00885601/ | | | C | | Unk | | Not Reported |
| | Piperacillin | | | C | | Unk | | Not Reported |
| | Cordarone | | | C | | Unk | | Not Reported |
| | Rovamycine /00074401/ | | | C | | Unk | | Not Reported |
| | Cefotaxime | | | C | | Unk | | Not Reported |
| | Heparin AI | | | C | | Unk | | Not Reported |
| | Ciprofloxacin | | | C | | Unk | | Not Reported |
| | Tazobactam | | | C | | Unk | | Not Reported |
| | Solupred /00016217/ | | | C | | Unk | | Not Reported |
| | Bisoce | | | C | | Unk | | Not Reported |